MRNA encoding checkpoint cancer vaccines and uses thereof
By activate T cells by using polynucleotide constructs encoding IDO and PD-L1 antigen peptides and lipid nanoparticle compositions, the problem of low survival rates in existing patients with advanced skin melanoma and NSCLC has been solved, achieving the goal of Effective killing and prolong survival of tumor cells.
Patent Information
- Application Number
- CN202380021591.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-28
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure BDA0004990825510000094 
Figure BDA0004990825510000101 
Figure BDA0004990825510000551
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 311,716, filed on February 18, 2022, and U.S. Provisional Application No. 63 / 381,460, filed on October 28, 2022. The contents of the foregoing applications are hereby incorporated by reference in their entirety. Background of the Invention
[0004] In the United States, melanoma is the fifth most common cancer diagnosis. It accounts for 5.3% of all new cancer diagnoses and 1.5% of all cancer-related deaths. Skin melanoma is a cancer that begins in skin melanocytes (pigment-producing cells). If diagnosed in the local stage, the 5-year survival rate is about 95%. However, for regional or metastatic disease (stage IIIB+), the 5-year survival rate drops to about 30% to 60%. In the United States, about 18,000 new patients are diagnosed with stage IIIB+ skin melanoma. Advanced melanoma is a rare and serious type of skin cancer, and although it only accounts for 1% of skin cancer cases, it is the cause of most skin cancer-related deaths. The current standard of care is a combination of pembrolizumab, nivolumab, or nivolumab + ipilimumab.
[0005] NSCLC is often undetectable and remains asymptomatic until it progresses to an advanced stage. Approximately 115,000 people are diagnosed with metastatic NSCLC or progress to metastatic disease each year in the United States. Current treatments for metastatic NSCLC rely on the presence of PD-L1 expression. If tumor PD-L1 expression is greater than 50%, pembrolizumab or atezolizumab monotherapy is preferred, while for patients with PD-L1 expression less than 50%, chemotherapy in combination with pembrolizumab is preferred.
[0006] Although there are several treatments for cancers such as melanoma and NSCLC, there remains a pressing need to develop new treatment modalities and therapies that can improve treatment outcomes and prolong survival of cancer patients. Summary of the invention
[0007] The present disclosure provides, among other things, polynucleotide constructs and lipid nanoparticle (LNP) compositions comprising such polynucleotides, and uses thereof, wherein the polynucleotides encode checkpoint cancer vaccines (e.g., comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides). The LNP compositions disclosed herein comprise one or more mRNA molecules encoding (i) one or more IDO antigen peptides; and (ii) one or more PD-L1 antigen peptides and optionally auxiliary amino acid sequences. In one aspect, the LNP compositions disclosed herein can stimulate an immune response (e.g., stimulate effector T cells to target and kill inhibitory immune cells and tumor cells expressing IDO or PD-L1); induce T cells to induce recognition of tumor-associated antigens, induce helper T cells, promote T cell influx into the tumor site, and induce cytotoxic T cell-mediated tumor cell killing. Also disclosed herein is a method for treating cancer or stimulating an immune response in a subject using an LNP composition comprising a checkpoint cancer vaccine.
[0008] Other aspects of the disclosure are described in further detail below.
[0009] In one aspect, provided herein are polynucleotides (e.g., mRNA) encoding checkpoint cancer vaccines comprising (i) one or more indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more programmed death-ligand 1 (PD-L1) antigenic peptides. Optionally, the polynucleotides may also include sequences encoding auxiliary amino acid sequences. The present invention also relates to lipid nanoparticle (LNP) compositions comprising such polynucleotides.
[0010] On the other hand, the present disclosure provides a lipid nanoparticle (LNP) composition for immunomodulation, for example, for stimulating an immune response of IDO / PDL1-specific T cells or breaking immune tolerance (e.g., stimulating T effector cells by increasing the activation of T effector cells and / or attracting them to tumor cells that can express IDO and PDL1), the composition comprising mRNA, (i) one or more indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more programmed death-ligand 1 (PD-L1) antigenic peptides. Optionally, the mRNA may also encode an auxiliary amino acid sequence. In one embodiment, the LNP composition promotes CD4+ and / or CD8+ T cells to infiltrate tumor cells and promotes killing of tumor cells expressing IDO and / or PDL1.
[0011] In one aspect, the present invention provides a lipid nanoparticle (LNP) composition for stimulating T effector cells of a subject with melanoma or NSCLC, the composition comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more programmed death-ligand 1 (PD-L1) antigenic peptides. Optionally, the mRNA may also encode an auxiliary amino acid sequence.
[0012] In one embodiment, for example, as measured by an assay described herein, administration of an LNP composition disclosed herein improves a subject's cancer (e.g., as described herein) or delays its progression. In one embodiment, a checkpoint inhibitor (e.g., an anti-PD1 antibody, an anti-CTLA4 antibody, or a combination thereof) may also be administered to a subject.
[0013] In one embodiment of any of the LNP compositions disclosed herein, comprises an mRNA encoding a checkpoint cancer vaccine, wherein the mRNA comprises at least one chemical modification.
[0014] In one embodiment of any LNP composition disclosed herein, the LNP composition comprises: (i) an ionizable lipid, such as an ionizable amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
[0015] In one aspect, provided herein is a pharmaceutical composition comprising the LNP composition disclosed herein.
[0016] In one aspect, the present invention provides a method for regulating, for example, inducing or promoting an immune response in a subject, the method comprising administering to a subject in need thereof an effective amount of an LNP composition, the LNP composition comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides. Optionally, the mRNA may also encode an auxiliary amino acid sequence.
[0017] In another aspect, the present disclosure provides a method for stimulating T effector cells in a subject, the method comprising administering to the subject an effective amount of an LNP composition, the LNP composition comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides. Optionally, the mRNA may also encode an auxiliary amino acid sequence.
[0018] In another aspect, provided herein is a method for treating or preventing the spread or symptoms of cancer or its metastatic lesions (e.g., skin melanoma (e.g., 1L skin melanoma stage IIIB+) or NSCLC (e.g., 1LNSCLC)), the method comprising administering to a subject in need thereof an effective amount of an LNP composition comprising an mRNA encoding a checkpoint cancer vaccine comprising (i) one or more IDO peptides and (ii) one or more PD-L1 peptides. Optionally, the mRNA may also encode an auxiliary amino acid sequence.
[0019] In one embodiment of any of the methods disclosed herein, the checkpoint cancer vaccine comprises alternating antigenic peptides (eg, as multimers) of IDO and PD-L1.
[0020] In one embodiment of any of the methods disclosed herein, the LNP composition comprising mRNA encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides is administered in combination with another agent, such as an agent that further stimulates an immune response, such as a checkpoint inhibitor such as an anti-PD1 antibody or an anti-CTLA4 antibody.
[0021] In one embodiment, the other agent is administered in the form of a therapeutic protein. In another embodiment, the other agent is administered in the form of a polynucleotide encapsulated in an LNP. In one embodiment, the LNP composition and the other agent are in the same composition or in a separate composition.
[0022] In one embodiment, the LNP composition is administered substantially simultaneously or sequentially with the other agent. In one embodiment, for sequential administration, the LNP composition is administered before administering the other agent. In one embodiment, the order of administration is reversed. In one embodiment of any method disclosed herein, the cancer is a solid tumor, such as a locally advanced or metastatic solid tumor. In some embodiments, the cancer is selected from: skin melanoma (e.g., 1L skin melanoma IIIB+ stage), NSCLC (e.g., 1L NSCLC), bladder cancer (e.g., non-muscle invasive bladder cancer), head and neck cancer (e.g., head and neck squamous cell carcinoma), colorectal cancer (e.g., microsatellite stable colorectal cancer), basal cell carcinoma, or breast cancer (e.g., triple-negative breast cancer).
[0023] In one embodiment, the cancer is skin melanoma. In one embodiment, the skin melanoma is 1L skin melanoma stage IIIB+. In one embodiment, the melanoma is refractory melanoma. In one embodiment, the cancer is NSCLC. In one embodiment, the NSCLC is 1L NSCLC. In one embodiment, the NSCLC is locally advanced or metastatic and / or checkpoint inhibitor refractory NSCLC.
[0024] In some embodiments of any of the methods disclosed herein, the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structural lipid; (iii) a non-cationic auxiliary lipid or phospholipid; and (iv) a PEG-lipid. In some embodiments, the ionizable lipid comprises compound 25. In some embodiments of any of the methods disclosed herein, the LNP composition comprises an ionizable lipid containing compound 25 and a PEG-lipid containing PEG DMG.
[0025] In another aspect, disclosed herein is a kit comprising a container containing an LNP composition disclosed herein or a pharmaceutical LNP composition disclosed herein.
[0026] In some embodiments, the kit comprises a package insert comprising instructions for administration of the LNP composition or pharmaceutical LNP composition for treating cancer.
[0027] In some embodiments, the LNP composition comprises a pharmaceutically acceptable carrier.
[0028]
[00136] Other features of any of the LNP compositions for use, pharmaceutical compositions comprising the LNPs, methods, or compositions disclosed herein include the following aspects or embodiments.
[0029] In one aspect, the present disclosure provides a LNP composition comprising a polynucleotide, such as encoding a checkpoint cancer vaccine, such as comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides, such as described herein. Optionally, the polynucleotide may also include a sequence encoding an auxiliary amino acid sequence.
[0030] In one aspect, the LNP compositions disclosed herein include polynucleotides encoding checkpoint cancer vaccines comprising one or more IDO antigenic peptides. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with an IDO antigenic peptide amino acid sequence (e.g., SEQ ID NO: 1) or an antigenic fragment thereof provided in Table 1A. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence of an IDO amino acid sequence (e.g., SEQ ID NO: 1) provided in Table 1A or an antigenic fragment thereof. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence of SEQ ID NO: 1 or an antigenic fragment thereof.
[0031] In one embodiment, the polynucleotide encoding the IDO antigenic peptide comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the IDO antigenic peptide (e.g., mRNA) comprises the nucleotide sequence of SEQ ID NO: 2 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the IDO antigenic peptide comprises a codon-optimized nucleotide sequence.
[0032] In one aspect, the LNP composition disclosed herein comprises a polynucleotide encoding a checkpoint cancer vaccine comprising one or more PD-L1 antigen peptides. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with the PD-L1 antigen peptide amino acid sequence (e.g., SEQ ID NO: 3) or an antigenic fragment thereof provided in Table 1A. In one embodiment, the PD-L1 molecule comprises an amino acid sequence of the PD-L1 amino acid sequence (e.g., SEQ ID NO: 3) provided in Table 1A or an antigenic fragment thereof. In one embodiment, the PD-L1 molecule comprises an amino acid sequence of SEQ ID NO: 3 or an antigenic fragment thereof.
[0033] In one embodiment, the polynucleotide encoding the PD-L1 antigen peptide comprises a nucleotide sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with the sequence of SEQ ID NO: 4 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the PD-L1 antigen peptide (e.g., mRNA) comprises the nucleotide sequence of SEQ ID NO: 4 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the PD-L1 antigen peptide comprises a codon-optimized nucleotide sequence.
[0034] In one aspect, the LNP composition disclosed herein comprises a polynucleotide encoding a checkpoint cancer vaccine, which, for example, comprises one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides. In some embodiments, the checkpoint cancer vaccine comprises alternating IDO and PD-L1 antigen peptides. In one embodiment, the checkpoint cancer vaccine comprises one IDO antigen peptide and one PD-L1 antigen peptide. In one embodiment, the checkpoint cancer vaccine comprises two IDO antigen peptides and two PD-L1 antigen peptides. In one embodiment, the checkpoint cancer vaccine comprises three IDO antigen peptides and three PD-L1 antigen peptides. In one embodiment, the checkpoint cancer vaccine comprises four IDO antigen peptides and four PD-L1 antigen peptides. In some embodiments, the four IDO and four PD-L1 antigen peptides are arranged in an alternating manner. Therefore, in one embodiment, the checkpoint cancer vaccine comprises (i) an IDO antigen peptide, (ii) a PD-L1 antigen peptide, (iii) an IDO antigen peptide, (iv) a PD-L1 antigen peptide, (v) an IDO antigen peptide, (vi) a PD-L1 antigen peptide, (vii) an IDO antigen peptide and (viii) a PD-L1 antigen peptide.
[0035] In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an IDO amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof. In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof. In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence of SEQ ID NO: 5 or an antigenic fragment thereof.
[0036] In one embodiment, the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptide comprises a nucleotide sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence of SEQ ID NO: 6, 300, 301 or 302, or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptide (e.g., mRNA) comprises a nucleotide sequence of SEQ ID NO: 6, 300, 301 or 302, or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptide comprises a codon-optimized nucleotide sequence.
[0037] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the polynucleotide comprises at least one chemical modification. In one embodiment, the chemical modification is selected from the group consisting of pseudouridine, N1-methyl pseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-sulfanyl-1-methyl-1-deaza-pseudouridine, 2-sulfanyl-1-methyl-pseudouridine, 2-sulfanyl-5-aza-uridine, 2-sulfanyl-dihydropseudouridine, 2-sulfanyl-dihydrouridine, 2-sulfanyl-pseudouridine, 4-methoxy-2-sulfanyl-pseudouridine, 4-methoxy-pseudouridine, 4-sulfanyl-1-methyl-pseudouridine, 4-sulfanyl-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine. In one embodiment, the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof. In one embodiment, the chemical modification is N1-methylpseudouridine. In one embodiment, each mRNA in the lipid nanoparticle comprises a fully modified N1-methylpseudouridine.
[0038] In one embodiment of any of the LNP compositions, methods, or compositions for use disclosed herein, the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
[0039] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP composition comprises an ionizable lipid containing an amino lipid. In one embodiment, the ionizable lipid comprises a compound of any one of formula (I), formula (Ia), formula (Ib), formula (Ic), formula (II), formula (II-a), formula (II-b), formula (II-c), formula (II-d), formula (II-e), formula (II-f), formula (II-g), formula (II-h) or formula (III). In one embodiment, the ionizable lipid comprises a compound of formula (I). In one embodiment, the ionizable lipid comprises compound 18. In one embodiment, the ionizable lipid comprises compound 25.
[0040] In some embodiments, the lipid nanoparticle comprises an ionizable amino lipid compound of formula (I):
[0041] or an N-oxide thereof, or a salt or isomer thereof,
[0042] Where R' a For R' 分支 ;in
[0043] R' 分支 for: in Indicates a connection point;
[0044] Where R aα , R aβ , R aγ and R aδ Each independently selected from H, C 2-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0045] R 2 and R 3 Each independently selected from C 1-14 Alkyl and C 2-14 A group consisting of alkenyl groups;
[0046] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0047] in represents a connection point;
[0048] R 10 N(R) 2 ; Each R is independently selected from C1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0049] Each R 5 Independently selected from C 1-3 Alkyl, C 2-3 A group consisting of an alkenyl group and H;
[0050] Each R 6 Independently selected from C 1-3 Alkyl, C 2-3 A group consisting of an alkenyl group and H;
[0051] M and M' are each independently selected from the group consisting of -C(O)O- and -OC(O)-;
[0052] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0053] l is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0054] m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0055] In some embodiments, the ionizable amino lipid compound of formula (I) is selected from:
[0056]
[0057] In some embodiments, the lipid nanoparticles further comprise phospholipids, structural lipids, and PEG-lipids.
[0058] In some embodiments, the PEG-lipid is PEG DMG.
[0059] In some embodiments, the lipid nanoparticle comprises:
[0060] (i) 40-50 mol% of a compound of formula (I), 30-45 mol% of a structural lipid, 5-15 mol% of a phospholipid and 1-5 mol% of a PEG-lipid; or
[0061] (ii) 45-50 mol% of a compound of formula (I), 35-45 mol% of structural lipids, 8-12 mol% of phospholipids and 1.5 to 3.5 mol% of PEG-lipids.
[0062] In some embodiments, the lipid nanoparticles comprise Compound 25, DSPC, cholesterol, and PEG DMG.
[0063] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 20mol% to about 60mol% of ionizable lipids, about 5mol% to about 25mol% of non-cationic auxiliary lipids or phospholipids, about 25mol% to about 55mol% of sterols or other structural lipids and about 0.5mol% to about 15mol% of PEG lipids. In one embodiment of the LNP or methods disclosed herein, the LNP comprises about 35mol% to about 55mol% of ionizable lipids, about 5mol% to about 25mol% of non-cationic auxiliary lipids or phospholipids, about 30mol% to about 40mol% of sterols or other structural lipids and about 0mol% to about 10mol% of PEG lipids. In one embodiment of the LNP or methods disclosed herein, the LNP comprises about 50mol% of ionizable lipids, about 10mol% of non-cationic auxiliary lipids or phospholipids, about 38.5mol% of sterols or other structural lipids and about 1.5mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 49.83mol% of ionizable lipids, about 9.83mol% of non-cationic auxiliary lipids or phospholipids, about 30.33mol% of sterols or other structural lipids, and about 2.0mol% of PEG lipids. In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 45mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45.5mol% to about 49.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46mol% to about 49mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46.5mol% to about 48.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47mol% to about 48mol% of ionizable lipids.
[0064] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 45mol% to about 49.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 49mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 48.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 48mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 47.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 47mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45mol% to about 46.5mol% of ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 45 mol % to about 46 mol % ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 45 mol % to about 45.5 mol % ionizable lipids.
[0065] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 45.5mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46.5mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47.5mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48.5mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48.5mol% to about 50mol% of ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 49 mol % to about 50 mol % ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 49.5 mol % to about 50 mol % ionizable lipids.
[0066] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 45mol% to about 46mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45.5mol% to about 46.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46mol% to about 47mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46mol% to about 47mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46.5mol% to about 47.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47mol% to about 48mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47.5mol% to about 48.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48mol% to about 49mol% of ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 48.5mol% to about 49.5mol% ionizable lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 49mol% to about 50mol% ionizable lipids.
[0067] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 45mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 45.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 46.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 47.5mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48mol% of ionizable lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 48.5mol% of ionizable lipids. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 49mol% of ionizable lipids. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 49.5mol% of ionizable lipids. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 50mol% of ionizable lipids.
[0068] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 1mol% to about 5mol% PEG lipids. In one embodiment of the LNP of the present disclosure or methods, the LNP comprises about 1.5mol% to about 4.5mol% PEG lipids. In one embodiment of the LNP of the present disclosure or methods, the LNP comprises about 2mol% to about 4mol% PEG lipids. In one embodiment of the LNP of the present disclosure or methods, the LNP comprises about 2.5mol% to about 3.5mol% PEG lipids.
[0069] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 1mol% to about 4.5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 4mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 3.5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 3mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 2.5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 2mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1mol% to about 1.5mol% PEG lipids.
[0070] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 1.5mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 2mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 2.5mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 3mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 3.5mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 4mol% to about 5mol% PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 4.5mol% to about 5mol% PEG lipids.
[0071] In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 1mol% to about 2mol% of PEG lipid. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 1.5mol% to about 2.5mol% of PEG lipid. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 2mol% to about 3mol% of PEG lipid. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 3.5mol% to about 4.5mol% of PEG lipid. In one embodiment of the LNP of the present disclosure or the method, the LNP comprises about 4mol% to about 5mol% of PEG lipid.
[0072] In one embodiment of any one of the LNP compositions, methods or compositions disclosed herein for use, the LNP comprises about 1 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 1.5 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 2 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 2.5 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 3 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 3.5 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 4 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 4.5 mol% of PEG lipids. In one embodiment of the LNP or method disclosed herein, the LNP comprises about 5 mol% of PEG lipids.
[0073] In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 50 mol% of compound 25 and about 10 mol% of non-cationic auxiliary lipids or phospholipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises 50 mol% of compound 25 and about 10 mol% of non-cationic auxiliary lipids or phospholipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 50 mol% of compound 25 and 10 mol% of non-cationic auxiliary lipids or phospholipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises 50 mol% of compound 25 and 10 mol% of non-cationic auxiliary lipids or phospholipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 49.83 mol% of compound 25, about 9.83 mol% of non-cationic auxiliary lipids or phospholipids, about 30.33 mol% of sterols or other structural lipids and about 2.0 mol% of PEG lipids.
[0074] In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 48mol% of compound 25, about 11mol% of non-cationic auxiliary lipids or phospholipids, about 38.5mol% of sterols or other structural lipids and about 2.5mol% of PEG lipids. In one embodiment of the LNP or method of the present disclosure, the LNP comprises about 48mol% of compound 25, about 11mol% of DSPC, about 38.5mol% of cholesterol and about 2.5mol% of PEG-DMG.
[0075] In one embodiment of any of the LNP compositions, methods, or compositions disclosed herein for use, the LNP is formulated for intravenous, subcutaneous, or intramuscular delivery. In one embodiment, the LNP is formulated for intramuscular delivery.
[0076] In one embodiment, the LNP composition as disclosed herein is administered to a subject suffering from cancer. In some embodiments, the cancer is a solid tumor, for example, a locally advanced or metastatic solid tumor.
[0077] In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is melanoma. In some embodiments, the melanoma is a skin melanoma. In one embodiment, the skin melanoma is 1L skin melanoma IIIB+ stage. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is NSCLC. In one embodiment, the NSCLC is 1LNSCLC. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is bladder cancer. In some embodiments, the bladder cancer is non-muscle invasive bladder cancer. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is head and neck cancer. In some embodiments, the head and neck cancer is head and neck squamous cell carcinoma. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is colorectal cancer. In some embodiments, the colorectal cancer is microsatellite stable colorectal cancer. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is basal cell carcinoma. In one embodiment of any of the methods or compositions disclosed herein for use, the cancer is breast cancer. In some embodiments, the breast cancer is triple-negative breast cancer.
[0078] In one embodiment of any of the methods or compositions disclosed herein for use, the LNP composition is administered to the subject according to a dosing interval. In some embodiments, the dosing interval comprises a three-week cycle. In some embodiments, the LNP composition is administered to the subject once every three weeks for one or more cycles. In some embodiments, the dosing regimen comprises two cycles, three cycles, four cycles, five cycles, six cycles, seven cycles, eight cycles, or nine cycles.
[0079] In some embodiments, the LNP composition is administered at a dose of about 50 μg to about 1 mg, for example, about 100 μg to about 1 mg, about 200 μg to about 900 μg, about 300 μg to about 800 μg, about 400 μg to about 700 μg, about 500 μg to about 600 μg, about 200 μg to about 1 mg, about 300 μg to about 1 mg, about 400 μg to about 1 mg, about 500 μg to about 1 mg, about 600 μg to about 1 mg. μg to about 1 mg, about 700 μg to about 1 mg, about 800 μg to about 1 mg, about 900 μg to about 1 mg, about 100 μg to about 900 μg, about 100 μg to about 800 μg, about 100 μg to about 700 μg, about 100 μg to about 600 μg, about 100 μg to about 500 μg, about 100 μg to about 400 μg, about 100 μg to about 300 μg, or about 100 μg to about 200 μg. In some embodiments, the LNP composition is administered at a dose of about 100 μg to about 200 μg, about 200 μg to about 300 μg, about 300 μg to about 400 μg, about 400 μg to about 500 μg, about 500 μg to about 600 μg, about 600 μg to about 700 μg, about 700 μg to about 800 μg, about 800 μg to about 900 μg, or about 900 μg to about 1 mg.
[0080] In some embodiments, the LNP composition is administered at a dose of about 50 μg to about 75 μg (e.g., about 50 μg). In some embodiments, the LNP composition is administered at a dose of about 50 μg to about 150 μg (e.g., about 100 μg). In some embodiments, the LNP composition is administered at a dose of about 150 μg to about 250 μg (e.g., about 200 μg). In some embodiments, the LNP composition is administered at a dose of about 250 μg to about 350 μg (e.g., about 300 μg). In some embodiments, the LNP composition is administered at a dose of about 350 μg to about 450 μg (e.g., about 400 μg). In some embodiments, the LNP composition is administered at a dose of about 450 μg to about 550 μg (e.g., about 500 μg). In some embodiments, the LNP composition is administered at a dose of about 550 μg to about 650 μg (e.g., about 600 μg). In some embodiments, the LNP composition is administered at a dose of about 650 μg to about 750 μg (e.g., about 700 μg). In some embodiments, the LNP composition is administered at a dose of about 750 μg to about 850 μg (e.g., about 800 μg). In some embodiments, the LNP composition is administered at a dose of about 850 μg to about 950 μg (e.g., about 900 μg). In some embodiments, the LNP composition is administered at a dose of about 950 μg to about 1 mg (e.g., about 1 mg).
[0081] In some embodiments, the LNP composition is administered intramuscularly (IM).
[0082] In one embodiment of any of the methods or compositions disclosed herein for use, the subject is a mammal, such as a human.
[0083] Other features of any of the aforementioned LNP compositions or methods using the LNP compositions include one or more of the following enumerated embodiments. Those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only routine experiments. The following enumerated embodiments are intended to encompass such equivalents.
[0084] Other embodiments of the present disclosure
[0085] E1. A lipid nanoparticle (LNP) composition comprising a polynucleotide comprising mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0086] E2. A lipid nanoparticle composition for stimulating T effector cells, the composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides.
[0087] E3. A lipid nanoparticle composition for stimulating T effector cells, the composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides.
[0088] E4. An mRNA construct comprising a polynucleotide encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides.
[0089] E5. The LNP composition or mRNA construct of any one of embodiments E1-E4, wherein the IDO antigenic peptide comprises a fragment of a naturally occurring IDO molecule or a variant thereof.
[0090] E6. The LNP composition or mRNA construct of any one of embodiments E1-E5, wherein the IDO antigenic peptide is derived from IDO1 or IDO2.
[0091] E7. The LNP composition or mRNA construct of embodiment E6, wherein the IDO antigenic peptide is derived from IDO1.
[0092] E8. The LNP composition or mRNA construct of any one of embodiments E1-E7, wherein the IDO antigen peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 1.
[0093] E9. The LNP composition or mRNA construct of any one of embodiments E1-E8, wherein the polynucleotide encoding the IDO antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2 or an antigenic fragment thereof.
[0094] E10. The LNP composition or mRNA construct of any one of embodiments E1-E9, wherein the PD-L1 antigenic peptide comprises a fragment of a naturally occurring PD-L1 molecule or a variant thereof.
[0095] E11. The LNP composition or mRNA construct of any one of embodiments E1-E10, wherein the PD-L1 antigen peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 3.
[0096] E12. The LNP composition or mRNA construct of any one of embodiments E1-E11, wherein the polynucleotide encoding the PD-L1 antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 4 or an antigenic fragment thereof.
[0097] E13. The LNP composition or mRNA construct of any one of embodiments E1-E12, wherein the checkpoint cancer vaccine comprises two IDO antigen peptides and two PD-L1 antigen peptides.
[0098] E14. The LNP composition or mRNA construct of any one of embodiments E1-E12, wherein the checkpoint cancer vaccine comprises three IDO antigen peptides and three PD-L1 antigen peptides.
[0099] E15. The LNP composition or mRNA construct of any one of embodiments E1-E12, wherein the checkpoint cancer vaccine comprises four IDO antigen peptides and four PD-L1 antigen peptides.
[0100] E16. The LNP composition or mRNA construct of any one of embodiments E1-E15, wherein the checkpoint cancer vaccine comprises alternating IDO and PD-L1 antigenic peptides.
[0101] E17. The LNP composition or mRNA construct of embodiment E15 or E16, wherein the checkpoint cancer vaccine comprises (i) an IDO antigen peptide, (ii) a PD-L1 antigen peptide, (iii) an IDO antigen peptide, (iv) a PD-L1 antigen peptide, (v) an IDO antigen peptide, (vi) a PD-L1 antigen peptide, (vii) an IDO antigen peptide and (viii) a PD-L1 antigen peptide.
[0102] E18. The LNP composition or mRNA construct of any one of embodiments E15-E17, wherein the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the IDO amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof.
[0103] E19. The LNP composition or mRNA construct of any one of embodiments E16-E18, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 6 or an antigenic fragment thereof.
[0104] E20. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 300 or an antigenic fragment thereof.
[0105] E21. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 301 or an antigenic fragment thereof.
[0106] E22. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 302 or an antigenic fragment thereof.
[0107] E23. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence of SEQ ID NO: 300, the nucleotide sequence comprising from 5' to 3' end: a 5'UTR of SEQ ID NO: 56, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0108] E24. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence of SEQ ID NO: 301, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 272, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0109] E25. The LNP composition or mRNA construct of any one of embodiments E16-E19, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence of SEQ ID NO: 302, the nucleotide sequence comprising from 5' to 3' end: a 5'UTR of SEQ ID NO: 273, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0110] E26. The LNP composition or mRNA construct according to any one of the preceding embodiments, further comprising a polynucleotide encoding one or more auxiliary amino acid sequences.
[0111] E27. The LNP composition or mRNA construct of any one of the preceding embodiments, which results in:
[0112] (i) Stimulation of T effector cells;
[0113] (ii) cytotoxic T cell-mediated killing of suppressive immune cells and tumor cells overexpressing PD-L1 or IDO;
[0114] (iii) inducing anti-tumor immune responses; and / or
[0115] (iv) CD4+ and / or CD8+ T cells infiltrate tumor cells and kill tumor cells expressing IDO and / or PDL1.
[0116] E28. The LNP composition or mRNA construct of any of the preceding embodiments, which improves or delays cancer progression in a subject, e.g., as described herein.
[0117] E29. An LNP composition or mRNA construct as described in any of the preceding embodiments, wherein the polynucleotide comprising mRNA comprises at least one chemical modification, the mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0118] E30. The LNP composition or mRNA construct of embodiment E29, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
[0119] E31. The LNP composition or mRNA construct of embodiment E30, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.
[0120] E32. An LNP composition or mRNA construct as described in embodiment E31, wherein the chemical modification is N1-methylpseudouridine.
[0121] E33. The LNP composition or mRNA construct of any one of the preceding embodiments, wherein the mRNA in the lipid nanoparticle comprises fully modified N1-methylpseudouridine.
[0122] E34. An LNP composition as described in any of the preceding embodiments, wherein the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structural lipid; (iii) a non-cationic auxiliary lipid or phospholipid; and (iv) a PEG-lipid.
[0123] E35. The LNP composition of embodiment E34, wherein the ionizable lipid comprises an amino lipid.
[0124] E36. An LNP composition as described in embodiment E34 or E35, wherein the ionizable lipid comprises a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (Ic), Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d), Formula (II-e), Formula (II-f), Formula (II-g), Formula (II-h), or Formula (III).
[0125] E37. An LNP composition as described in any of embodiments E34-E36, wherein the ionizable lipid comprises Compound 18, Compound 25, Compound 301 or Compound 357.
[0126] E38. The LNP composition of embodiment E37, wherein the ionizable lipid comprises compound 25.
[0127] E39. An LNP composition as described in any of embodiments E34-E38, wherein the sterol or other structured lipid comprises cholesterol.
[0128] E40. The LNP composition of any one of embodiments E34-E39, wherein the non-cationic helper lipid or phospholipid comprises DSPC.
[0129] E41. The LNP composition of any one of embodiments E34-E40, wherein the PEG lipid comprises PEGDMG.
[0130] E42. An LNP composition as described in any of embodiments E34-E41, wherein the LNP comprises a molar ratio of about 20%-60% ionizable lipids: 5%-25% phospholipids: 25%-55% cholesterol; and 0.5%-15% PEG lipids.
[0131] E43. An LNP composition as described in embodiment E42, wherein the LNP comprises a molar ratio of about 48 mol% ionizable lipids: about 11 mol% phospholipids: about 38.5 mol% cholesterol; and about 2.5 mol% PEG lipids.
[0132] E44. The LNP composition of embodiment E43, wherein the LNP comprises a molar ratio of about 48 mol % of Compound 25: about 11 mol % of DSPC: about 38.5 mol % of cholesterol; and about 2.5 mol % of PEG DMG.
[0133] E45. The LNP composition or mRNA construct of any of the preceding embodiments, formulated for intramuscular, subcutaneous, intravenous, intranasal, intraocular, rectal or oral delivery.
[0134] E46. The LNP composition or mRNA construct according to any one of the preceding embodiments, further comprising a pharmaceutically acceptable carrier or excipient.
[0135] E47. A pharmaceutical composition comprising the LNP composition or mRNA construct according to any one of the preceding embodiments.
[0136] E48. A method for modulating, e.g., stimulating, an immune response in a subject, the method comprising administering to a subject in need thereof an effective amount of an LNP composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0137] E49. A method for stimulating T effector cells in a subject, the method comprising administering to the subject an effective amount of an LNP composition comprising a polynucleotide comprising mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0138] E50. A method for treating or preventing cancer or its symptoms, the method comprising administering to a subject in need thereof an effective amount of an LNP composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0139] E51. The method of embodiment E50, wherein the cancer is a locally advanced or metastatic solid tumor.
[0140] E52. The method of embodiment E50, wherein the cancer is melanoma.
[0141] E53. The method of embodiment E52, wherein the melanoma is cutaneous melanoma.
[0142] E54. A method as described in embodiment 34, wherein the cutaneous melanoma is 1L cutaneous melanoma stage IIIB+.
[0143] E55. The method of embodiment E54, wherein the cancer is NSCLC.
[0144] E56. A method as described in embodiment E55, wherein the NSCLC is 1LNSCLC.
[0145] E57. The method of embodiment E50, wherein the cancer is bladder cancer.
[0146] E58. The method of embodiment E57, wherein the bladder cancer is non-muscle invasive bladder cancer.
[0147] E59. The method of embodiment E50, wherein the cancer is head and neck cancer.
[0148] E60. The method of embodiment E59, wherein the head and neck cancer is head and neck squamous cell carcinoma.
[0149] E61. The method of embodiment E50, wherein the cancer is colorectal cancer.
[0150] E62. A method as described in embodiment E61, wherein the colorectal cancer is microsatellite stable colorectal cancer.
[0151] E63. The method of embodiment E50, wherein the cancer is basal cell carcinoma.
[0152] E64. The method of embodiment E50, wherein the cancer is breast cancer.
[0153] E65. The method of embodiment E64, wherein the breast cancer is triple-negative breast cancer.
[0154] E66. The method of any one of embodiments E48-E65, wherein the IDO antigenic peptide comprises a fragment of a naturally occurring IDO molecule or a variant thereof.
[0155] E67. The method of any one of embodiments E48-E66, wherein the IDO antigenic peptide is derived from IDO1 or IDO2.
[0156] E68. The method of embodiment E67, wherein the IDO antigenic peptide is derived from IDO1.
[0157] E69. The method of any one of embodiments E48-E68, wherein the IDO antigen peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 1.
[0158] E70. The method of any one of embodiments E48 to E69, wherein the polynucleotide encoding the IDO antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2 or an antigenic fragment thereof.
[0159] E71. The method of any one of embodiments E48-E70, wherein the PD-L1 antigenic peptide comprises a fragment of a naturally occurring PD-L1 molecule or a variant thereof.
[0160] E72. The method of any one of embodiments E48-E71, wherein the PD-L1 antigen peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:3.
[0161] E73. The method of any one of embodiments E48 to E72, wherein the polynucleotide encoding the PD-L1 antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 4 or an antigenic fragment thereof.
[0162] E74. The method of any one of embodiments E48-E73, wherein the checkpoint cancer vaccine comprises two IDO antigen peptides and two PD-L1 antigen peptides.
[0163] E75. The method of any one of embodiments E48-E73, wherein the checkpoint cancer vaccine comprises three IDO antigen peptides and three PD-L1 antigen peptides.
[0164] E76. The method of any one of embodiments E48-E73, wherein the checkpoint cancer vaccine comprises four IDO antigen peptides and four PD-L1 antigen peptides.
[0165] E77. The method of any one of embodiments E48-E76, wherein the checkpoint cancer vaccine comprises alternating IDO and PD-L1 antigenic peptides.
[0166] E78. A method as described in embodiment E76 or E77, wherein the checkpoint cancer vaccine comprises (i) an IDO antigen peptide, (ii) a PD-L1 antigen peptide, (iii) an IDO antigen peptide, (iv) a PD-L1 antigen peptide, (v) an IDO antigen peptide, (vi) a PD-L1 antigen peptide, (vii) an IDO antigen peptide and (viii) a PD-L1 antigen peptide.
[0167] E79. The method of any one of embodiments E76 to E78, wherein the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the IDO amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof.
[0168] E80. The method of any one of embodiments E77 to E79, wherein the polynucleotides encoding the alternating IDO and PD-L1 antigenic peptides comprise a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 6 or an antigenic fragment thereof.
[0169] E81. The method of any one of embodiments E77 to E80, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 300 or an antigenic fragment thereof.
[0170] E82. The method of any one of embodiments E77 to E80, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 301 or an antigenic fragment thereof.
[0171] E83. The method of any one of embodiments E77 to E80, wherein the polynucleotides encoding the alternating IDO and PD-L1 antigenic peptides comprise a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 302 or an antigenic fragment thereof.
[0172] E84. The method of any one of embodiments E77 to E80, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises the nucleotide sequence of SEQ ID NO: 300, the nucleotide sequence comprising from 5' to 3' end: a 5'UTR of SEQ ID NO: 56, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0173] E85. The method of any one of embodiments E77 to E80, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises the nucleotide sequence of SEQ ID NO: 301, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 272, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0174] E86. The method of any one of embodiments E77 to E80, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises the nucleotide sequence of SEQ ID NO: 302, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 273, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0175] E87. A method as described in any of the preceding embodiments, wherein the composition further comprises a polynucleotide encoding one or more auxiliary amino acid sequences.
[0176] E88. The method according to any one of the preceding embodiments, which results in:
[0177] (i) Stimulation of T effector cells;
[0178] (ii) cytotoxic T cell-mediated killing of suppressive immune cells and tumor cells overexpressing PD-L1 or IDO;
[0179] (iii) inducing anti-tumor immune responses; and / or
[0180] (iv) CD4+ and / or CD8+ T cells infiltrate tumor cells and kill tumor cells expressing IDO and / or PDL1.
[0181] E89. The method as described in any of the preceding embodiments, which improves or delays the progression of cancer in a subject, e.g., as described herein.
[0182] E90. A method as described in any of the preceding embodiments, wherein the polynucleotide comprising mRNA encoding a checkpoint cancer vaccine comprises at least one chemical modification, and the checkpoint cancer vaccine comprises one or more (e.g., 1, 2, 3, 4 or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
[0183] E91. A method as described in embodiment E90, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-l-methyl-1-deaza-pseudouridine, 2-thiol-l-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-l-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
[0184] E92. A method as described in embodiment E91, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.
[0185] E93. A method as described in embodiment E92, wherein the chemical modification is N1-methylpseudouridine.
[0186] E94. A method as described in any of the preceding embodiments, wherein the mRNA in the lipid nanoparticle comprises fully modified N1-methylpseudouridine.
[0187] E95. A method as described in any of the preceding embodiments, wherein the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structural lipid; (iii) a non-cationic auxiliary lipid or phospholipid; and (iv) a PEG-lipid.
[0188] E96. A method as described in embodiment E95, wherein the ionizable lipid comprises an amino lipid.
[0189] E97. A method as described in embodiments E95 or E96, wherein the ionizable lipid comprises a compound of any one of Formula (I), Formula (la), Formula (lb), Formula (Ic), Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d), Formula (II-e), Formula (II-f), Formula (II-g), Formula (II-h) or Formula (III).
[0190] E98. A method as described in any one of embodiments E95-E97, wherein the ionizable lipid comprises a compound of formula (I).
[0191] E99. A method as described in any one of embodiments E95-E98, wherein the ionizable lipid comprises Compound 18, Compound 25, Compound 301 or Compound 357.
[0192] E100. A method as described in embodiment E99, wherein the ionizable lipid comprises compound 25.
[0193] E101. The method of any one of embodiments E95-E100, wherein the sterol or other structured lipid comprises cholesterol.
[0194] E102. The method of any one of embodiments E95-E101, wherein the non-cationic helper lipid or phospholipid comprises DSPC.
[0195] E103. The method of any one of embodiments E95-E102, wherein the PEG lipid comprises PEG DMG.
[0196] E104. A method as described in any of embodiments E95-E103, wherein the LNP comprises a molar ratio of about 20%-60% ionizable lipid: 5%-25% phospholipid: 25%-55% cholesterol; and 0.5%-15% PEG lipid.
[0197] E105. A method as described in embodiment E104, wherein the LNP comprises a molar ratio of about 48 mol% ionizable lipid: about 11 mol% phospholipid: about 38.5 mol% cholesterol; and about 2.5 mol% PEG lipid.
[0198] E106. The method of embodiment E105, wherein the LNP comprises a molar ratio of about 48 mol% of Compound 25: about 11 mol% of DSPC: about 38.5 mol% of cholesterol; and about 2.5 mol% of PEG DMG.
[0199] E107. The method of any one of embodiments E48-E106, wherein the LNP composition is administered at a dose of 100 μg to about 1 mg.
[0200] E108. A method as described in embodiment E107, wherein the LNP composition is administered at a dose of 50 μg to 150 μg, 150 μg to 250 μg, 250 μg to 350 μg, 350 μg to 450 μg, 450 μg to 550 μg, 550 μg to 650 μg, 650 μg to 750 μg, 750 μg to 850 μg, 850 μg to 950 μg, or 950 μg to 1 mg.
[0201] E109. The method of embodiment E108, wherein the LNP composition is administered at a dose of 50 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg or 1 mg.
[0202] E110. The method of any one of embodiments E48-E109, wherein the LNP composition is administered intramuscularly.
[0203] E111. The method of any one of embodiments E48-E110, wherein the LNP composition is administered to the subject according to a dosing interval, e.g., as described herein.
[0204] E112. The method of embodiment E111, wherein the dosing interval is implemented within at least 1 week, 2 weeks, 3 weeks or 4 weeks.
[0205] E113. The method of embodiment E112, wherein the dosing interval comprises one cycle, eg, a 21 day or 3 week cycle.
[0206] E114. The method of embodiment E112, wherein the LNP composition is administered to the subject on day 1 of a 3-week cycle.
[0207] E115. The method of embodiment E114, wherein the LNP composition is administered for at least 2, 3, 4, 5, 6, 7, 8 or 9 cycles.
[0208] E116. The method of any one of embodiments E48-E115, wherein the method further comprises administering to the subject another therapeutic agent.
[0209] E117. The method of embodiment E116, wherein the additional therapeutic agent is a checkpoint inhibitor.
[0210] E118. The method of embodiment E117, wherein the check point inhibitor is selected from the group consisting of an anti-PD-1 agent and an anti-CTLA4 agent.
[0211] E119. The method of embodiment E118, wherein the checkpoint inhibitor comprises pembrolizumab.
[0212] E120. The method of E119, wherein pembrolizumab is administered to the subject according to a dosing interval, e.g., as described herein.
[0213] E121. The method of embodiment E121, wherein the dosing interval is implemented within at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks.
[0214] E122. The method of embodiment E121, wherein the dosing interval comprises one cycle, eg, a 6-week cycle.
[0215] E123. The method of embodiment E122, wherein the LNP composition is administered to the subject on day 1 of a 6-week cycle.
[0216] E124. The method of embodiment E123, wherein the LNP composition is administered for at least 2, 3, 4 or 5 cycles.
[0217] E125. The method of any one of embodiments E119-E124, wherein pembrolizumab is administered at a dose of about 400 mg. BRIEF DESCRIPTION OF THE DRAWINGS
[0218] Figure 1 Figure 2 is a graph comparing antigen-specific IFNγ ELISpot responses to mRNA-4359 in HLA-A*02:01 transgenic and wild-type mice in the context of PD-L1 restimulation.
[0219] Figure 2 Figure 2 is a graph comparing antigen-specific IFNγ ELISpot responses to mRNA-4359 in HLA-A*02:01 transgenic and wild-type mice in the context of IDO1 restimulation.
[0220] Figure 3 Graph depicting flow cytometric analysis of antigen-specific CD8+IFNγ+ T cell responses to mRNA-4359 in HLA-A*02:01 transgenic and wild-type mice.
[0221] Figure 4AGraph showing T cell responses after vaccination as measured by the number of INFγ spot forming units (SFU) normalized to 1 million PBMCs over time.
[0222] FIG. 4B to FIG. 4C A pair of heat maps showing IDO1 (4B) and PD-L1 (4C) responses in peripheral blood before and after vaccination.
[0223] FIG. 4D to FIG. 4E A pair of graphs showing the changes in IFNγ SFU / million PBMCs in IDO-specific cells (4D) and PD-L1-specific cells (4E).
[0224] Figure 5 Schematic illustration of the IS / ID model.
[0225] FIG. 6A to FIG. 6D is a series of graphs showing IFNγ SFU / million PBMCs in IDO1 complete responders (6A), IDO1 partial responders (6B), PD-L1 complete responders (6C), or PD-L1 partial responders (6D).
[0226] FIG. 7A to FIG. 7D is a series of graphs showing the first-order and full-order Sobol index for IDO1 complete responders (7A), IDO1 partial responders (7B), PD-L1 complete responders (7C), or PD-L1 partial responders (7D).
[0227] FIG. 8A to FIG. 8B A pair of graphs showing the predicted dose-parameter effect curves for peptide vaccines (8A) and mRNA vaccines (8B).
[0228] 9A to 9D is a series of graphs showing the expected steady-state peak and trough values for IDO1 complete responders (9A), IDO1 partial responders (9B), PD-L1 complete responders (9C), or PD-L1 partial responders (9D) at different doses.
[0229] FIG. 10A to FIG. 10C is a series of graphs showing dosing regimen simulations. DETAILED DESCRIPTION
[0230] Using the compositions and methods described herein, immune cells (e.g., T cells) can be primed to recognize tumor-associated antigens and / or activated, for example, to have cytotoxic properties. For example, T effector cells can be primed to mediate an anti-cancer response in a subject, thereby killing suppressive immune cells and tumor cells expressing IDO or PDL1. In one embodiment, the methods and compositions of the present invention can be used to induce or promote an anti-tumor immune response in a subject with cancer.
[0231] An exemplary method for treating cancer includes administering to a subject a checkpoint cancer vaccine comprising a polynucleotide, the polynucleotide comprising, for example, an mRNA sequence encoding one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides as described herein. Optionally, the vaccine may also include an mRNA sequence encoding an auxiliary amino acid sequence. Without wishing to be bound by theory, it is believed that in some embodiments, systemic PD-1 / PD-L1 blockade may further amplify the effect, thereby causing further immune activation and excellent disease control. Therefore, in one embodiment, a checkpoint inhibitor, such as an anti-PD1 antibody, an anti-CTLA4 antibody, or a combination thereof, may also be administered to the subject.
[0232] Therefore, disclosed herein is a lipid nanoparticle (LNP) composition comprising an mRNA encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides, and optionally one or more auxiliary amino acid sequences; and uses thereof. The LNP composition disclosed herein comprises an mRNA therapeutic encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides, and optionally one or more auxiliary amino acid sequences. In one aspect, the LNP composition disclosed herein can trigger T effector cells and / or stimulate an anti-tumor immune response in vivo. Also disclosed herein is a method for using a LNP composition comprising a checkpoint cancer vaccine to stimulate an immune response of IDO / PDL1-specific T cells to promote an immunostimulatory environment and / or promote killing of cancer cells expressing IDO / PDL1, thereby treating cancer (e.g., melanoma or NSCLC), wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides.
[0233] definition
[0234] Administration: As used herein, "administration" refers to a method of delivering a composition to a subject or patient. The method of administration can be selected to target delivery (e.g., specific delivery) to a particular area or system of the body. For example, administration can be parenteral (e.g., intramuscular).
[0235] Approximately, approximately: As used herein, the term "approximately" or "approximately" refers to a value similar to the reference value when applied to one or more values of interest. In certain embodiments, unless otherwise specified or clearly visible from the context, the term "approximately" or "approximately" refers to a range of values (except for the case where this numerical value will exceed 100% of the possible value) in either direction (greater than or less than) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in the reference value. For example, when used in the case of the amount of a given compound in the lipid component of LNP, "approximately" can mean + / - 5% of the listed value. For example, LNPs including lipid components with about 40% of a given compound can include 30%-50% of the compound. As another example, an LNP comprising a lipid component having about 50% of a given compound may comprise 45%-55% of the compound.
[0236] Chimeric molecule: As used herein, the term "chimeric molecule" refers to a molecule having at least two parts (e.g., IDO antigenic peptide and PD-L1 antigenic peptide) from different sources or origins. For example, the two parts may be derived from two different polypeptides. Each part may be a full-length polypeptide or a fragment thereof (e.g., an antigenic fragment). In certain embodiments, the two polypeptides are from two different organisms. In other embodiments, the two polypeptides are from the same organism. The two different polypeptides may both be naturally occurring or both synthetic, or one naturally occurring and the other synthetic. In some embodiments, the two parts of the chimeric molecule have different properties. The property may be a biological property, such as a function or activity in vitro, in vitro, or in vivo. The property may also be a physical or chemical property, such as binding affinity or specificity. In some embodiments, the two parts are covalently linked together. For example, the two parts may be directly linked, such as by a single covalent bond (e.g., a peptide bond), or indirectly linked, such as via a linker (e.g., a peptide linker). In some embodiments, a chimeric molecule is produced by joining two or more polynucleotides that originally encode separate polypeptides. In some embodiments, the two or more polynucleotides form a single open reading frame.
[0237] Conjugated: As used herein, the term "conjugated" when used with respect to two or more moieties means that the moieties are physically associated or linked to each other, either directly or via one or more other moieties acting as linkers, to form a sufficiently stable structure such that the moieties remain physically associated under the conditions (e.g., physiological conditions) under which the structure is used. In some embodiments, the two or more moieties may be conjugated by direct covalent chemical bonding. In other embodiments, the two or more moieties may be conjugated by ionic bonding or hydrogen bonding.
[0238] Contact: As used herein, the term "contact" means to establish a physical connection between two or more entities. For example, contacting a cell with an mRNA or lipid nanoparticle composition means that the cell shares a physical connection with the mRNA or lipid nanoparticle. Methods for contacting cells with external entities in vivo, in vitro, and ex vivo are well known in the biological field. In an exemplary embodiment of the present disclosure, the step of contacting mammalian cells with a composition (e.g., a nanoparticle or pharmaceutical composition of the present disclosure) is implemented in vivo. For example, a lipid nanoparticle composition may be contacted with a cell (e.g., a mammalian cell) that may be located in an organism (e.g., a mammal) by any suitable route of administration (e.g., parenteral administration to an organism, including intravenous, intramuscular, intradermal, and subcutaneous administration). For cells present in vitro, the composition may be contacted with the cell, for example, by adding the composition (e.g., lipid nanoparticle) to the culture medium of the cell, and may involve or result in transfection. In addition, the nanoparticle composition may contact more than one cell.
[0239] Delivery: As used herein, the term "delivery" means providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic agent to a subject may involve administering to the subject an LNP comprising the therapeutic and / or prophylactic agent (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes). Administering LNPs to a mammal or mammalian cell may involve contacting one or more cells with a lipid nanoparticle.
[0240] Encapsulation: As used herein, the term "encapsulation" means to enclose, surround, or package. In some embodiments, a compound, polynucleotide (e.g., mRNA), or other composition can be completely encapsulated, partially encapsulated, or substantially encapsulated. For example, in some embodiments, an mRNA of the present disclosure can be encapsulated in a lipid nanoparticle (e.g., a liposome).
[0241] Encapsulation efficiency: As used herein, "encapsulation efficiency" refers to the amount of therapeutic and / or prophylactic agent that becomes part of the LNP relative to the initial total amount of therapeutic and / or prophylactic agent used in the preparation of the LNP. For example, if 97 mg of the total 100 mg of therapeutic and / or prophylactic agent initially provided to the composition is encapsulated in the LNP, the encapsulation efficiency can be expressed as 97%. As used herein, "encapsulation" can refer to completely, substantially or partially enclosing, enclosing, surrounding or packaging.
[0242] Effective amount: As used herein, the "effective amount" of the term agent is an amount sufficient to achieve a beneficial or desired result (e.g., clinical result), and therefore, "effective amount" depends on the situation of its application. For example, in the case of the amount of target cell delivery enhancing lipids in the lipid composition (e.g., LNP) of the present disclosure, the effective amount of target cell delivery enhancing lipids is an amount sufficient to achieve a beneficial or desired result compared to a lipid composition (e.g., LNP) lacking target cell delivery enhancing lipids. Non-limiting examples of beneficial or desired results achieved by lipid compositions (e.g., LNPs) include increasing the percentage of transfected cells and / or increasing the expression level of proteins encoded by nucleic acids associated with lipid compositions (e.g., LNPs) / encapsulated by them. In the case of administering lipid nanoparticles containing target cell delivery enhancing lipids so that target cells in a subject take up an effective amount of lipid nanoparticles, the effective amount of LNPs containing target cell delivery enhancing lipids is an amount sufficient to achieve a beneficial or desired result compared to LNPs lacking target cell delivery enhancing lipids. Non-limiting examples of beneficial or desired results in subjects include increasing the percentage of transfected cells, increasing the expression level of a nucleic acid encoded by an LNP containing a target cell delivery enhancing lipid / encapsulated by it, and / or increasing the in vivo preventive or therapeutic effect of a nucleic acid or its encoded protein associated with / encapsulated by an LNP containing a target cell delivery enhancing lipid or compared to an LNP lacking a target cell delivery enhancing lipid. In some embodiments, when administered to a subject suffering from or susceptible to infection, disease, disorder, and / or illness, a therapeutically effective amount of LNP containing a target cell delivery enhancing lipid is sufficient to treat the infection, disease, disorder, and / or illness, improve its symptoms, diagnose, prevent, and / or delay its onset. In another embodiment, an effective amount of lipid nanoparticles is sufficient to express the desired protein in at least about 5%, 10%, 15%, 20%, 25% or more of the target cells. For example, an effective amount of LNPs containing target cell delivery enhancing lipids can be an amount that results in transfection of at least 5%, 10%, 15%, 20%, 25%, 30% or 35% of the target cells following a single intravenous injection.
[0243] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, 5' cap formation, and / or 3' end processing); (3) translation of the RNA into a polypeptide or protein; and (4) post-translational modification of the polypeptide or protein.
[0244] Ex vivo: As used herein, the term "ex vivo" refers to an event that occurs outside of an organism (eg, an animal, plant, or microorganism, or a cell or tissue thereof). An ex vivo event can occur in an environment that is minimally altered from the natural (eg, in vivo) environment.
[0245] Fragment: As used herein, "fragment" refers to a portion. For example, a protein fragment may include a polypeptide obtained by digestion of a full-length protein isolated from cultured cells or obtained via recombinant DNA technology.
[0246] GC-rich: As used herein, the term "GC-rich" refers to the nucleobase composition of a polynucleotide (e.g., mRNA) or any portion thereof (e.g., RNA element), comprising guanine (G) and / or cytosine (C) nucleobases or derivatives or analogs thereof, wherein the GC content is greater than about 50%. The term "GC-rich" refers to all or a portion of a polynucleotide, including but not limited to, a gene, a noncoding region, a 5'UTR, a 3'UTR, an open reading frame, an RNA element, a sequence motif, or any discrete sequence, fragment, or segment thereof, which comprises about 50% GC content. In some embodiments of the present disclosure, a GC-rich polynucleotide or any portion thereof comprises only guanine (G) and / or cytosine (C) nucleobases.
[0247] GC content: As used herein, the term "GC content" refers to the percentage of nucleobases in a polynucleotide (e.g., mRNA) or a portion thereof (e.g., an RNA element) that are guanine (G) and cytosine (C) nucleobases or derivatives or analogs thereof (from all possible nucleobases in DNA and in RNA, including adenine (A) and thymine (T) or uracil (U) and derivatives or analogs thereof). The term "GC content" refers to all or a portion of a polynucleotide, including (but not limited to) a gene, a noncoding region, a 5' or 3' UTR, an open reading frame, an RNA element, a sequence motif, or any discrete sequence, fragment, or segment thereof.
[0248] IDO antigenic peptide: As used herein, the term "IDO antigenic peptide" refers to full-length naturally occurring IDO (e.g., mammalian IDO, e.g., human IDO, e.g., associated with UniProt: P14902 and / or NCBI Gene ID: 3620; or associated with UniProt Q6ZQWO and / or NCBI Gene ID 169355), an IDO fragment (e.g., an antigenic fragment), or an IDO variant having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a naturally occurring wild-type IDO or a fragment thereof (e.g., an antigenic fragment). In some embodiments, the IDO molecule is an IDO gene product, e.g., an IDO polypeptide.
[0249] PD-L1 antigen peptide: As used herein, the term "PD-L1 antigen peptide" refers to a full-length naturally occurring PD-L1 (e.g., mammalian PD-L1, e.g., human PD-L1, e.g., associated with UniProt: Q9NZQ7; NCBI Gene ID: 29126), a PD-L1 fragment (e.g., an antigenic fragment), or a PD-L1 variant having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with a naturally occurring wild-type PD-L1 or a fragment thereof (e.g., an antigenic fragment). In some embodiments, the PD-L1 molecule is a PD-L1 gene product, e.g., a PD-L1 polypeptide.
[0250] Heterologous: As used herein, "heterologous" indicates a sequence (e.g., an amino acid sequence or a polynucleotide encoding an amino acid sequence) that is not normally found in a given polypeptide or polynucleotide. For example, an amino acid sequence corresponding to a domain or motif of one protein may be heterologous to a second protein.
[0251] Separated: As used herein, the term "separated" refers to a substance or entity that has been separated from at least some of the components associated with it (whether in nature or in an experimental setting). A separated substance may have different purity levels relative to the substance to which it is associated. A separated substance and / or entity may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more of the other components with which it was originally associated. In some embodiments, the separation agent is greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or greater than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components.
[0252] Liposome: As used herein, "liposome" means a structure that includes a lipid-containing membrane encapsulating an aqueous interior. A liposome can have one or more lipid membranes. Liposomes include unilamellar liposomes (also referred to in the art as unilamellar liposomes) and multilamellar liposomes (also referred to in the art as multilamellar liposomes).
[0253] Modified: As used herein, "modified" or "modification" refers to an altered state or change in composition or structure of a polynucleotide (e.g., mRNA). Polynucleotides can be modified in a variety of ways, including chemically, structurally, and / or functionally. For example, a polynucleotide can be structurally modified by incorporating one or more RNA elements, wherein the RNA elements comprise sequences and / or RNA secondary structures that provide one or more functions (e.g., translational regulatory activity). Thus, the polynucleotides of the present disclosure may comprise one or more modifications (e.g., may comprise one or more chemical, structural, or functional modifications, including any combination thereof).
[0254] Modified: As used herein, "modified" refers to an altered state or structure of a molecule of the present disclosure. A molecule can be modified in many ways, including chemically, structurally, and functionally. In one embodiment, an mRNA molecule of the present disclosure is modified by the introduction of non-natural nucleosides and / or nucleotides, such as when the modification is associated with natural ribonucleotides A, U, G, and C. Although different from the chemical structure of A, C, G, U ribonucleotides, atypical nucleotides (e.g., cap structures) are not considered "modified".
[0255] mRNA: As used herein, "mRNA" refers to messenger ribonucleic acid. mRNA may be naturally occurring or non-naturally occurring. For example, mRNA may include modified and / or non-naturally occurring components, such as one or more nucleobases, nucleosides, nucleotides, or linkers. mRNA may include a cap structure, a chain terminating nucleoside, a stem-loop, a poly A sequence, and / or a polyadenylation signal. mRNA may have a nucleotide sequence encoding a polypeptide. Translation of mRNA (e.g., in vivo translation of mRNA in mammalian cells) may produce a polypeptide. Traditionally, the basic components of an mRNA molecule include at least a coding region, a 5'-untranslated region (5'-UTR), a 3'UTR, a 5' cap, and a poly A sequence.
[0256] Nanoparticles: As used herein, "nanoparticles" refer to particles having any structural features with a scale less than about 1000nm, which exhibit novel properties compared to bulk samples of the same material. Conventionally, nanoparticles have any structural features with a scale less than about 500nm, less than about 200nm, or about 100nm. Also conventionally, nanoparticles have any structural features with a scale of about 50nm to about 500nm, about 50nm to about 200nm, or about 70 to about 120nm. In exemplary embodiments, nanoparticles are particles with one or more sizes of the order of magnitude of about 1-1000nm. In other exemplary embodiments, nanoparticles are particles with one or more sizes of the order of magnitude of about 10-500nm. In other exemplary embodiments, nanoparticles are particles with one or more sizes of the order of magnitude of about 50-200nm. The diameter of a spherical nanoparticle will be, for example, between about 50-100 nanometers or between 70-120 nanometers. Nanoparticles are most often presented as a unit in terms of their transport and properties. It should be noted that novel properties that distinguish nanoparticles from the corresponding bulk material typically emerge in the size range below 1000 nm or at about 100 nm in size, but nanoparticles can have larger sizes, such as for particles that are elliptical, tubular, etc. Although the sizes of most molecules will fit within the above overview, individual molecules are not typically referred to as nanoparticles.
[0257] Nucleic acid: As used herein, the term "nucleic acid" is used in its broadest sense and encompasses any compound and / or substance that includes a nucleotide polymer. These polymers are generally referred to as polynucleotides. Exemplary nucleic acids or polynucleotides disclosed herein include, but are not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), DNA-RNA hybrids, RNAi inducers, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, RNA that induces triple helix formation, threose nucleic acids (TNA), glycol nucleic acids (GNA), peptide nucleic acids (PNA), locked nucleic acids (LNA, including LNA with β-D-ribose configuration, α-LNA with α-L-ribose configuration (diastereomers of LNA), 2'-amino-LNA with 2'-amino functionalization, and 2'-amino-α-LNA with 2'-amino functionalization) or hybrids thereof.
[0258] Nucleic acid structure: As used herein, the term "nucleic acid structure" (interchangeably used with "polynucleotide structure") refers to the arrangement or organization of the atoms, chemical constituents, elements, motifs and / or sequences of connected nucleotides, or derivatives or analogs thereof, that constitute a nucleic acid (e.g., mRNA). The term also refers to the two-dimensional or three-dimensional state of a nucleic acid. Thus, the term "RNA structure" refers to the arrangement or organization of the atoms, chemical constituents, elements, motifs and / or sequences of connected nucleotides, or derivatives or analogs thereof, that constitute an RNA molecule (e.g., mRNA), and / or refers to the two-dimensional and / or three-dimensional state of an RNA molecule. Based on the increased organizational complexity, nucleic acid structure can be further divided into four organizational categories, referred to herein as "molecular structure," "primary structure," "secondary structure," and "tertiary structure."
[0259] Nucleobase: As used herein, the term "nucleobase" (or "nucleotide base" or "nitrogenous base") refers to a purine or pyrimidine heterocyclic compound found in nucleic acids, including any derivatives or analogs of natural purines and pyrimidines that impart improved properties (e.g., binding affinity, nuclease resistance, chemical stability) to nucleic acids or portions or segments thereof. Adenine, cytosine, guanine, thymine, and uracil are the nucleobases found primarily in natural nucleic acids. Other natural, non-natural, and / or synthetic nucleobases as known in the art and / or described herein may be incorporated into nucleic acids.
[0260] Nucleoside / Nucleotide: As used herein, the term "nucleoside" refers to a compound containing a sugar molecule (e.g., ribose in RNA or deoxyribose in DNA) covalently linked to a nucleobase (e.g., purine or pyrimidine) or a derivative or analog thereof (also referred to herein as a "nucleobase"), or a derivative or analog thereof, but lacking an internucleoside linking group (e.g., a phosphate group). As used herein, the term "nucleotide" refers to a nucleoside covalently bonded to an internucleoside linking group (e.g., a phosphate group) or any derivative, analog, or modification thereof, which confers improved chemical and / or functional properties (e.g., binding affinity, nuclease resistance, chemical stability) to a nucleic acid or a portion or segment thereof.
[0261] Open reading frame: As used herein, the term "open reading frame" abbreviated as "ORF" refers to a segment or region of an mRNA molecule that encodes a polypeptide. An ORF comprises a stretch of consecutive non-overlapping in-frame codons, starting with a start codon and ending with a stop codon, and is translated by ribosomes.
[0262] Patient: As used herein, "patient" refers to a subject who may seek or need treatment, requires treatment, is receiving treatment, will receive treatment, or is under the care of a trained professional for a particular disease or disorder. In certain embodiments, the patient is a human patient. In some embodiments, the patient is a patient with an autoimmune disease, such as described herein.
[0263] Pharmaceutically acceptable: The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and are commensurate with a reasonable benefit / risk ratio.
[0264] Pharmaceutically acceptable excipients: As used herein, the phrase "pharmaceutically acceptable excipients" refers to any ingredient other than the compounds described herein (e.g., a vehicle capable of suspending or dissolving the active compound) and which has substantially non-toxic and non-inflammatory properties to the patient. Excipients may include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colorants), softeners, emulsifiers, fillers (diluents), film formers or coatings, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and hydration water. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium hydrogen phosphate, calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0265] Pharmaceutically acceptable salts: As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form (e.g., by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkaline or organic salts of acidic residues such as carboxylic acids; etc. Representative acid addition salts include acetate, acetic acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like; and non-toxic ammonium, quaternary ammonium and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts of the present disclosure include conventional non-toxic salts of the parent compound formed, for example, by non-toxic inorganic or organic acids. Pharmaceutically acceptable salts of the present disclosure can be synthesized by conventional chemical methods from a parent compound containing a basic or acidic moiety. Typically, such salts can be prepared by reacting the free acid or base form of the compound with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two; typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, PH Stahl and CG Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.
[0266] Polypeptide: As used herein, the term "polypeptide" or "polypeptide of interest" refers to a polymer of amino acid residues, typically joined by peptide bonds, which may be produced naturally (eg, isolated or purified) or synthetically.
[0267] RNA: As used herein, "RNA" refers to ribonucleic acid that may be naturally or non-naturally occurring. For example, RNA may include modified and / or non-naturally occurring components, such as one or more nucleobases, nucleosides, nucleotides, or linkers. RNA may include a cap structure, a chain-terminating nucleoside, a stem-loop, a poly A sequence, and / or a polyadenylation signal. RNA may have a nucleotide sequence encoding a polypeptide of interest. For example, RNA may be a messenger RNA (mRNA). Translation of an mRNA encoding a specific polypeptide (e.g., in vivo translation of an mRNA in a mammalian cell) may produce an encoded polypeptide. RNA may be selected from a non-limiting group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, long non-coding RNA (lncRNA), and mixtures thereof.
[0268] RNA element: As used herein, the term "RNA element" refers to a portion, fragment or segment of an RNA molecule that provides a biological function and / or has a biological activity (e.g., translational regulatory activity). Modification of a polynucleotide by incorporating one or more RNA elements (e.g., those described herein) provides one or more desirable functional properties for the modified polynucleotide. The RNA elements as described herein may be naturally occurring, non-naturally occurring, synthetic, engineered, or any combination thereof. For example, naturally occurring RNA elements that provide regulatory activity include elements found throughout transcripts of viruses, prokaryotes, and eukaryotic organisms (e.g., humans). RNA elements, particularly eukaryotic mRNAs and translated viral RNAs, have been shown to be involved in mediating many functions in cells. Exemplary natural RNA elements include, but are not limited to, translation initiation elements (e.g., internal ribosome entry site (IRES), see Kieft et al., (2001) RNA 7(2):194-206), translation enhancer elements (e.g., APP mRNA translation enhancer element, see Rogers et al., (1999) J Biol Chem 274(10):6421-6431), mRNA stability elements (e.g., AU-rich elements (ARE), see Garneau et al., (2007) Nat Rev Mol Cell Biol 8(2):113-126), translation repression elements (see, e.g., Blumer et al., (2002) Mech Dev 110(1-2):97-112), protein-binding RNA elements (e.g., iron response elements, see Selezneva et al., (2013) J Mol Biol 425(18):3301-3310), cytoplasmic polyadenylation elements (Villalba et al., (2011) Curr Opin Genet Dev 21(4):452-457), and catalytic RNA elements (e.g., ribozymes, see Scott et al., (2009) Biochim Biophys Acta 1789(9-10):634-641).
[0269] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting a full or nearly full degree or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, are completed and / or proceed to completion or to achieve or avoid an absolute result. Thus, the term "substantially" is used herein to reflect the potential imperfections inherent in many biological and chemical phenomena.
[0270] Suffering from: An individual who is "suffering from" a disease, disorder, and / or condition has been diagnosed with or exhibits one or more symptoms of the disease, disorder, and / or condition.
[0271] Therapeutic agent: The term "therapeutic agent" refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and / or prophylactic effect and / or elicits a desired biological and / or pharmacological effect.
[0272] Transfection: As used herein, the term "transfection" refers to a process by which a substance (eg, a polynucleotide, eg, mRNA) is introduced into a cell.
[0273] Subject: As used herein, the term "subject" refers to any organism to which the disclosed compositions may be administered, for example, for experimental, diagnostic, preventive and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants. In some embodiments, the subject may be a patient.
[0274] Treat: As used herein, the term "treat" refers to partially or completely alleviating, ameliorating, improving, relieving, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or characteristics of a particular infection, disease, condition, and / or disorder. For example, "treating" cancer may refer to inhibiting the survival, growth, and / or spread of a tumor. Treatment may be administered to subjects who do not show signs of a disease, condition, and / or disorder and / or to subjects who show only early signs of a disease, condition, and / or disorder, thereby reducing the risk of developing pathologies associated with the disease, condition, and / or disorder.
[0275] Prevention: As used herein, the term "prevention" refers to the partial or complete inhibition of the onset of one or more symptoms or characteristics of a particular infection, disease, disorder, and / or condition.
[0276] Unmodified: As used herein, "unmodified" refers to any substance, compound, or molecule prior to being altered in any way. Unmodified can (but not always) refer to the wild-type or native form of a biomolecule. A molecule can undergo a series of modifications, whereby each modified molecule can serve as an "unmodified" starting molecule for subsequent modifications.
[0277] Variant: As used herein, the term "variant" refers to a molecule that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the activity of the wild-type molecule, e.g., as measured by an art-recognized assay.
[0278] IDO antigen peptide
[0279] Indoleamine-pyrrole 2,3-dioxygenase (IDO) is an intracellular monomeric heme-containing enzyme that controls the breakdown of tryptophan in the kynurenine pathway (Cemil B and Sarisozen C (2017) Journal of Oncological Sciences 3:2, pp. 52-56). IDO has two isoforms, IDO1 and IDO2, which convert tryptophan to kynurenine at different enzymatic rates. IDO2 is narrowly expressed and IDO1 is more widely expressed, for example in endothelial cells, antigen presenting cells, fibroblasts, macrophages, and dendritic cells.
[0280] In one aspect, the present disclosure provides an LNP composition comprising, for example, a polynucleotide encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises one or more (e.g., 1, 2, 3, 4 or more) IDO antigenic peptides (e.g., derived from IDO1 or IDO2), for example, as described herein.
[0281] In one embodiment, the IDO antigenic peptide is derived from IDO1. In one embodiment, the one or more IDO antigenic peptides comprise a naturally occurring IDO1 molecule, a fragment (e.g., an antigenic fragment) of a naturally occurring IDO1 molecule, or a variant thereof. In one embodiment, the IDO antigenic peptide comprises a variant (e.g., an IDO1 variant) of a naturally occurring IDO1 molecule or a fragment thereof. In one embodiment, a LNP composition comprising a polynucleotide encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) IDO1 antigenic peptides and one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigenic peptides may be administered alone or in combination with another agent.
[0282] In one aspect, the LNP compositions disclosed herein comprise polynucleotides encoding checkpoint cancer vaccines comprising one or more (e.g., 1, 2, 3, 4 or more) IDO1 antigenic peptides. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with an IDO amino acid sequence (e.g., SEQ ID NO: 1) or an antigenic fragment thereof provided in Table 1A. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence of an IDO amino acid sequence (e.g., SEQ ID NO: 1) provided in Table 1A or an antigenic fragment thereof. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence of SEQ ID NO: 1 or an antigenic fragment thereof. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence of SEQ ID NO: 1 or an antigenic fragment thereof. In one embodiment, the IDO antigenic peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 1 or an antigenic fragment thereof. In one embodiment, the IDO antigenic peptide comprises SEQ ID NO: 1 or an antigenic fragment thereof.
[0283] In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) IDO1 antigenic peptides comprises a nucleotide sequence (e.g., a codon-optimized nucleotide sequence) that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) IDO1 antigenic peptides comprises a nucleotide sequence (e.g., a codon-optimized nucleotide sequence) of SEQ ID NO: 2 or an antigenic fragment thereof.
[0284] In one embodiment, a polynucleotide (e.g., mRNA) encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO1 antigenic peptides further comprises one or more elements, such as a 5'UTR and / or a 3'UTR. In one embodiment, the 5'UTR and / or 3'UTR comprises one or more microRNA (mIR) binding sites, such as those disclosed herein. Exemplary 5'UTRs and 3'UTRs are disclosed in the section entitled "5'UTR and 3'UTR" herein.
[0285] PD-L1 molecule
[0286] PD-L1 (also known as programmed death ligand 1, CD274, B7-H1) is a membrane-anchored protein that is expressed on hematopoietic cells, including antigen presenting cells, such as dendritic cells and macrophages. PD-L1 is also expressed on activated T cells, B cells and monocytes, as well as peripheral non-hematopoietic tissues, including liver, heart, skeletal muscle, placenta, lungs and kidneys (Dai S et al. (2014) Cell Immunol 290, 72-79). PD-L1 binds to its cognate receptor PD-1, which is a co-inhibitory transmembrane receptor expressed on T cells, B cells, natural killer cells and thymocytes. The engagement of PD-1 with PD-L1 can inhibit T cell receptor (TCR) signal transduction via the recruitment of regulatory phosphatases, which leads to a reduction in IL2 production and glucose metabolism. Sustained interaction of PD-1 and PD-L1 can induce T cell anergy or convert naive cells into induced regulatory T cells (iTregs). The PD-L1 / PD-1 pathway has important functions in immune regulation (e.g., inhibiting T cell proliferation, cytotoxic activity, and cytokine production) and promotes the development and function of Tregs.
[0287] In one aspect, the present disclosure provides an LNP composition comprising, for example, a polynucleotide encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides, e.g., as described herein.
[0288] In one embodiment, the one or more PD-L1 antigen peptides include naturally occurring PD-L1 molecules, fragments of naturally occurring PD-L1 molecules (e.g., antigen fragments) or variants thereof. In one embodiment, the PD-L1 antigen peptides include variants of naturally occurring PD-L1 molecules (e.g., PD-L1 variants) or fragments thereof. In one embodiment, an LNP composition comprising a polynucleotide encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides may be administered alone or in combination with another agent.
[0289] In one aspect, the LNP compositions disclosed herein comprise polynucleotides encoding checkpoint cancer vaccines comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with the IDO amino acid sequence (e.g., SEQ ID NO: 3) or an antigenic fragment thereof provided in Table 1A. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence of the PD-L1 amino acid sequence (e.g., SEQ ID NO: 3) provided in Table 1A or an antigenic fragment thereof. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence of SEQ ID NO: 3 or an antigenic fragment thereof. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence of SEQ ID NO: 3 or an antigenic fragment thereof. In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 3 or an antigenic fragment thereof. In one embodiment, the PD-L1 antigen peptide comprises SEQ ID NO: 3 or an antigenic fragment thereof.
[0290] In one embodiment, the PD-L1 antigen peptide comprises an amino acid sequence of a leader sequence and / or an affinity tag (e.g., a leader sequence described herein and / or an affinity tag described herein). In one embodiment, the PD-L1 antigen peptide does not comprise an amino acid sequence of a leader sequence and / or an affinity tag (e.g., a leader sequence described herein and / or an affinity tag described herein).
[0291] In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides comprises a nucleotide sequence (e.g., a codon-optimized nucleotide sequence) that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 4 or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides comprises a nucleotide sequence (e.g., a codon-optimized nucleotide sequence) of SEQ ID NO: 4 or an antigenic fragment thereof.
[0292] In one embodiment, the polynucleotide (e.g., mRNA) encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides comprises a nucleotide sequence encoding a leader sequence and / or an affinity tag (e.g., a leader sequence described herein and / or an affinity tag described herein). In one embodiment, the polynucleotide (e.g., mRNA) encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides does not comprise a nucleotide sequence encoding a leader sequence and / or an affinity tag (e.g., a leader sequence described herein and / or an affinity tag described herein).
[0293] In one embodiment, the polynucleotide (e.g., mRNA) encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides further comprises one or more elements, such as 5'UTR and / or 3'UTR. In one embodiment, the 5'UTR and / or 3'UTR comprises one or more microRNA (mIR) binding sites, such as those disclosed herein. Exemplary 5'UTRs and 3'UTRs are disclosed in the section entitled "5'UTR and 3'UTR" herein.
[0294] Exemplary Checkpoint Cancer Vaccines
[0295] Exemplary checkpoint cancer vaccines include, but are not limited to, those containing one or more (e.g., 1, 2, 3, 4, or more) IDO antigenic peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigenic peptides. In one embodiment, the checkpoint cancer vaccine comprises alternating IDO and PD-L1 antigenic peptides.
[0296] In one embodiment, the checkpoint cancer vaccine comprises one IDO antigen peptide and one PD-L1 antigen peptide. In one embodiment, the checkpoint cancer vaccine comprises two IDO antigen peptides and two PD-L1 antigen peptides. In one embodiment, the checkpoint cancer vaccine comprises three IDO antigen peptides and three PD-L1 antigen peptides. In one embodiment, the checkpoint cancer vaccine comprises four IDO antigen peptides and four PD-L1 antigen peptides. In some embodiments, the four IDO and four PD-L1 antigen peptides are arranged in an alternating manner. Therefore, in one embodiment, the checkpoint cancer vaccine comprises (i) IDO antigen peptide, (ii) PD-L1 antigen peptide, (iii) IDO antigen peptide, (iv) PD-L1 antigen peptide, (v) IDO antigen peptide, (vi) PD-L1 antigen peptide, (vii) IDO antigen peptide and (viii) PD-L1 antigen peptide.
[0297] In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an IDO amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof. In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence provided in Table 1A (e.g., SEQ ID NO: 5) or an antigenic fragment thereof. In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence of SEQ ID NO: 5 or an antigenic fragment thereof.
[0298] In one embodiment, the alternating IDO and PD-L1 antigenic peptides comprise the amino acid sequence of a leader sequence and / or an affinity tag. In one embodiment, the alternating IDO and PD-L1 antigenic peptides do not comprise the amino acid sequence of a leader sequence and / or an affinity tag.
[0299] In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence of SEQ ID NO: 6, 300, 301 or 302, or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising alternating IDO and PD-L1 antigenic peptides (e.g., mRNA) comprises a nucleotide sequence of SEQ ID NO: 6, 300, 301 or 302, or an antigenic fragment thereof. In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprising alternating IDO and PD-L1 antigenic peptides comprises a codon-optimized nucleotide sequence.
[0300] In some embodiments, the polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises the nucleotide sequence of SEQ ID NO: 300, which from 5' to 3' end consists of: a 5'UTR of SEQ ID NO: 56, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0301] In some embodiments, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises, from the 5' to the 3' end,
[0302] (i) a 5' cap, such as provided herein, e.g., cap C1;
[0303] (ii) a 5'UTR, such as a sequence provided herein, such as SEQ ID NO:56;
[0304] (iii) an open reading frame encoding alternating IDO and PD-L1 antigen peptides, such as a sequence-optimized nucleic acid sequence encoding alternating IDO and PD-L1 antigen peptides as shown in SEQ ID NO: 6;
[0305] (iv) at least one stop codon (if not present at the 5' end of the 3'UTR);
[0306] (v) a 3'UTR, such as a sequence provided herein, such as SEQ ID NO: 108; and
[0307] (vi) a poly A tail as provided herein (eg, SEQ ID NO: 502).
[0308] In some embodiments, the polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises the nucleotide sequence of SEQ ID NO: 301, which from 5' to 3' end consists of: a 5'UTR of SEQ ID NO: 272, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0309] In some embodiments, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises, from the 5' to the 3' end,
[0310] (i) a 5' cap, such as provided herein, e.g., cap C1;
[0311] (ii) a 5'UTR, such as a sequence provided herein, such as SEQ ID NO: 272;
[0312] (iii) an open reading frame encoding alternating IDO and PD-L1 antigen peptides, such as a sequence-optimized nucleic acid sequence encoding alternating IDO and PD-L1 antigen peptides as shown in SEQ ID NO: 6;
[0313] (iv) at least one stop codon (if not present at the 5' end of the 3'UTR);
[0314] (v) a 3'UTR, such as a sequence provided herein, such as SEQ ID NO: 108; and
[0315] (vi) a poly A tail as provided herein (eg, SEQ ID NO: 502).
[0316] In some embodiments, a polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises a nucleotide sequence of SEQ ID NO: 302, which from 5' to 3' end consists of: a 5'UTR of SEQ ID NO: 273, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0317] In some embodiments, the polynucleotide encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides comprises, from the 5' to the 3' end,
[0318] (i) a 5' cap, such as provided herein, e.g., cap C1;
[0319] (ii) a 5'UTR, such as a sequence provided herein, such as SEQ ID NO: 273;
[0320] (iii) an open reading frame encoding alternating IDO and PD-L1 antigen peptides, such as a sequence-optimized nucleic acid sequence encoding alternating IDO and PD-L1 antigen peptides as shown in SEQ ID NO: 6;
[0321] (iv) at least one stop codon (if not present at the 5' end of the 3'UTR);
[0322] (v) a 3'UTR, such as a sequence provided herein, such as SEQ ID NO: 108; and
[0323] (vi) a poly A tail as provided herein (eg, SEQ ID NO: 502).
[0324] In one embodiment, the polynucleotide encoding the checkpoint cancer vaccine comprises the nucleotide sequence of variant 1, variant 2, or variant 3 as set forth in Table 2A.
[0325] In one aspect, the LNP compositions disclosed herein include polynucleotides encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine including, for example, one or more IDO antigen peptides and one or more PD-L1 antigen peptides as described herein. In one embodiment, the checkpoint cancer vaccine includes a half-life extender, such as a protein (or fragment thereof) that is bound to a serum protein (e.g., albumin, IgG, FcRn, or transferrin). In one embodiment, the half-life extender is an immunoglobulin Fc region or a variant thereof, such as IgG1Fc.
[0326] In one embodiment, the checkpoint cancer vaccine further comprises a targeting moiety. In one embodiment, the targeting moiety comprises an antibody molecule (e.g., Fab or scFv), a receptor molecule (e.g., a receptor, a receptor fragment, or a functional variant thereof), a ligand molecule (e.g., a ligand, a ligand fragment, or a functional variant thereof), or a combination thereof.
[0327] Table 1A: Exemplary IDO and PD-L1 antigen peptide sequences
[0328]
[0329]
[0330] In some embodiments, a polynucleotide of the present disclosure (e.g., a polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more IDO antigenic peptides and one or more PD-L1 antigenic peptides) comprises (1) a 5' cap, e.g., as disclosed herein, e.g., as provided in Table 2A or as described herein, (2) a 5' UTR, e.g., as provided in Table 2A, (3) a nucleotide sequence ORF provided in Table 2A, e.g., SEQ ID NO: 2 or 5, (4) a stop codon, (5) a 3' UTR, e.g., as provided in Table 2A, and (6) a tail (e.g., a poly A tail), e.g., as disclosed herein, e.g., a poly A tail of about 100 residues (e.g., SEQ ID NO: 502).
[0331] In some embodiments, the polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides comprises the nucleotide sequence of SEQ ID NO: 300, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 56, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0332] In some embodiments, the polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides comprises the nucleotide sequence of SEQ ID NO: 301, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 272, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0333] In some embodiments, the polynucleotide comprising an mRNA nucleotide sequence encoding a checkpoint cancer vaccine comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides comprises the nucleotide sequence of SEQ ID NO: 302, which comprises from 5' to 3' end: a 5'UTR of SEQ ID NO: 273, an ORF sequence of SEQ ID NO: 6, and a 3'UTR of SEQ ID NO: 108.
[0334] In some embodiments, all 5'UTR, ORF and / or 3'UTR sequences include the modifications set forth in Table 2A. In some embodiments, one, both or all of the 5'UTR, ORF and / or 3'UTR sequences do not include the modifications set forth in Table 2A. In some embodiments, the 5'UTR set forth in Table 2A further comprises a first nucleotide that is "A" or "G".
[0335]
[0336]
[0337]
[0338] LNPs for Therapeutics
[0339] In particular, a LNP composition is disclosed herein, comprising a polynucleotide encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises one or more IDO antigen peptides and one or more PD-L1 antigen peptides, and the LNP composition can be administered alone or in combination with another agent (e.g., standard of care therapy). In one embodiment, the other agent is a polypeptide, such as a protein, a fusion protein, a soluble protein, or an antibody (e.g., an antibody fragment, Fab, scFv, a single domain Ab, a humanized antibody, a bispecific antibody, and / or a multispecific antibody). In one embodiment, the LNP composition and the other agent are in the same composition or in a separate composition. In one embodiment, the LNP composition and the other agent are administered substantially simultaneously or sequentially.
[0340] Lipid content of LNP
[0341] As described above, in terms of lipids, the LNPs disclosed herein comprise (i) ionizable lipids; (ii) sterols or other structural lipids; (iii) non-cationic auxiliary lipids or phospholipids; (iv) PEG lipids. These lipid classes are described in more detail below.
[0342] Ionizable lipids
[0343] Lipid nanoparticles of the present disclosure include one or more ionizable lipids. In certain embodiments, ionizable lipids of the present disclosure include central amine moieties and at least one biodegradable group. The ionizable lipids described herein can be advantageously used in lipid nanoparticles of the present disclosure for delivering nucleic acid molecules to mammalian cells or organs. The structure of ionizable lipids shown below includes prefix I, to distinguish it from other lipids of the present invention.
[0344] In some aspects, the present disclosure relates to an ionizable amino lipid compound of formula (I):
[0345] or an N-oxide thereof, or a salt or isomer thereof,
[0346] Where R' a For R' 分支 ;in
[0347] R' 分支 for: in Indicates a connection point;
[0348] Where R aα , R aβ , R aγ and R aδ Each independently selected from H, C 2-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0349] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0350] C 2-14 A group consisting of alkenyl groups;
[0351] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0352] in represents a connection point;
[0353] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0354] Each R 5 Independently selected from C 1-3 alkyl,
[0355] C 2-3 A group consisting of an alkenyl group and H;
[0356] Each R 6 Independently selected from C 1-3 alkyl,
[0357] C 2-3 A group consisting of an alkenyl group and H;
[0358] M and M' are each independently selected from -C(O)O- and
[0359] -OC(O)-group;
[0360] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0361] l is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0362] m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0363] In some embodiments of the compound of formula (I), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aα , R aβ , R aγ and R aδ Each is H; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 ) n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0364] In some embodiments of the compound of formula (I), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aα , R aβ , R aγ and R aδ Each is H; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 ) n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 3; and m is 7.
[0365] In some embodiments of the compound of formula (I), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aα C 2-12 Alkyl; R aβ , R aγ and R aδ Each is H; R 2 and R 3 Each is C 1-14 Alkyl; R 4 for R 10 NH(C 1-6 alkyl); n2 is 2; R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0366] In some embodiments of the compound of formula (I), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aα , R aβ and R aδ Each is H; R aγ C 2-12 Alkyl; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 )n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0367] In some embodiments, the compound of formula (I) is selected from:
[0368]
[0369] In some embodiments, the compound of formula (I) is:
[0370] In some embodiments, the compound of formula (I) is:
[0371] In some embodiments, the compound of formula (I) is:
[0372] In some embodiments, the compound of formula (I) is:
[0373]
[0374] In some aspects, the present disclosure relates to a compound of formula (Ia):
[0375] or an N-oxide thereof, or a salt or isomer thereof,
[0376] Where R' a For R' 分支 ;in
[0377] R' 分支 for: in Indicates a connection point;
[0378] Where R aβ , R aγ and R aδ Each independently selected from H, C 2-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0379] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0380] C 2-14 A group consisting of alkenyl groups;
[0381] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0382] in represents a connection point;
[0383] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0384] Each R 5 Independently selected from C 1-3 alkyl,
[0385] C 2-3 A group consisting of an alkenyl group and H;
[0386] Each R 6 Independently selected from C 1-3 alkyl,
[0387] C 2-3 A group consisting of an alkenyl group and H;
[0388] M and M' are each independently selected from -C(O)O- and
[0389] -OC(O)-group;
[0390] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0391] l is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0392] m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0393] In some aspects, the present disclosure relates to a compound of formula (Ib):
[0394] or an N-oxide thereof, or a salt or isomer thereof,
[0395] Where R' a For R' 分支 ;in
[0396] R' 分支 for: in Indicates a connection point;
[0397] Where R aα , R aβ , R aγ and R aδ Each independently selected from H, C 2-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0398] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0399] C 2-14 A group consisting of alkenyl groups;
[0400] R 4 For -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5;
[0401] Each R 5 Independently selected from C 1-3 alkyl,
[0402] C 2-3 A group consisting of an alkenyl group and H;
[0403] Each R 6 Independently selected from C 1-3 alkyl,
[0404] C 2-3 A group consisting of an alkenyl group and H;
[0405] M and M' are each independently selected from -C(O)O- and
[0406] -OC(O)-group;
[0407] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0408] l is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0409] m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0410] In some embodiments of Formula (I) or (Ib), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aβ , R aγ and Raδ Each is H; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 ) n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0411] In some embodiments of Formula (I) or (Ib), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aβ , R aγ and R aδ Each is H; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 ) n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 3; and m is 7.
[0412] In some embodiments of Formula (I) or (Ib), R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aβ and R aδ Each is H; R aγ C 2-12 Alkyl; R 2 and R 3 Each is C 1-14 Alkyl; R 4 For -(CH 2 ) n OH; n is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0413] In some aspects, the present disclosure relates to a compound of formula (Ic):
[0414] or an N-oxide thereof, or a salt or isomer thereof,
[0415] Where R' a For R' 分支 ;in
[0416] R' 分支 for: in Indicates a connection point;
[0417] Where R aα , R aβ , R aγ and R aδ Each independently selected from H, C 2-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0418] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0419] C 2-14 A group consisting of alkenyl groups;
[0420] R 4 for
[0421] in Indicates a connection point;
[0422] in
[0423] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0424] Each R 5 Independently selected from C 1-3 alkyl,
[0425] C 2-3 A group consisting of an alkenyl group and H;
[0426] Each R 6 Independently selected from C 1-3 alkyl,
[0427] C 2-3 A group consisting of an alkenyl group and H;
[0428] M and M' are each independently selected from -C(O)O- and
[0429] -OC(O)-group;
[0430] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0431] l is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0432] m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0433] In some embodiments, R' a For R' 分支 ; R' 分支 for Indicates the connection point; R aβ , R a γ and R aδ Each is H; R aα C 2-12 Alkyl; R 2 and R 3 Each is C 1-14 Alkyl; R 4 for Indicates the connection point; R 10 NH(C 1-6 alkyl); n2 is 2; each R 5 is H; each R 6 is H; M and M' are each -C(O)O-; R' is C 1-12 alkyl; l is 5; and m is 7.
[0434] In some embodiments, the compound of formula (Ic) is:
[0435]
[0436] In some aspects, the present disclosure relates to a compound of formula (II):
[0437] or an N-oxide thereof, or a salt or isomer thereof,
[0438] Where R' a For R' 分支 or R' 环状 ;in
[0439] R' 分支 for: And R' 环状 for: and
[0440] R' b for:
[0441] in Indicates a connection point;
[0442] R aγ and R aδ Each independently selected from H, C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups, wherein R aγ and R aδ At least one of which is selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0443] R bγ and R bδ Each independently selected from H, C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups, wherein R bγ and R bδ At least one of which is selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0444] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0445] C 2-14 A group consisting of alkenyl groups;
[0446] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0447] in represents a connection point;
[0448] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0449] Each R' is independently C 1-12 Alkyl or C 2-12 alkenyl;
[0450] Y a C 3-6 Carbon ring;
[0451] R*”a Choose from C 1-15 Alkyl and C 2-15 alkenyl; and
[0452] s is 2 or 3;
[0453] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0454] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0455] In some aspects, the present disclosure relates to compounds of formula (II-a):
[0456] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0457] R' 分支 for: And R' b for:
[0458] in Indicates a connection point;
[0459] R aγ and R aδ Each independently selected from H, C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups, wherein R aγ and R aδ At least one of which is selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0460] R bγ and R bδ Each independently selected from H, C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups, wherein R bγ and R bδ At least one of which is selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0461] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0462] C 2-14 A group consisting of alkenyl groups;
[0463] R 4Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0464] in represents a connection point;
[0465] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0466] Each R' is independently C 1-12 Alkyl or C 2-12 alkenyl;
[0467] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0468] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0469] In some aspects, the present disclosure relates to a compound of formula (II-b):
[0470] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0471] R' 分支 for: And R' b for:
[0472] in Indicates a connection point;
[0473] R aγ and R bγ Each independently selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0474] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0475] C 2-14 A group consisting of alkenyl groups;
[0476] R 4Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0477] in represents a connection point;
[0478] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0479] Each R' is independently C 1-12 Alkyl or C 2-12 alkenyl;
[0480] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0481] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0482] In some aspects, the present disclosure relates to a compound of formula (II-c):
[0483] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0484] R' 分支 for: And R' b for:
[0485] in Indicates a connection point;
[0486] Where R aγ Choose from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0487] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0488] C 2-14 A group consisting of alkenyl groups;
[0489] R 4 Selected from the group consisting of: -(CH 2 )n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0490] in represents a connection point;
[0491] R 10 N(R) 2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0492] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0493] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0494] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0495] In some aspects, the present disclosure relates to a compound of formula (II-d):
[0496] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0497] R' 分支 for: And R' b for:
[0498] in Indicates a connection point;
[0499] Where R aγ and R bγ Each independently selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0500] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5; and
[0501] in represents a connection point;
[0502] R 10 N(R)2 ; Each R is independently selected from C 1-6 Alkyl, C 2-3 alkenyl and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;
[0503] Each R' is independently C 1-12 Alkyl or C 2-12 alkenyl;
[0504] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0505] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0506] In some aspects, the present disclosure relates to a compound of formula (II-e):
[0507] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0508] R' 分支 for: And R' b for:
[0509] in Indicates a connection point;
[0510] Where R aγ Choose from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0511] R 2 and R 3 Each independently selected from C 1-14 Alkyl and
[0512] C 2-14 A group consisting of alkenyl groups;
[0513] R 4 For -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5;
[0514] R' is C 1-12 Alkyl or C 2-12 alkenyl;
[0515] m is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9;
[0516] l is selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
[0517] In some embodiments of the compound of Formula (II), (II-a), (II-b), (II-c), (II-d) or (II-e), m and l are each independently selected from 4, 5 and 6. In some embodiments of the compound of Formula (II), (II-a), (II-b), (II-c), (II-d) or (II-e), m and l are each 5.
[0518] In some embodiments of the compounds of Formula (II), (II-a), (II-b), (II-c), (II-d) or (II-e), each R' is independently C 1-12 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), each R' is independently C 2-5 alkyl.
[0519] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' b for: And R 2 and R 3 Each independently is C 1-14 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' b for: And R 2 and R 3 Each independently is C 6-10 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' b for: And R 2 and R 3 Each is C 8 alkyl.
[0520] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: R aγ C 1-12Alkyl, and R 2 and R 3 Each independently is C 6-10 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: R aγ C 2-6 Alkyl, and R 2 and R 3 Each independently is C 6-10 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: R aγ C 2-6 Alkyl, and R 2 and R 3 Each is C 8 alkyl.
[0521] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: And R aγ and R bγ Each is C 1-12 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: And R aγ and R bγ Each is C 2-6 alkyl.
[0522] In some embodiments of the compounds of Formula (II), (II-a), (II-b), (II-c), (II-d) or (II-e), m and l are each independently selected from 4, 5 and 6, and each R' is independently C 1-12In some embodiments of the compounds of Formula (II), (II-a), (II-b), (II-c), (II-d) or (II-e), m and l are each 5, and each R' is independently C 2-5 alkyl.
[0523] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each independently selected from 4, 5 and 6, and each R' is independently C 1-12 Alkyl, and R aγ and R bγ Each is C 1-12 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each 5, and each R' is independently C 2-5 Alkyl, and R aγ and R bγ Each is C 2-6 alkyl.
[0524] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: m and l are each independently selected from 4, 5 and 6, R' is C 1-12 Alkyl, R aγ C 1-12 Alkyl, and R 2 and R 3 Each independently is C 6-10 In some embodiments of the compounds of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: m and l are 5 respectively, R' is C 2-5 Alkyl, R aγ C 2-6 Alkyl, and R 2 and R3 Each is C 8 alkyl.
[0525] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d), or Formula (II-e), R 4 for Where R 10 NH(C 1-6 alkyl) and n2 is 2. In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R 4 for Where R 10 NH(CH 3 ) and n2 is 2.
[0526] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each independently selected from 4, 5 and 6, and each R' is independently C 1-12 Alkyl, R aγ and R bγ Each is C 1-12 Alkyl, and R 4 for Where R 10 NH(C 1-6 alkyl), and n2 is 2. In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each 5, and each R' is independently C 2-5 Alkyl, R aγ and R bγ Each is C 2-6 Alkyl, and R 4 for Where R 10 NH(CH 3 ) and n2 is 2.
[0527] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: m and l are each independently selected from 4, 5 and 6, R' is C 1-12 Alkyl, R 2 and R 3 Each independently is C 6-10 Alkyl, R aγ C 1-12 Alkyl, and R 4 for Where R 10 NH(C 1-6 alkyl) and n2 is 2. In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: And R' b for: m and l are 5 respectively, R' is C 2-5 Alkyl, R aγ C 2-6 Alkyl, R 2 and R 3 Each is C 8 Alkyl, and R 4 for Where R 10 NH(CH 3 ) and n2 is 2.
[0528] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d), or Formula (II-e), R 4 For -(CH 2 ) n OH and n is 2, 3 or 4. In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R 4 For -(CH 2 ) n OH and n is 2.
[0529] In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each independently selected from 4, 5 and 6, and each R' is independently C 1-12 Alkyl, R aγ and Rbγ Each is C 1-12 Alkyl, R 4 For -(CH 2 ) n OH, and n is 2, 3 or 4. In some embodiments of the compound of Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d) or Formula (II-e), R' 分支 for: R' b for: m and l are each 5, and each R' is independently C 2-5 Alkyl, R aγ and R bγ Each is C 2-6 Alkyl, R 4 For -(CH 2 ) n OH, and n is 2.
[0530] In some aspects, the present disclosure relates to a compound of formula (II-f):
[0531] or its N-oxide, or its salt or isomer, wherein R' a For R' 分支 or R' 环状 ;in
[0532] R' 分支 for: And R' b for:
[0533] in Indicates a connection point;
[0534] R aγ C 1-12 alkyl;
[0535] R 2 and R 3 Each independently is C 1-14 alkyl;
[0536] R 4 For -(CH 2 ) n OH, wherein n is selected from the group consisting of 1, 2, 3, 4 and 5;
[0537] R' is C 1-12 alkyl;
[0538] m is selected from 4, 5 and 6; and
[0539] l is selected from 4, 5 and 6.
[0540] In some embodiments of the compound of Formula (II-f), m and l are each 5, and n is 2, 3 or 4.
[0541] In some embodiments of the compound of formula (II-f), R' is C 2-5 Alkyl, R aγ C 2-6 Alkyl, and R 2 and R 3 Each is C 6-10 alkyl.
[0542] In some embodiments of the compound of formula (II-f), m and l are each 5, n is 2, 3 or 4, R' is C 2-5 Alkyl, R a γ C 2-6 Alkyl, and R 2 and R 3 Each is C 6-10 alkyl.
[0543] In some aspects, the present disclosure relates to a compound of formula (II-g):
[0544] in
[0545] R aγ C 2-6 alkyl;
[0546] R' is C 2-5 Alkyl; and
[0547] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 3, 4 and 5; and
[0548] in Represents the connection point, R 10 NH(C 1-6 alkyl), and n2 is selected from the group consisting of 1, 2 and 3.
[0549] In some aspects, the present disclosure relates to a compound of formula (II-h):
[0550] in
[0551] R aγ and R bγ Each independently is C 2-6 alkyl;
[0552] Each R' is independently C2-5 Alkyl; and
[0553] R 4 Selected from the group consisting of: -(CH 2 ) n OH, wherein n is selected from the group consisting of 3, 4 and 5; and
[0554] in Represents the connection point, R 10 NH(C 1-6 alkyl), and n2 is selected from the group consisting of 1, 2 and 3.
[0555] In some embodiments of the compound of Formula (II-g) or Formula (II-h), R 4 for in
[0556] R 10 NH(CH 3 ) and n2 is 2.
[0557] In some embodiments of the compound of Formula (II-g) or Formula (II-h), R 4 For -(CH 2 ) 2 OH.
[0558] In some aspects, the present disclosure relates to a compound having formula (III):
[0559]
[0560] or a salt or isomer thereof, wherein
[0561] R 1 , R 2 , R 3 , R 4 and R 5 Independently selected from C 5-20 Alkyl, C 5-20 the group consisting of alkenyl, -R"MR', -R*YR", -YR" and -R*OR";
[0562] Each M is independently selected from the group consisting of: -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O) 2 -, aryl and heteroaryl;
[0563] X 1 , X2 and X 3 are independently selected from the group consisting of: a bond, -CH 2 -、-(CH 2 ) 2 -, -CHR-, -CHY-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)-CH 2 -、-CH 2 -C(O)-, -C(O)O-CH 2 -、-OC(O)-CH 2 -、-CH 2 -C(O)O-, -CH 2 -OC(O)-, -CH(OH)-, -C(S)- and -CH(SH)-;
[0564] Each Y is independently C 3-6 Carbon ring;
[0565] Each R* is independently selected from C 1-12 Alkyl and C 2-12 A group consisting of alkenyl groups;
[0566] Each R is independently selected from C 1-3 Alkyl and C 3-6 A group consisting of carbon rings;
[0567] Each R' is independently selected from C 1-12 Alkyl, C 2-12 A group consisting of an alkenyl group and H; and
[0568] Each R" is independently selected from C 3-12 Alkyl and C 3-12 alkenyl, and wherein:
[0569] i)X 1 , X 2 and X 3 At least one of them is not -CH 2 -; and / or
[0570] ii) R 1 , R 2 , R 3 , R 4 and R 5 At least one of them is -R"MR'.
[0571] In some embodiments, R 1 , R 2 , R 3 , R 4 and R 5 Each is C 5-20 Alkyl; X1 -CH 2 -; and X 2 and X 3 Each is -C(O)-.
[0572] In some embodiments, the compound of formula (III) is:
[0573]
[0574] The central amine portion of the lipid according to any formula herein (e.g., a compound having any of Formula (A)-7, (la)-8, (lb)-9, (lc)-11, (II-a)-11, (II-b)-11, (II-c)-11, (II-d)-11, (II-e)-11, (II-f)-11, (II-g)-11, (II-h)-11, or (III) (each of which begins with the letter I for clarity)) may be protonated at physiological pH. Thus, the lipid may have a positive charge or a partial positive charge at physiological pH. Such lipids may be referred to as cationic lipids or ionizable (amino) lipids. The lipid may also be zwitterionic, i.e., a neutral molecule having both a positive charge and a negative charge.
[0575] In some embodiments, the amount of an ionizable amino lipid of the present invention (e.g., a compound having any of Formula (A)-7, (la)-8, (lb)-9, (lc)-11, (II-a)-11, (II-b)-11, (II-c)-11, (II-d)-11, (II-e)-11, (II-f)-11, (II-g)-11, (II-h)-11, or (III) (for clarity, each of the formulas begins with the letter I)) in the lipid composition is in the range of about 1 mol% to 99 mol%.
[0576] In one embodiment, the amount of an ionizable amino lipid of the invention (e.g., a compound having any of Formula (A), (Ia), (Ib), (Ic), (II), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (II-h), or (III) (III) (each of which begins with the letter I for clarity) in the lipid composition is at least about 1 mol%, 2 mol%, 3 mol%, 4 mol%, 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol%, 15 mol%, 16 mol%, 17 mol%, 18 mol%, 19 mol%, 20 mol%, 21 mol%, 22 mol%, 23 mol%, 24 mol%, 25 mol%, 26 mol%, 27 mol%, 28 mol%, 29 mol%, 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, 45 mol%, 46 mol%, 47 mol%, 48 mol%, 49 mol%, 50 %, 9mol%, 10mol%, 11mol%, 12mol%, 13mol%, 14mol%, 15mol%, 16mol%, 17mol%, 18mol%, 19mol%, 20mol%, 21mol%, 22mol%, 23mol%, 24mol%, 25mol%, 26mol%, 27mol%, 28mol%, 29mol%, 30mol%, 31mol%, 32mol%, 33mol%, 34mol%, 35mol%, 36mol%, 37mol%, 38mol%, 39 mol%, 40mol%, 41mol%, 42mol%, 43mol%, 44mol%, 45mol%, 46mol%, 47mol%, 48mol%, 49mol%, 50mol%, 51mol%, 52mol%, 53mol%, 54m ol%, 55mol%, 56mol%, 57mol%, 58mol%, 59mol%, 60mol%, 61mol%, 62mol%, 63mol%, 64mol%, 65mol%, 66mol%, 67mol%, 68mol%, 69mo l%, 70mol%, 71mol%, 72mol%, 73mol%, 74mol%, 75mol%, 76mol%, 77mol%, 78mol%, 79mol%, 80mol%, 81mol%, 82mol%, 83mol%, 84mol %, 85 mol%, 86 mol%, 87 mol%, 88 mol%, 89 mol%, 90 mol%, 91 mol%, 92 mol%, 93 mol%, 94 mol%, 95 mol%, 96 mol%, 97 mol%, 98 mol% or 99 mol%.
[0577] In one embodiment, the amount of an ionizable amino lipid of the invention (e.g., a compound having any of Formula (A), (Ia), (Ib), (Ic), (II), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (II-h), or (III) (each of which begins with the letter I for clarity)) in the lipid composition is in the range of about 30 mol % to about 70 mol %, about 35 mol % to about 65 mol %, about 40 mol % to about 60 mol %, and about 45 mol % to about 55 mol %.
[0578] In a specific embodiment, the amount of an ionizable amino lipid of the invention (e.g., a compound having any of Formula (A)-7, (la)-8, (lb)-9, (lc)-11, (II-a)-11, (II-b)-11, (II-c)-11, (II-d)-11, (II-e)-11, (II-f)-11, (II-g)-11, (II-h)-11, or (III) (for clarity, each of the formulas begins with the letter I)) in the lipid composition is about 45 mol%.
[0579] In a specific embodiment, the amount of an ionizable amino lipid of the invention (e.g., a compound having any of Formula (A)-7, (la)-8, (lb)-9, (lc)-11, (II-a)-11, (II-b)-11, (II-c)-11, (II-d)-11, (II-e)-11, (II-f)-11, (II-g)-11, (II-h)-11, or (III) (for clarity, each of the formulas begins with the letter I)) in the lipid composition is about 40 mol%.
[0580] In a specific embodiment, the amount of an ionizable amino lipid of the invention (e.g., a compound having any of Formula (A)-7, (la)-8, (lb)-9, (lc)-11, (II-a)-11, (II-b)-11, (II-c)-11, (II-d)-11, (II-e)-11, (II-f)-11, (II-g)-11, (II-h)-11, or (III) (for clarity, each of the formulas begins with the letter I)) in the lipid composition is about 50 mol%.
[0581] In addition to the ionizable amino lipids disclosed herein (e.g., compounds having any of Formula (A), (Ia), (Ib), (Ic), (II), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (II-h), or (III) (each of which begins with the letter I for clarity)), the lipid-based compositions (e.g., lipid nanoparticles) disclosed herein may also include other components, such as cholesterol and / or cholesterol analogs, non-cationic helper lipids, structural lipids, PEG-lipids, and any combinations thereof.
[0582] Other ionizable lipids of the present invention can be selected from the non-limiting group consisting of: 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethylamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethylamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-trioctadecane (KL25), 1,2-dilinoleyloxy-N,N -dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 4-(dimethylamino)butyric acid heptathriacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy -N,N-dimethylaminopropane (DODMA), (13Z,165Z)-N,N-dimethyl-3-nonyldocosahexa-13-16-dien-1-amine (L608), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadec-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)- In some embodiments, (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2R)) and (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2S)). In addition to these ionizable lipids, the ionizable amino lipid may also be a lipid including a cyclic amine group.
[0583] The ionizable lipids of the present invention may also be compounds disclosed in International Publication No. WO 2017 / 075531 A1, which is hereby incorporated by reference in its entirety.
[0584] The ionizable lipid of the present invention may also be a compound disclosed in International Publication No. WO 2015 / 199952 A1, which is hereby incorporated by reference in its entirety.
[0585] In any of the foregoing or related aspects, the ionizable lipids of the LNPs of the present disclosure comprise any compound, for example, a compound having any of Formula (A)-7, Formula (la), Formula (lb), Formula (Ic), Formula (II), Formula (II-a), Formula (II-b), Formula (II-c), Formula (II-d), Formula (II-e), Formula (II-f), Formula (II-g), Formula (II-h), or Formula (III) (for clarity, each of these formulas begins with the letter I).
[0586] In any of the foregoing or related aspects, the ionizable lipid of the LNP of the present disclosure comprises a compound comprising any one of Compound Nos. 18, 25, 301 and 357.
[0587] In any of the foregoing or related aspects, the ionizable lipids of the LNPs of the present disclosure comprise at least one compound selected from the group consisting of Compound No. 18, Compound No. 25, Compound No. 301, and Compound No. 357. In another embodiment, the ionizable lipids of the LNPs of the present disclosure comprise a compound selected from the group consisting of Compound No. 18, Compound No. 25, Compound No. 301, and Compound No. 357. In another embodiment, the ionizable lipids of the LNPs of the present disclosure comprise Compound 18. In another embodiment, the ionizable lipids of the LNPs of the present disclosure comprise Compound 25.
[0588] In any of the foregoing or related aspects, the synthesis of compounds of the invention (e.g., compounds comprising any of compounds Nos. 18, 25, 301, and 357) follows the synthesis description in U.S. Provisional Patent Application No. 62 / 733,315 filed on September 19, 2018.
[0589] Representative synthetic routes:
[0590] Compound I-182: 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester
[0591] 3-Methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione
[0592]
[0593] To a solution of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1g, 7mmol) in 100mL diethyl ether, a solution of 2M methylamine in THF (3.8mL, 7.6mmol) was added, and a precipitate was formed. The mixture was stirred at room temperature for 24 hours and then filtered to collect the solid. The solid was washed with diethyl ether and air-dried, then dissolved in hot EtOAc and filtered. The filtrate was cooled to room temperature and then cooled to 0°C to obtain a precipitate, which was separated by filtration, washed with cold EtOAc, air-dried, and then dried under vacuum to produce 3-methoxy-4-(methylamino)cyclobutane-3-ene-1,2-dione (0.70g, 5mmol, 73%) as a solid. 1 HNMR (300 MHz, DMSO-d 6 )δ: ppm 8.50 (br.d, 1H, J = 69Hz); 4.27 (s, 3H); 3.02 (sdd, 3H, J = 42Hz, 4.5Hz).
[0594] 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester
[0595]
[0596] To a solution of 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (200 mg, 0.28 mmol) in 10 mL of ethanol was added 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione (39 mg, 0.28 mmol). The reaction mixture was stirred at room temperature for 20 hours and then concentrated in vacuo to give a residue. The residue was purified by silica gel chromatography (0-100% (1% NH 4 The residue was purified by HPLC-MS / MS (50% by weight, 10% by weight, 20% by weight of 4-(4-(4-(2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (138 mg, 0.17 mmol, 60%) as a solid. UPLC / ELSD: RT = 3. min. MS (ES): C 51 H 95 N 3 O 6 m / z(MH + ) is 833.4.1 H NMR (300 MHz, CDCl 3 )δ:ppm 7.86 (br.s., 1H); 4.86 (quintet, 1H, J = 6Hz); 4.05 (t, 2H, J = 6Hz); 3.92 (d, 2H, J = 3Hz); 3.20 (s, 6H); 2.63 (br.s, 2H); 2.42 (b r.s,3H);2.28(m,4H);1.74(br.s,2H);1.61(m,8H);1.50(m,5H);1.41(m,3H);1.25(br.m,47H);0.88(t,9H,J=7.5Hz).
[0597] Compound I-301: 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-oxo-8-(undec-3-yloxy)octyl)amino)octanoic acid heptadecan-9-yl ester
[0598]
[0599] Compound I-301 was prepared similarly to compound 182, except that 8-((3-aminopropyl)(8-oxo-8-(undec-3-yloxy)octyl)amino)octanoic acid heptadecan-9-yl ester (500 mg, 0.66 mmol) was used instead of 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester. After aqueous workup, the product was purified by silica gel chromatography (0-50% (1% NH 4 The residue was purified by HPLC (50% by weight, 1% by weight, 20% by weight of MeOH in dichloromethane) to give heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-oxo-8-(undec-3-yloxy)octyl)amino)octanoate (180 mg, 32%) as a solid. HPLC / UV (254 nm): RT = 6.77 min. MS (CI): C 52 H 97 N 3 O 6 m / z(MH + ) is 860.7. 1 H NMR (300 MHz, CDCl 3): δppm4.86-4.79(m,2H); 3.66(bs,2H); 3.25(d,3H,J=4.9Hz); 2.56-2.52(m,2H); 2.42-2.37(m,4H); 2.28(dd,4H,J =2.7Hz,7.4Hz); 1.78-1.68(m,3H); 1.64-1.50(m,16H); 1.48-1.38(m,6H); 1.32-1.18(m,43H); 0.88-0.84(m,12H).
[0600] Cholesterol / Structural Lipids
[0601] The LNPs described herein comprise one or more structural lipids.
[0602] As used herein, the term "structural lipid" refers to sterols, and also refers to lipids containing sterol moieties. Incorporating structural lipids into lipid nanoparticles can help alleviate the aggregation of other lipids in the particles. Structural lipids may include, but are not limited to, cholesterol, coprosterol, ergosterol, brassicasterol, tomatine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof. In certain embodiments, the structural lipid is cholesterol. In certain embodiments, the structural lipid includes cholesterol and corticosteroids (e.g., prednisolone, dexamethasone, prednisone, and hydrocortisone) or a combination thereof.
[0603] In some embodiments, the structural lipid is a sterol. As defined herein, "sterol" is a steroid subgroup consisting of steroids. In certain embodiments, the structural lipid is a steroid. In certain embodiments, the structural lipid is cholesterol. In certain embodiments, the structural lipid is an analog of cholesterol. In certain embodiments, the structural lipid is alpha-tocopherol. Examples of structural lipids include (but are not limited to) the following:
[0604]
[0605]
[0606] The targeted cell delivery LNPs described herein comprise one or more structural lipids.
[0607] As used herein, the term "structured lipid" refers to sterol, and also refers to a lipid containing a sterol portion. Incorporation of structured lipids into lipid nanoparticles can help alleviate the aggregation of other lipids in the particle. In certain embodiments, the structured lipids include cholesterol and corticosteroids (e.g., prednisolone, dexamethasone, prednisone and hydrocortisone) or a combination thereof.
[0608] In some embodiments, the structured lipid is a sterol. As defined herein, "sterol" is a subgroup of steroids consisting of steroids. The structured lipid may include, but is not limited to, sterols (e.g., plant sterols or animal sterols).
[0609] In certain embodiments, the structural lipid is a steroid. For example, sterols may include, but are not limited to, cholesterol, β-sterol, coprosterol, ergosterol, sterol, campesterol, stigmasterol, brassicasterol, ergosterol, tomatine, tomatine, ursolic acid, α-tocopherol, and the like.
[0610] In certain embodiments, the structured lipid is cholesterol. In certain embodiments, the structured lipid is an analog of cholesterol.
[0611] Compound ratio
[0612] The lipid nanoparticles of the invention may include structural components as described herein. The structural components of the lipid nanoparticles may be individual compounds or mixtures of one or more structural compounds of the invention.
[0613] Non-cationic helper lipids / phospholipids
[0614] In some embodiments, the lipid-based compositions (e.g., LNPs) described herein include one or more non-cationic helper lipids. In some embodiments, the non-cationic helper lipids are phospholipids. In some embodiments, the non-cationic helper lipids are phospholipid substitutes or alternatives.
[0615] As used herein, the term "non-cationic helper lipid" refers to a lipid comprising at least one fatty acid chain of at least 8 carbons in length and at least one polar head group portion. In one embodiment, the helper lipid is not phosphatidylcholine (PC). In one embodiment, the non-cationic helper lipid is a phospholipid or a phospholipid substituted substance. In some embodiments, the phospholipid or phospholipid substituted substance can be, for example, one or more saturated or (poly) unsaturated phospholipids, or a phospholipid substituted substance or a combination thereof. In general, a phospholipid comprises a phospholipid portion and one or more fatty acid portions.
[0616] The phospholipid moiety may be selected, for example, from the non-limiting group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin.
[0617] The fatty acid moiety can be selected, for example, from the non-limiting group consisting of lauric acid, myristic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.
[0618] Phospholipids include, but are not limited to, glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid. Phospholipids also include phospho-sphingolipids such as sphingomyelin.
[0619] In some embodiments, the non-cationic helper lipid is a DSPC analog, a DSPC substitute, oleic acid, or an oleic acid analog.
[0620] In some embodiments, the non-cationic helper lipid is a non-phosphatidylcholine (PC) zwitterionic lipid, a DSPC analog, oleic acid, an oleic acid analog, or a 1,2-distearoyl-i77-glycero-3-phosphocholine (DSPC) substituted.
[0621] Phospholipids
[0622] Phospholipids
[0623] The lipid composition of the lipid nanoparticle composition disclosed herein may comprise one or more phospholipids, such as one or more saturated or (poly)unsaturated phospholipids or combinations thereof. In general, a phospholipid comprises a phospholipid portion and one or more fatty acid portions.
[0624] The phospholipid moiety may be selected, for example, from the non-limiting group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin.
[0625] The fatty acid moiety can be selected, for example, from the non-limiting group consisting of lauric acid, myristic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.
[0626] Specific phospholipids can promote fusion with membranes. For example, cationic phospholipids can interact with one or more negatively charged phospholipids of membranes (e.g., cell membranes or intracellular membranes). The fusion of phospholipids with membranes can allow one or more elements (e.g., therapeutic agents) containing lipid compositions (e.g., LNPs) to pass through the membrane, thereby allowing, for example, one or more elements to be delivered to target tissues.
[0627] Also contemplated are non-natural phospholipid species, including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes. For example, phospholipids can be functionalized or cross-linked with one or more alkynes (e.g., alkenyl groups with one or more double bonds replaced by triple bonds). Under appropriate reaction conditions, alkynyl groups can undergo copper-catalyzed cycloadditions when exposed to azides. Such reactions can be used to functionalize the lipid bilayer of nanoparticle compositions to facilitate membrane penetration or cell recognition, or can be used to conjugate nanoparticle compositions with useful components such as targeting or imaging moieties (e.g., dyes).
[0628] Phospholipids include, but are not limited to, glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid. Phospholipids also include phospho-sphingolipids such as sphingomyelin.
[0629] In some embodiments, the phospholipids of the present invention include 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), l,2-dipalmitoyl-sn- 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diacetoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (MEPC), 1,2-di-o-octadecenoyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-di-linolenoyl-sn-glycero-3-phosphocholine, 1,2-diacetoyl-sn-glycero-3-phosphocholine, 1,2-di-o-octadeceno ...ethanolamine (MEPC) 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dialinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-racem-(1-glycerol) sodium salt (DOPG), sphingomyelin and mixtures thereof.
[0630] In certain embodiments, the phospholipids that can be used or potentially used in the present invention are analogs or variants of DSPC. In certain embodiments, the phospholipids that can be used or potentially used in the present invention are compounds of formula (IV):
[0631]
[0632] or a salt thereof, wherein:
[0633] Each R 1 are independently optionally substituted alkyl; or optionally two R 1 Together with the intervening atoms, they form an optionally substituted monocyclic carbocyclyl or an optionally substituted monocyclic heterocyclyl; or optionally three R 1 Together with the intervening atoms, they are joined to form an optionally substituted bicyclic carbocyclyl or an optionally substituted bicyclic heterocyclyl;
[0634] n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0635] m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0636] A has the formula:
[0637] L 2 Each instance of is independently a bond or an optionally substituted C 1-6 Alkylene, wherein optionally substituted C 1-6 A methylene unit of the alkylene group is optionally replaced by: O, N(R N )、S、C(O)、C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O or NR N C(O)N(R N );
[0638] R 2 Each instance of is independently optionally substituted C 1-30 Alkyl, optionally substituted C 1-30 alkenyl or optionally substituted C 1-30 alkynyl; optionally wherein R 2 The one or more methylene units are independently replaced by optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N )、O、S、C(O)、C(O)N(R N), NR N C(O),NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N )、C(S)、C(S)N(R N ), NR N C(S),NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O) 2 、S(O) 2 O、OS(O) 2 O、N(R N )S(O), S(O)N(R N )、N(R N )S(O)N(R N )、OS(O)N(R N )、N(R N )S(O)O、S(O) 2 、N(R N )S(O) 2 、S(O) 2 N(R N )、N(R N )S(O) 2 N(R N )、OS(O) 2 N(R N ) or N(R N )S(O) 2 O;
[0639] R N Each instance of is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
[0640] Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and
[0641] p is 1 or 2;
[0642] Provided that the compound does not have the formula:
[0643]
[0644] Where R 2 Each instance of is independently unsubstituted alkyl, unsubstituted alkenyl, or unsubstituted alkynyl.
[0645] In some embodiments, the phospholipid can be one or more of the phospholipids described in US Application No. 62 / 520,530.
[0646] Phospholipid head modification
[0647] In certain embodiments, the phospholipids useful or potentially useful in the present invention comprise a modified phospholipid head (e.g., a modified choline group). In certain embodiments, the phospholipid with a modified head is DSPC or an analog thereof with a modified quaternary amine. For example, in the embodiment of formula (IV), at least one R 1 In certain embodiments, at least one R 1 is not hydrogen or methyl. In certain embodiments, the compound of formula (IV) is one of the following formulae:
[0648]
[0649] or a salt thereof, wherein:
[0650] each t is independently 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0651] each u is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
[0652] Each v is independently 1, 2 or 3.
[0653] In certain embodiments, the compound of formula (IV) is a compound of formula (IV-a):
[0654]
[0655] or a salt thereof.
[0656] In certain embodiments, the phospholipids that can be used or potentially used in the present invention contain a cyclic portion instead of a glyceride portion. In certain embodiments, the phospholipids that can be used in the present invention are DSPC or its analogs having a cyclic portion instead of a glyceride portion. In certain embodiments, the compound of formula (IV) is a compound of formula (IV-b):
[0657]
[0658] or a salt thereof.
[0659] Phospholipid tail modification
[0660] In certain embodiments, the phospholipids useful or potentially useful in the present invention include a modified tail. In certain embodiments, the phospholipids useful or potentially useful in the present invention are DSPC or an analog thereof with a modified tail. As described herein, the "modified tail" may be a tail having a shorter or longer aliphatic chain, an aliphatic chain with a branch, an aliphatic chain with a substituent, an aliphatic chain with one or more methylene groups replaced by a cyclic or heteroatom group, or any combination thereof. For example, in certain embodiments, the (IV) compound is a compound of formula (IV-a) or a salt thereof, wherein R 2 At least one instance of R 2 Each instance of is optionally substituted C 1-30 Alkyl, where R 2 The one or more methylene units are independently replaced by optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N )、O、S、C(O)、C(O)N(R N ), NR N C(O),NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N )、C(S)、C(S)N(R N ), NR N C(S),NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O) 2 、S(O) 2 O、OS(O) 2 O、N(R N )S(O), S(O)N(R N )、N(R N )S(O)N(R N )、OS(O)N(R N )、N(R N)S(O)O、S(O) 2 、N(R N )S(O) 2 、S(O) 2 N(R N )、N(R N )S(O) 2 N(R N )、OS(O) 2 N(R N ) or N(R N )S(O) 2 O.
[0661] In certain embodiments, the compound of formula (IV) is a compound of formula (IV-c):
[0662]
[0663] or a salt thereof, wherein:
[0664] Each x is independently an integer between 0 and 30, inclusive; and
[0665] Each instance of G is independently selected from the group consisting of optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N )、O、S、C(O)、C(O)N(R N ), NR N C(O),NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N )、C(S)、C(S)N(R N ), NR N C(S),NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O) 2 、S(O) 2 O、OS(O) 2 O、N(R N)S(O), S(O)N(R N )、N(R N )S(O)N(R N )、OS(O)N(R N )、N(R N )S(O)O、S(O) 2 、N(R N )S(O) 2 、S(O) 2 N(R N )、N(R N )S(O) 2 N(R N )、OS(O) 2 N(R N ) or N(R N )S(O) 2 O. Each possibility represents a separate embodiment of the present invention.
[0666] In certain embodiments, the phospholipids useful or potentially useful in the present invention comprise a modified phosphorylcholine moiety in which the alkyl chain connecting the quaternary amine to the phosphoryl group is not ethylene (e.g., n is not 2). Thus, in certain embodiments, the phospholipids useful or potentially useful in the present invention are compounds of formula (IV), wherein n is 1, 3, 4, 5, 6, 7, 8, 9, or 10. For example, in certain embodiments, the compound of formula (IV) is one of the following formulas:
[0667]
[0668] or a salt thereof.
[0669] Alternative lipids
[0670] In certain embodiments, phospholipids useful or potentially useful in the present invention comprise a modified phosphorylcholine moiety in which the alkyl chain linking the quaternary amine to the phosphoryl group is not ethylene (eg, n is not 2). Thus, in certain embodiments, phospholipids may be used.
[0671] In certain embodiments, alternative lipids are used in place of the phospholipids of the disclosure.
[0672] In certain embodiments, the alternative lipid of the present invention is oleic acid.
[0673] In certain embodiments, the alternative lipid is one of:
[0674]
[0675]
[0676] PEG lipids
[0677] The lipid composition of the pharmaceutical compositions disclosed herein may comprise one or more polyethylene glycol (PEG) lipids.
[0678] As used herein, the term "PEG-lipid" refers to a lipid modified by polyethylene glycol (PEG). Non-limiting examples of PEG-lipids include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, and PEG-modified 1,2-diacyloxypropane-3-amines. Such lipids are also referred to as PEGylated lipids. For example, PEG lipids may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipids.
[0679] In some embodiments, the PEG-lipid includes, but is not limited to, 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-l,2-dimyristyloxypropyl-3-amine (PEG-c-DMA).
[0680] In one embodiment, the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
[0681] In some embodiments, the lipid portion of the PEG-lipid comprises a lipid having a length of about C. 14 to about C 22 , preferably about C 14 to about C 16 In some embodiments, the PEG moiety (e.g., mPEG-NH 2 ) is about 1000, 2000, 5000, 10,000, 15,000, or 20,000 Daltons. In one embodiment, the PEG-lipid is PEG 2k -DMG.
[0682] In one embodiment, the lipid nanoparticles described herein may comprise a PEG lipid that is a non-diffusible PEG. Non-limiting examples of non-diffusible PEGs include PEG-DSG and PEG-DSPE.
[0683] PEG-lipids are known in the art, such as those described in U.S. Pat. No. 8,158,601 and International Publication No. WO 2015 / 130584 A2, which are incorporated herein by reference in their entireties.
[0684] In general, some of the other lipid components of the various formulas described herein (e.g., PEG lipids) can be synthesized as described in International Patent Application No. PCT / US2016 / 000129, filed on December 10, 2016, entitled "Compositions and Methods for Delivery of Therapeutic Agents," which is incorporated by reference in its entirety.
[0685] The lipid component of lipid nanoparticle composition can include one or more molecules comprising polyethylene glycol, such as PEG or PEG modified lipids. Such substances can alternatively be referred to as pegylated lipids. PEG lipids are lipids modified with polyethylene glycol. PEG lipids can be selected from the following non-limiting groups including: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and mixtures thereof. For example, PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC or PEG-DSPE lipids.
[0686] In some embodiments, the PEG-modified lipid is a modified form of PEG DMG. PEG-DMG has the following structure:
[0687]
[0688] In one embodiment, the PEG lipid that can be used in the present invention can be the PEGylated lipid described in International Publication No. WO2012099755, the contents of which are incorporated herein by reference in their entirety. Any of these exemplary PEG lipids described herein can be modified to include a hydroxyl group on the PEG chain. In certain embodiments, the PEG lipid is a PEG-OH lipid. As generally defined herein, a "PEG-OH lipid" (also referred to herein as a "hydroxy-PEGylated lipid") is a PEGylated lipid with one or more hydroxyl groups (-OH) on a lipid. In certain embodiments, the PEG-OH lipid includes one or more hydroxyl groups on the PEG chain. In certain embodiments, PEG-OH or hydroxy-PEGylated lipids include an -OH group at the end of the PEG chain. Each possibility represents a separate embodiment of the present invention.
[0689] In certain embodiments, the PEG lipids useful in the present invention are compounds of formula (V). Provided herein are compounds of formula (V):
[0690]
[0691] or a salt thereof, wherein:
[0692] R 3 For-OR O ;
[0693] R O is hydrogen, optionally substituted alkyl or an oxygen protecting group;
[0694] r is an integer between 1 and 100, inclusive;
[0695] L 1 is optionally substituted C 1-10 Alkylene, wherein the optionally substituted C 1-10 At least one methylene group of the alkylene group is independently replaced by an optionally substituted carbocyclylene group, an optionally substituted heterocyclylene group, an optionally substituted arylene group, an optionally substituted heteroarylene group, O, N(R N )、S、C(O)、C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O or NR N C(O)N(R N );
[0696] D is a moiety obtained by click chemistry or a moiety cleavable under physiological conditions;
[0697] m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0698] A has the formula:
[0699] L 2 Each instance of is independently a bond or an optionally substituted C 1-6 Alkylene, wherein optionally substituted C 1-6 A methylene unit of the alkylene group is optionally replaced by: O, N(R N )、S、C(O)、C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O or NR N C(O)N(R N );
[0700] R 2 Each instance of is independently optionally substituted C 1-30 Alkyl, optionally substituted C 1-30 alkenyl or optionally substituted C 1-30 alkynyl; optionally wherein R 2 The one or more methylene units are independently replaced by optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N )、O、S、C(O)、C(O)N(R N ), NR N C(O),NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N )、C(S)、C(S)N(R N ), NR N C(S),NR N C(S)N(R N), S(O), OS(O), S(O)O, OS(O)O, OS(O) 2 、S(O) 2 O、OS(O) 2 O、N(R N )S(O), S(O)N(R N )、N(R N )S(O)N(R N )、OS(O)N(R N )、N(R N )S(O)O、S(O) 2 、N(R N )S(O) 2 、S(O) 2 N(R N )、N(R N )S(O) 2 N(R N )、OS(O) 2 N(R N ) or N(R N )S(O) 2 O;
[0701] R N Each instance of is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
[0702] Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and
[0703] p is 1 or 2.
[0704] In certain embodiments, the compound of formula (V) is a PEG-OH lipid (ie, R 3 For-OR O , and R O is hydrogen). In certain embodiments, the compound of formula (V) is a compound of formula (V-OH):
[0705]
[0706] or a salt thereof.
[0707] In certain embodiments, the PEG lipids useful in the present invention are PEGylated fatty acids. In certain embodiments, the PEG lipids useful in the present invention are compounds of formula (VI). Compounds of formula (VI) are provided herein:
[0708]
[0709] or a salt thereof, wherein:
[0710] R 3 For-OR O ;
[0711] R O is hydrogen, optionally substituted alkyl or an oxygen protecting group;
[0712] r is an integer between 1 and 100, inclusive;
[0713] R 5 is optionally substituted C 10-40 Alkyl, optionally substituted C 10-40 alkenyl or optionally substituted C 10-40 alkynyl; and optionally R 5 wherein one or more methylene groups are replaced by an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, N(R N )、O、S、C(O)、C(O)N(R N ), NR N C(O),NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N )、C(S)、C(S)N(R N ), NR N C(S),NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O) 2 、S(O) 2 O、OS(O) 2 O、N(R N )S(O), S(O)N(R N )、N(R N )S(O)N(R N )、OS(O)N(R N )、N(R N )S(O)O、S(O) 2 、N(R N )S(O)2 、S(O) 2 N(R N )、N(R N )S(O) 2 N(R N )、OS(O) 2 N(R N ) or N(R N )S(O) 2 O; and
[0714] R N Each instance of is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.
[0715] In certain embodiments, the compound of formula (VI) is a compound of formula (VI-OH):
[0716]
[0717] or a salt thereof. In some embodiments, r is 45. In another aspect of the foregoing or related aspects, a PEG lipid of the invention is provided, wherein r is 40-50.
[0718] In other embodiments, the compound of formula (VI) is:
[0719]
[0720] or a salt thereof.
[0721] In one embodiment, the compound of formula (VI) is
[0722]
[0723] (PEG compound I).
[0724] In some aspects, the lipid composition of the pharmaceutical compositions disclosed herein does not comprise PEG-lipid.
[0725] In some embodiments, the PEG-lipid can be one or more of the PEG lipids described in U.S. Application No. 62 / 520,530.
[0726] In some embodiments, the PEG lipids of the present invention include PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and mixtures thereof. In some embodiments, the PEG-modified lipid is PEG-DMG, PEG-c-DOMG (also referred to as PEG-DOMG), PEG-DSG and / or PEG-DPG.
[0727] In certain embodiments, compared with existing LNP formulations comprising PEG lipids, the LNP provided herein exhibits increased PEG shedding. As used herein, "PEG shedding" refers to the cleavage of PEG groups from PEG lipids. In many cases, the cleavage of PEG groups from PEG lipids occurs via serum-driven esterase cleavage or hydrolysis. In certain embodiments, the PEG lipid provided herein is designed to control the PEG shedding rate. In certain embodiments, the LNP provided herein exhibits greater than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein exhibits greater than 50% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein exhibits greater than 60% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein shows greater than 70% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP shows greater than 80% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP shows greater than 90% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein shows greater than 90% PEG shedding after about 6 hours in human serum.
[0728] In other embodiments, the LNP provided herein shows less than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein shows less than 60% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein shows less than 70% PEG shedding after about 6 hours in human serum. In certain embodiments, the LNP provided herein shows less than 80% PEG shedding after about 6 hours in human serum.
[0729] In addition to the PEG lipids provided herein, the LNP may also include one or more other lipid components. In certain embodiments, the PEG lipid is present in the LNP at a molar ratio of 0.15%-15% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of 0.15%-5% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of 1%-5% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of 0.15%-2% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of 1%-2% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of about 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2% relative to other lipids. In certain embodiments, the PEG lipid is present at a molar ratio of about 1.5% relative to other lipids.
[0730] In one embodiment, the amount of PEG-lipid in the lipid composition of the pharmaceutical composition disclosed herein ranges from about 0.1 mol% to about 5 mol%, about 0.5 mol% to about 5 mol%, about 1 mol% to about 5 mol%, about 1.5 mol% to about 5 mol%, about 2 mol% to about 5 mol%, about 0.1 mol% to about 4 mol%, about 0.5 mol% to about 4 mol%, about 1 mol% to about 4 mol%, about 1.5 mol% to about 4 mol%, about 2 mol% to about 4 mol%, From about 0.1 mol% to about 3 mol%, from about 0.5 mol% to about 3 mol%, from about 1 mol% to about 3 mol%, from about 1.5 mol% to about 3 mol%, from about 2 mol% to about 3 mol%, from about 0.1 mol% to about 2 mol%, from about 0.5 mol% to about 2 mol%, from about 1 mol% to about 2 mol%, from about 1.5 mol% to about 2 mol%, from about 0.1 mol% to about 1.5 mol%, from about 0.5 mol% to about 1.5 mol%, or from about 1 mol% to about 1.5 mol%.
[0731] In one embodiment, the amount of PEG-lipid in the lipid composition disclosed herein is about 2 mol%. In one embodiment, the amount of PEG-lipid in the lipid composition disclosed herein is about 1.5 mol%.
[0732] In one embodiment, the amount of PEG-lipid in the lipid composition disclosed herein is at least about 0.1 mol%, 0.2 mol%, 0.3 mol%, 0.4 mol%, 0.5 mol%, 0.6 mol%, 0.7 mol%, 0.8 mol%, 0.9 mol%, 1 mol%, 1.1 mol%, 1.2 mol%, 1.3 mol%, 1.4 mol%, 1.5 mol%, 1.6 mol%, 1.7 mol%, 1.8 mol%, 1.9 mol%, 2 mol%, 2.1 mol%, 2.2 mol%, 2.3 mol%, or more. %, 2.4mol%, 2.5mol%, 2.6mol%, 2.7mol%, 2.8mol%, 2.9mol%, 3mol%, 3.1mol%, 3.2mol%, 3.3mol%, 3.4mol%, 3.5mol%, 3.6mol%, 3. 7 mol%, 3.8 mol%, 3.9 mol%, 4 mol%, 4.1 mol%, 4.2 mol%, 4.3 mol%, 4.4 mol%, 4.5 mol%, 4.6 mol%, 4.7 mol%, 4.8 mol%, 4.9 mol% or 5 mol%.
[0733] Exemplary Synthesis:
[0734] Compound: HO-PEG 2000 -Ester-C18
[0735]
[0736] To a nitrogen filled flask containing palladium on carbon (10 wt.%, 74 mg, 0.070 mmol) was added benzyl-PEG 2000 -ester-C18 (822 mg, 0.35 mmol) and MeOH (20 mL). The flask was evacuated and H 2 The mixture was backfilled three times and heated at room temperature and 1 atm H 2 The mixture was stirred at 40 °C for 12 h. The mixture was filtered through celite, rinsed with DCM, and the filtrate was concentrated in vacuo to give the desired product (692 mg, 88%). Using this method n=40-50. In one embodiment, n of the resulting polydisperse mixture is mentioned by an average value of 45.
[0737] For example, the r value can be determined based on the molecular weight of the PEG part in the PEG lipid. For example, a molecular weight of 2,000 (e.g., PEG2000) corresponds to an n value of about 45. For a given composition, the n value can mean the distribution of values within the generally accepted range of the industry, because polymers are generally found to be the distribution of different polymer chain lengths. For example, those skilled in the art who understand the polydispersity of such polymeric compositions will appreciate that an n value of 45 (e.g., in a structural formula) can represent the distribution of values between 40-50 in an actual PEG-containing composition (e.g., a DMG PEG200 peg lipid composition).
[0738] In some aspects, the target cell delivery lipid of the pharmaceutical compositions disclosed herein does not comprise a PEG-lipid.
[0739] In one embodiment, the target cell delivery LNP of the present disclosure comprises PEG-lipid.In one embodiment, the PEG lipid is not PEG DMG.In some aspects, the PEG-lipid is selected from the group consisting of: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and its mixture.In some aspects, the PEG lipid is selected from the group consisting of: PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC and PEG-DSPE lipid.In other aspects, the PEG-lipid is PEG-DMG.
[0740] In one embodiment, the target cell delivery LNPs of the present disclosure comprise PEG-lipids having a chain length longer than about 14, or longer than about 10 if branched.
[0741] As used herein, the term "alkyl", "alkyl group" or "alkylene" means a straight or branched chain saturated hydrocarbon including one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more carbon atoms), which is optionally substituted. 1-14 "Alkyl" means an optionally substituted straight or branched chain saturated hydrocarbon comprising 1 to 14 carbon atoms. Unless otherwise specified, the alkyl groups described herein refer to both unsubstituted and substituted alkyl groups.
[0742] As used herein, the term "alkenyl", "alkenyl group" or "alkenylene" means a straight or branched chain hydrocarbon comprising two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more carbon atoms) and at least one double bond, which is optionally substituted. 2-14 "Alkenyl" means an optionally substituted straight or branched chain hydrocarbon comprising 2 to 14 carbon atoms and at least one carbon-carbon double bond. Alkenyl may comprise one, two, three, four or more carbon-carbon double bonds. For example, C 18 The alkenyl group may include one or more double bonds. 18 The alkenyl group may be linoleyl. Unless otherwise specified, the alkenyl groups described herein refer to both unsubstituted and substituted alkenyl groups.
[0743] As used herein, the term "alkynyl," "alkynyl group," or "alkynylene" means a straight or branched chain hydrocarbon comprising two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more carbon atoms) and at least one carbon-carbon triple bond, which is optionally substituted. 2-14 "Alkynyl" means an optionally substituted straight or branched chain hydrocarbon containing 2 to 14 carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups may contain one, two, three, four or more carbon-carbon triple bonds. For example, C 18 Alkynyl groups may include one or more carbon-carbon triple bonds. Unless otherwise specified, alkynyl groups described herein refer to both unsubstituted and substituted alkynyl groups.
[0744] As used herein, the term "carbocycle" or "carbocyclyl" means an optionally substituted monocyclic or polycyclic ring system comprising one or more carbon atom rings. The ring may be a three-membered, four-membered, five-membered, six-membered, seven-membered, eight-membered, nine-membered, ten-membered, eleven-membered, twelve-membered, thirteen-membered, fourteen-membered, fifteen-membered, sixteen-membered, seventeen-membered, eighteen-membered, nineteen-membered, or twenty-membered ring. The notation "C 3-6 "Carbocycle" means a carbocycle including a monocyclic ring having 3-6 carbon atoms. The carbocycle may include one or more carbon-carbon double or triple bonds, and may be non-aromatic or aromatic (e.g., cycloalkyl or aryl). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2 dihydronaphthyl. As used herein, the term "cycloalkyl" means a non-aromatic carbocycle, and may or may not include any double or triple bonds. Unless otherwise specified, the carbocycles described herein refer to both unsubstituted and substituted carbocyclic groups, i.e., optionally substituted carbocycles.
[0745] As used herein, the term "heterocycle" or "heterocyclyl" means an optionally substituted monocyclic or polycyclic system including one or more rings, wherein at least one ring includes at least one heteroatom. The heteroatom may be, for example, a nitrogen, oxygen or sulfur atom. The ring may be a three-, four-, five-, six-, seven-, eight-, nine-, ten-, eleven-, twelve-, thirteen- or fourteen-membered ring. The heterocycle may include one or more double or triple bonds and may be non-aromatic or aromatic (e.g., heterocycloalkyl or heteroaryl). Examples of heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolidinyl, morpholinyl, pyrrolyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, thienyl, pyridyl, piperidinyl, quinolyl and isoquinolyl. As used herein, the term "heterocycloalkyl" means a non-aromatic heterocycle, and may or may not include any double or triple bonds. Unless otherwise specified, the heterocycles described herein refer to both unsubstituted and substituted heterocyclyls, i.e., optionally substituted heterocycles.
[0746] As used herein, the term "heteroalkyl", "heteroalkenyl" or "heteroalkynyl" refers to an alkyl, alkenyl, alkynyl, as defined herein, respectively, which further comprises one or more (e.g., 1, 2, 3 or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus), wherein the one or more heteroatoms are inserted between adjacent carbon atoms within the parent carbon chain and / or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. Unless otherwise specified, the heteroalkyl, heteroalkenyl or heteroalkynyl described herein refers to unsubstituted and substituted heteroalkyl, heteroalkenyl or heteroalkynyl, i.e., optionally substituted heteroalkyl, heteroalkenyl or heteroalkynyl.
[0747] As used herein, a "biodegradable group" is a group that can contribute to a more rapid metabolism of lipids in a mammalian entity. The biodegradable group can be selected from the group consisting of (but not limited to) -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, aryl and heteroaryl. As used herein, "aryl" is an optionally substituted carbocyclic group comprising one or more aromatic rings. Examples of aryl groups include phenyl and naphthyl. As used herein, "heteroaryl" is an optionally substituted heterocyclic group comprising one or more aromatic rings. Examples of heteroaryl groups include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl and thiazolyl. Both aryl and heteroaryl groups can be optionally substituted. For example, M and M' may be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole and thiazole. In each formula herein, M and M' may be independently selected from the list of biodegradable groups above. Unless otherwise specified, the aryl or heteroaryl described herein refers to both unsubstituted and substituted groups, i.e., optionally substituted aryl or heteroaryl.
[0748] Unless otherwise specified, alkyl, alkenyl and cyclic groups (e.g., carbocyclic and heterocyclic groups) may be optionally substituted. Optional substituents may be selected from the group consisting of, but not limited to, halogen atoms (e.g., chloride, bromide, fluoride or iodide groups), carboxylic acids (e.g., C(O)OH), alcohols (e.g., hydroxyl, OH), esters (e.g., C(O)OR OC(O)R), aldehydes (e.g., C(O)H), carbonyls (e.g., C(O)R, or represented by C=O), acyl halides (e.g., C(O)X, wherein X is a halide selected from bromide, fluoride, chloride and iodide), carbonates (e.g., OC(O)OR), alkoxy groups (e.g., OR), acetals (e.g., C(OR)2R"", wherein each OR is an alkoxy group which may be the same or different, and R"" is an alkyl or alkenyl group), phosphates (e.g., P(O) 4 3- ), thiols (e.g. SH), sulfoxides (e.g. S(O)R), sulfinic acids (e.g. S(O)OH), sulfonic acids (e.g. S(O) 2 OH), thioaldehyde (e.g. C(S)H), sulfate (e.g. S(O) 4 2- ), sulfonyl (such as S(O) 2 ), amides (e.g. C(O)NR 2 or N(R)C(O)R), azido (e.g. N 3 ), nitro (such as NO 2), cyano (e.g. CN), isocyano (e.g. NC), acyloxy (e.g. OC(O)R), amino (e.g. NR 2 , NRH or NH 2 ), carbamoyl (e.g. OC(O)NR 2 , OC(O)NRH or OC(O)NH 2 ), sulfonamides (such as S(O) 2 NR 2 、S(O) 2 NRH, S(O) 2 NH 2 、N(R)S(O) 2 R、N(H)S(O) 2 R、N(R)S(O) 2 H or N(H)S(O) 2 H), alkyl, alkenyl, and cyclic groups (e.g., carbocyclic or heterocyclic groups). In any of the foregoing, R is an alkyl or alkenyl group as defined herein. In some embodiments, the substituents themselves may be further substituted with, for example, one, two, three, four, five, or six substituents as defined herein. For example, C 1-6 The alkyl group can be further substituted with one, two, three, four, five, or six substituents as described herein.
[0749] The nitrogen-containing compounds of the present disclosure can be converted to N-oxides by treatment with an oxidant (e.g., 3-chloroperoxybenzoic acid (mCPBA) and / or hydrogen peroxide) to obtain other compounds of the present disclosure. Therefore, when valence and structure permit, all nitrogen-containing compounds shown and claimed are considered to include both the compounds shown and their N-oxide derivatives (which can be named N→O or N+-O-). In addition, in other cases, the nitrogen in the compounds of the present disclosure can be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds can be prepared by oxidizing the parent amine with an oxidant (e.g., mCPBA). When valence and structure permit, all nitrogen-containing compounds shown and claimed are also considered to cover the compounds shown and their N-hydroxy (i.e., N-OH) and N-alkoxy (i.e., N-OR, wherein R is substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, C 1 -C 6 alkynyl, 3- to 14-membered carbocyclic or 3- to 14-membered heterocyclic) derivatives.
[0750] Exemplary Other LNP Components
[0751] The lipid composition of the pharmaceutical composition disclosed herein may include one or more components in addition to those components described above. For example, the lipid composition may include one or more permeability enhancer molecules, carbohydrates, polymers, surface modifiers (e.g., surfactants) or other components. For example, the permeability enhancer molecule may be a molecule described in U.S. Patent Application Publication No. 2005 / 0222064. Carbohydrates may include monosaccharides (e.g., glucose) and polysaccharides (e.g., glycogen and its derivatives and analogs).
[0752] The polymer may be included in the pharmaceutical composition disclosed herein and / or used to encapsulate or partially encapsulate the pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition in the form of lipid nanoparticles). The polymer may be biodegradable and / or biocompatible. The polymer may be selected from, but not limited to, polyamines, polyethers, polyamides, polyesters, polyurethanes, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylene, polyethylene, polyethylene imine, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitrile, and polyarylates.
[0753] LNPs containing checkpoint cancer vaccines
[0754] Disclosed herein, inter alia, are LNP compositions for stimulating T cells (e.g., T effector cells) for treating cancer in a subject, the LNP compositions comprising polynucleotides encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more IDO antigen peptides and one or more PD-L1 antigen peptides. In another embodiment, the present invention relates to LNPs comprising polynucleotides comprising mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides. The LNP compositions disclosed herein can be used to induce T cells in vivo or in vitro, stimulate and activate T effector cells and / or induce killing of immunosuppressive (regulatory) immune cells and cancer cells that overexpress IDO and PD-L1.
[0755] In one aspect, an LNP composition comprising a polynucleotide encoding a checkpoint cancer vaccine comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
[0756] In one aspect, the LNP composition comprising a polynucleotide encoding IDO (eg, IDO1 or IDO2) comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
[0757] In one aspect, an LNP composition comprising a polynucleotide encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
[0758] In another aspect, the LNP compositions of the present disclosure are used in a method of treating cancer in a subject or in a method of stimulating an immune response in a subject.
[0759] In one aspect, an LNP composition comprising a polynucleotide encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides can be administered with another agent, e.g., as described herein.
[0760] Additional features of LNP compositions for use in combination therapy are provided in the section entitled "LNPs for use in therapy."
[0761] In one embodiment, the ratio between the lipid composition and the polynucleotide may range from about 10:1 to about 60:1 (wt / wt).
[0762] Nanoparticle composition
[0763] In some embodiments, the pharmaceutical compositions disclosed herein are formulated as lipid nanoparticles (LNPs). Therefore, the disclosure also provides nanoparticle compositions comprising (i) a lipid composition comprising a delivery agent (e.g., a compound as described herein), and (ii) a polynucleotide encoding a polypeptide of the present invention. In such nanoparticle compositions, the lipid composition disclosed herein can encapsulate a polynucleotide encoding a polypeptide of the present invention.
[0764] The size of the nanoparticle composition is generally micrometer-sized or smaller, and may include a lipid bilayer. The nanoparticle composition encompasses lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipid complexes (lipoplexes). For example, the nanoparticle composition may be a liposome with a lipid bilayer having a diameter of 500 nm or less.
[0765] Nanoparticle compositions include, for example, lipid nanoparticles (LNPs), liposomes, and lipid complexes. In some embodiments, the nanoparticle composition is a vesicle comprising one or more lipid bilayers. In certain embodiments, the nanoparticle composition comprises two or more concentric bilayers separated by aqueous compartments. The lipid bilayers may be functionalized and / or cross-linked to each other. The lipid bilayer may include one or more ligands, proteins, or channels.
[0766] In one embodiment, lipid nanoparticles include ionizable amino lipids, structural lipids, phospholipids and mRNA. In some embodiments, the LNP includes ionizable amino lipids, PEG-modified lipids, sterols and structural lipids. In some embodiments, the LNP has a molar ratio of about 40%-50% ionizable amino lipids; about 5%-15% structural lipids; about 30%-45% sterols; and about 1%-5% PEG-modified lipids.
[0767] In some embodiments, the polydispersity value of the LNP is less than 0.4. In some embodiments, the LNP has a net neutral charge at neutral pH. In some embodiments, the average diameter of the LNP is 50-150 nm. In some embodiments, the average diameter of the LNP is 80-100 nm.
[0768] As generally defined herein, the term "lipid" refers to a small molecule having a hydrophobic or amphipathic nature. Lipids may be naturally occurring or synthetic. Examples of lipid classes include, but are not limited to, fats, waxes, sterol-containing metabolites, vitamins, fatty acids, glycerolipids, glycerophospholipids, sphingolipids, glycolipids and polyketides and prenol lipids. In some cases, the amphipathic nature of some lipids results in the formation of liposomes, vesicles or membranes in aqueous media.
[0769] In some embodiments, lipid nanoparticles (LNP) may include ionizable amino lipids. As used herein, the term "ionizable amino lipids" has its common meaning in the art, and may refer to lipids comprising one or more charged moieties. In some embodiments, ionizable amino lipids may be positively charged or negatively charged. Ionizable amino lipids may be positively charged, in which case they may be referred to as "cationic lipids". In certain embodiments, ionizable amino lipid molecules may include amine groups, and may be referred to as ionizable amino lipids. As used herein, "charged moiety" is a chemical moiety that carries a formal electronic charge, such as monovalent (+1 or -1), divalent (+2 or -2), trivalent (+3 or -3), etc. The charged moiety may be an anion (i.e., negatively charged) or a cation (i.e., positively charged). Examples of positively charged moieties include amine groups (e.g., primary amines, secondary amines and / or tertiary amines), ammonium groups, pyridinium groups, guanidinium groups and imidazolium groups. In a specific embodiment, the charged moiety includes an amine group. Examples of negatively charged groups or their precursors include carboxylate groups, sulfonate groups, sulfate groups, phosphonate groups, phosphate groups, hydroxyl groups, etc. In some cases, the charge of the charged moiety can vary with environmental conditions, for example, pH changes can change the charge of the moiety, and / or make the moiety charged or uncharged. In general, the charge density of the molecule can be selected as desired.
[0770] It should be understood that the terms "charged" or "charged moiety" do not refer to a "partial negative charge" or "partial positive charge" on a molecule. The terms "partial negative charge" and "partial positive charge" have their ordinary meanings in the art. A "partial negative charge" can be created when a functional group contains a polarized bond such that electron density is pulled toward one atom of the bond, thereby creating a partial negative charge on the atom. In general, one of ordinary skill in the art will recognize bonds that can be polarized in this manner.
[0771] Ionizable amino lipids are sometimes referred to in the art as “ionizable cationic lipids.” In one embodiment, the ionizable amino lipid may have a positively charged hydrophilic head and a hydrophobic tail, the hydrophilic head and the hydrophobic tail being connected via a linker structure.
[0772] In addition to these ionizable amino lipids, the ionizable amino lipid may also be a lipid including a cyclic amine group.
[0773] In one embodiment, the ionizable amino lipid may be selected from, but not limited to, the ionizable amino lipids described in International Publication Nos. WO2013086354 and WO2013116126; the contents of each of which are incorporated herein by reference in their entirety.
[0774] In another embodiment, the ionizable amino lipid may be selected from, but is not limited to, the formula CLI-CLXXXXII of US Patent No. 7,404,969; each of which is herein incorporated by reference in its entirety.
[0775] In one embodiment, the lipid may be a cleavable lipid, such as those described in International Publication No. WO2012170889, which is incorporated herein by reference in its entirety. In one embodiment, the lipid may be synthesized by methods known in the art and / or as described in International Publication No. WO2013086354; the contents of each of the International Publications are incorporated herein by reference in their entirety.
[0776] Nanoparticle compositions can be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of nanoparticle compositions. Zeta potential can be measured using dynamic light scattering or potentiometric titration (e.g., potentiometric titration). Particle size can also be determined using dynamic light scattering. Multiple characteristics of nanoparticle compositions, such as particle size, polydispersity index, and zeta potential can also be measured using instruments such as Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK).
[0777] The size of the nanoparticles may help counteract biological responses such as, but not limited to, inflammation, or may increase the biological effect of the polynucleotide.
[0778] As used herein, "size" or "average size" in the context of a nanoparticle composition refers to the average diameter of the nanoparticle composition.
[0779] In one embodiment, the polynucleotide encoding the polypeptide is formulated in a lipid nanoparticle having a diameter of about 10 to about 100 nm, such as, but not limited to, about 10 to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm, about 30 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, From about 100 nm to about 80 nm, from about 100 nm to about 90 nm, from about 100 nm to about 100 nm, from about 150 nm to about 80 nm, from about 150 nm to about 90 nm, from about 150 nm to about 100 nm, from about 150 nm to about 80 nm, from about 150 nm to about 90 nm, from about 150 nm to about 100 nm, from about 150 nm to about 80 nm, from about 150 nm to about 90 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 80 nm, from about 150 nm to about 90 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm, from about 150 nm to about 100 nm,
[0780] In one embodiment, the diameter of the nanoparticle is about 10 to 500 nm. In one embodiment, the diameter of the nanoparticle is greater than 100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm, greater than 300 nm, greater than 350 nm, greater than 400 nm, greater than 450 nm, greater than 500 nm, greater than 550 nm, greater than 600 nm, greater than 650 nm, greater than 700 nm, greater than 750 nm, greater than 800 nm, greater than 850 nm, greater than 900 nm, greater than 950 nm, or greater than 1000 nm.
[0781] In some embodiments, the nanoparticle composition has a maximum dimension of 1 μm or less (e.g., 1 μm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, or less).
[0782] The nanoparticle composition can be relatively homogeneous. The polydispersity index can be used to indicate the homogeneity of the nanoparticle composition, such as the particle size distribution of the nanoparticle composition. A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. The polydispersity index of the nanoparticle composition can be from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of the nanoparticle composition disclosed herein can be from about 0.10 to about 0.20.
[0783] The zeta potential of a nanoparticle composition can be used to indicate the electrokinetic potential of the composition. For example, the zeta potential can describe the surface charge of a nanoparticle composition. Nanoparticle compositions with relatively low charges (positive or negative) are generally desirable because materials with higher charges can interact undesirably with cells, tissues, and other elements in the body. In some embodiments, the zeta potential of the nanoparticle compositions disclosed herein may be from about -10 mV to about +20 mV, about -10 mV to about +15 mV, about 10 mV to about +10 mV, about -10 mV to about +5 mV, about -10 mV to about 0 mV, about -10 mV to about -5 mV, about -5 mV to about +20 mV, about -5 mV to about +15 mV, about -5 mV to about +10 mV, about -5 mV to about +5 mV, about -5 mV to about 0 mV, about 0 mV to about +20 mV, about 0 mV to about +15 mV, about 0 mV to about +10 mV, about 0 mV to about +5 mV, about +5 mV to about +20 mV, about +5 mV to about +15 mV, or about +5 mV to about +10 mV.
[0784] In some embodiments, the zeta potential of the lipid nanoparticles may be from about 0 mV to about 100 mV, from about 0 mV to about 90 mV, from about 0 mV to about 80 mV, from about 0 mV to about 70 mV, from about 0 mV to about 60 mV, from about 0 mV to about 50 mV, from about 0 mV to about 40 mV, from about 0 mV to about 30 mV, from about 0 mV to about 20 mV, from about 0 mV to about 10 mV, from about 10 mV to about 100 mV, from about 10 mV to about 90 mV, from about 10 mV to about 80 mV, from about 10 mV to about 70 mV, from about 10 mV to about 60 mV, from about 10 mV to about 50 mV, from about 10 mV to about 40 mV, from about 10 mV to about 30 mV, from about 10 mV to about 20 mV, from about 20 mV to about 100 mV, about 20 mV to about 90 mV, about 20 mV to about 80 mV, about 20 mV to about 70 mV, about 20 mV to about 60 mV, about 20 mV to about 50 mV, about 20 mV to about 40 mV, about 20 mV to about 30 mV, about 30 mV to about 100 mV, about 30 mV to about 90 mV, about 30 mV to about 80 mV, about 30 mV to about 70 mV, about 30 mV to about 60 mV, about 30 mV to about 50 mV, about 30 mV to about 40 mV, about 40 mV to about 100 mV, about 40 mV to about 90 mV, about 40 mV to about 80 mV, about 40 mV to about 70 mV, about 40 mV to about 60 mV, and about 40 mV to about 50 mV. In some embodiments, the zeta potential of the lipid nanoparticles may be about 10 mV to about 50 mV, about 15 mV to about 45 mV, about 20 mV to about 40 mV, and about 25 mV to about 35 mV. In some embodiments, the zeta potential of the lipid nanoparticles may be about 10 mV, about 20 mV, about 30 mV, about 40 mV, about 50 mV, about 60 mV, about 70 mV, about 80 mV, about 90 mV, and about 100 mV.
[0785] The term "encapsulation efficiency" of a polynucleotide describes the amount of polynucleotide encapsulated or otherwise associated with the nanoparticle composition after preparation relative to the initial amount provided. As used herein, "encapsulation" can refer to complete, substantial or partial encapsulation, enclosure, surrounding or packaging.
[0786] It is desirable that the encapsulation efficiency is high (eg, close to 100%). For example, the encapsulation efficiency can be measured by comparing the amount of polynucleotides in a solution containing the nanoparticle composition before and after disintegration of the nanoparticle composition with one or more organic solvents or detergents.
[0787] Fluorescence can be used to measure the amount of free polynucleotides in solution. For the nanoparticle compositions described herein, the encapsulation efficiency of polynucleotides can be at least 50%, such as 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In some embodiments, the encapsulation efficiency can be at least 80%. In certain embodiments, the encapsulation efficiency can be at least 90%.
[0788] The amount of a polynucleotide present in a pharmaceutical composition disclosed herein may depend on factors such as the size of the polynucleotide, the desired target and / or application or other properties of the nanoparticle composition, and the properties of the polynucleotide.
[0789] For example, the amount of mRNA that can be used in a nanoparticle composition can depend on the size (expressed as length or molecular mass), sequence, and other characteristics of the mRNA. The relative amounts of polynucleotides in a nanoparticle composition can also vary.
[0790] The relative amounts of lipid compositions and polynucleotides present in the lipid nanoparticle compositions of the present disclosure can be optimized based on considerations of efficacy and tolerability. For compositions that include mRNA as the polynucleotide, the N:P ratio can be used as a useful metric.
[0791] Since the N:P ratio of the nanoparticle composition controls both expression and tolerance, nanoparticle compositions with low N:P ratios and strong expression are desirable. The N:P ratio varies depending on the ratio of lipid to RNA in the nanoparticle composition.
[0792] In general, lower N: P ratios are preferred. The one or more RNAs, lipids, and amounts thereof may be selected to provide an N: P ratio of about 2: 1 to about 30: 1, such as 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 12: 1, 14: 1, 16: 1, 18: 1, 20: 1, 22: 1, 24: 1, 26: 1, 28: 1, or 30: 1. In certain embodiments, the N: P ratio may be about 2: 1 to about 8: 1. In other embodiments, the N: P ratio is about 5: 1 to about 8: 1. In certain embodiments, the N: P ratio is between 5: 1 and 6: 1. In a specific aspect, the N: P ratio is about 5.67: 1.
[0793] In addition to providing nanoparticle compositions, the present disclosure also provides methods for producing lipid nanoparticles containing encapsulated polynucleotides. This method includes using any pharmaceutical composition disclosed herein and producing lipid nanoparticles according to methods known in the art for producing lipid nanoparticles. See, e.g., Wang et al. (2015) “Delivery of oligonucleotides with lipid nanoparticles” Adv. Drug Deliv. Rev. 87:68-80; Silva et al. (2015) “Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles” Curr. Pharm. Technol. 16:940-954; Naseri et al. (2015) “Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application” Adv. Pharm. Bull. 5:305-13; Silva et al. (2015) “Lipid nanoparticles for the delivery of biopharmaceuticals” Curr. Pharm. Biotechnol. 16:291-302, and references cited therein.
[0794] In some embodiments, the ratio between the lipid composition and the polynucleotide can be about 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1 : 1, 34: 1, 35: 1, 36: 1, 37: 1, 38: 1, 39: 1, 40: 1, 41: 1, 42: 1, 43: 1, 44: 1, 45: 1, 46: 1, 47: 1, 48: 1, 49: 1, 50: 1, 51: 1, 52: 1, 53: 1, 54: 1, 55: 1, 56: 1, 57: 1, 58: 1, 59: 1 or 60: 1 (wt / wt). In some embodiments, the wt / wt ratio of the lipid composition to the polynucleotide encoding the therapeutic agent is about 20: 1 or about 15: 1.
[0795] In some embodiments, the pharmaceutical compositions disclosed herein may contain more than one polypeptide. For example, the pharmaceutical compositions disclosed herein may contain two or more polynucleotides (eg, RNA, eg, mRNA).
[0796] In one embodiment, the lipid nanoparticles described herein can comprise a polynucleotide (e.g., mRNA) at a lipid: polynucleotide weight ratio of 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, or 70:1, or a range or any of these ratios, such as, but not limited to, 5:1 to about 10:1, about 5:1 to about 15:1, about 5:1 to about 20:1, about 5:1 to about 25:1, about 5:1 to about 30:1, about 5:1 to about 35:1, about 5:1 to about 40:1, about 5:1 to about 45:1, about 5:1 to about 50:1, about 5:1 to about 55:1, about 5:1 to about 60:1, about 5:1 to about 1 to about 70:1, about 10:1 to about 15:1, about 10:1 to about 20:1, about 10:1 to about 25:1, about 10:1 to about 30:1, about 10:1 to about 35:1, about 10:1 to about 40:1, about 10:1 to about 45:1, about 10:1 to about 50:1, about 10:1 to about 55:1, about 10:1 to about 60:1, about 10:1 to about 70:1, about 15:1 to about 20:1, about 15:1 to about 25:1, about 15:1 to about 30:1, about 15:1 to about 35:1, about 15:1 to about 40:1, about 15:1 to about 45:1, about 15:1 to about 50:1, about 15:1 to about 55:1, about 15:1 to about 60:1, or about 15:1 to about 70:1.
[0797] In one embodiment, the lipid nanoparticles described herein can comprise a polynucleotide at a concentration of about 0.1 mg / ml to 2 mg / ml, such as, but not limited to, 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml, 0.9 mg / ml, 1.0 mg / ml, 1.1 mg / ml, 1.2 mg / ml, 1.3 mg / ml, 1.4 mg / ml, 1.5 mg / ml, 1.6 mg / ml, 1.7 mg / ml, 1.8 mg / ml, 1.9 mg / ml, 2.0 mg / ml or greater than 2.0 mg / ml.
[0798] Methods of using LNP compositions comprising checkpoint cancer vaccines
[0799] In one aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP), such as an LNP composition described herein, comprising a polynucleotide and optionally one or more auxiliary amino acid sequences, wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides, and the composition is used, for example, according to the methods described herein to treat cancer in a subject.
[0800] In another aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP), such as an LNP composition described herein, comprising a polynucleotide and optionally one or more auxiliary amino acid sequences, wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides, and the composition is used to stimulate an immune response in a subject, such as according to the methods described herein.
[0801] In another aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP), such as an LNP composition described herein, comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides, the composition being used, for example, according to the methods described herein, to stimulate effector T cells to target and kill, for example, tumor cells expressing IDO or PD-L1 in a subject.
[0802] In another aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP), such as an LNP composition described herein, comprising a polynucleotide and optionally one or more auxiliary amino acid sequences or a combination thereof, wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides, and the composition is used to stimulate T cells, such as T effector cells, for example, according to the methods described herein.
[0803] In another aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP) (e.g., an LNP composition described herein), wherein the LNP comprises a polynucleotide and optionally one or more auxiliary amino acid sequences, wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides, and the composition is used, for example, according to the methods described herein to induce T cell-mediated vaccine-activated T cell killing of tumor cells.
[0804] In another aspect, the present disclosure provides a composition comprising a lipid nanoparticle (LNP), such as the LNP composition described herein, comprising a polynucleotide and optionally one or more auxiliary amino acid sequences, wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides, and the composition is used to treat cancer in a subject.
[0805] In a related aspect, provided herein is a method of treating cancer in a subject, the method comprising administering to the subject an effective amount of a lipid nanoparticle (LNP) comprising a polynucleotide and optionally one or more auxiliary amino acid sequences (e.g., an LNP composition described herein), wherein the polynucleotide comprises an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides.
[0806] In embodiments of any of the methods disclosed herein, administration of LNPs, e.g., as measured by an assay described herein, improves or delays cancer progression in a subject, e.g., as described herein. In embodiments, the improvement or delay in disease progression is compared to disease progression in an otherwise similar subject, e.g., a subject who has not been contacted with an LNP composition comprising a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides and optionally one or more auxiliary amino acid sequences.
[0807] In embodiments, the delay in cancer progression is a delay of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1.5 years, 2 years, 3 years, 4 years, or 5 years, or longer.
[0808] In some embodiments, the checkpoint cancer vaccine stimulates effector T cells, which target and kill inhibitory immune cells and tumor cells expressing target antigens. Therefore, in some embodiments, IDO-specific and PD-L1-specific T cells kill immunosuppressive (regulatory) immune cells and cancer cells that overexpress IDO and PD-L1. In some embodiments, treatment causes vaccine-activated T cells to kill other tumors. In addition, in some embodiments, the administration of checkpoint cancer vaccines causes T cell initiation, thereby leading to recognition of other tumor-associated antigens and leading to increased killing of tumors by tumor-specific cytotoxic T cells. Without wishing to be bound by theory, it is believed that systemic PD-1 / PD-L1 blockade can further amplify the effect, thereby causing further immune activation and excellent disease control.
[0809] In one embodiment, the cancer is a solid tumor, for example, a locally advanced or metastatic solid tumor. In one embodiment, the cancer is melanoma. In one embodiment, the melanoma is a skin melanoma. In one embodiment, the skin melanoma is 1L skin melanoma stage IIIB+. In one embodiment, the cancer is NSCLC. In one embodiment, the NSCLC is 1L NSCLC. In one embodiment, the cancer is bladder cancer. In some embodiments, the bladder cancer is non-muscle invasive bladder cancer. In one embodiment, the cancer is head and neck cancer. In some embodiments, the head and neck cancer is head and neck squamous cell carcinoma. In one embodiment, the cancer is colorectal cancer. In some embodiments, the colorectal cancer is microsatellite stable colorectal cancer. In one embodiment, the cancer is basal cell carcinoma. In one embodiment, the cancer is breast cancer. In some embodiments, the breast cancer is triple-negative breast cancer.
[0810] LNP administration and dosing regimen
[0811] In some embodiments, any LNP disclosed herein can be administered according to a dosing interval, for example, as described herein. In some embodiments, the dosing interval comprises an initial dose of a LNP composition and one or more subsequent doses of the same LNP composition (e.g., 1-50 doses, 5-50 doses, 10-50 doses, 15-50 doses, 20-50 doses, 25-50 doses, 30-50 doses, 35-50 doses, 40-50 doses, 45-50 doses, 1-45 doses, 1-40 doses, 1-35 doses, 1-30 doses, 1-25 doses, 1-20 doses, 1-15 doses, 1-10 doses, 1-5 doses).
[0812] In some embodiments, the dosing interval comprises one or more doses of the LNP composition and one or more doses of another dose.
[0813] In some embodiments, the dosing interval is implemented over at least 1 week, 2 weeks, 3 weeks, or 4 weeks.
[0814] In some embodiments, the dosing interval comprises a cycle, such as a seven-day cycle. In some embodiments, the cycle comprises 3 weeks (e.g., 21 days).
[0815] In some embodiments, the LNP composition is administered once every three weeks for one or more cycles. In some embodiments, the dosing regimen comprises two cycles, three cycles, four cycles, five cycles, six cycles, seven cycles, eight cycles, or nine cycles.
[0816] In some embodiments, the LNP composition is administered to a subject at a dose of about 50 μg to about 1 mg, for example, about 100 μg to about 1 mg, about 200 μg to about 900 μg, about 300 μg to about 800 μg, about 400 μg to about 700 μg, about 500 μg to about 600 μg, about 200 μg to about 1 mg, about 300 μg to about 1 mg, about 400 μg to about 1 mg, about 500 μg to about 1 mg, about 600 μg to about 1 mg, about 700 μg to about 1 mg, about 800 μg to about 1 mg, about 900 μg to about 1 mg. 1 mg, about 100 μg to about 900 μg, about 100 μg to about 800 μg, about 100 μg to about 700 μg, about 100 μg to about 600 μg, about 100 μg to about 500 μg, about 100 μg to about 400 μg, about 100 μg to about 300 μg, about 100 μg to about 200 μg, about 200 μg to about 400 μg, about 300 μg to about 500 μg, about 400 μg to about 600 μg, about 500 μg to about 700 μg, about 600 μg to about 800 μg, or about 700 μg to about 900 μg.
[0817] In some embodiments, the LNP composition is administered at a dose of about 100 μg to about 200 μg, about 200 μg to about 300 μg, about 300 μg to about 400 μg, about 400 μg to about 500 μg, about 500 μg to about 600 μg, about 600 μg to about 700 μg, about 700 μg to about 800 μg, about 800 μg to about 900 μg, or about 900 μg to about 1 mg. In some embodiments, the LNP composition is administered at a dose of about 50 μg to about 150 μg, about 150 μg to about 250 μg, about 250 μg to about 350 μg, about 350 μg to about 450 μg, about 450 μg to about 550 μg, about 550 μg to about 650 μg, about 650 μg to about 750 μg, about 750 μg to about 850 μg, about 850 μg to about 950 μg, or about 950 μg to about 1 mg. In some embodiments, the LNP composition is administered at a dose of about 100 μg, about 200 μg, about 300 μg, about 400 μg, about 500 μg, about 600 μg, about 700 μg, about 800 μg, about 900 μg, or about 1 mg.
[0818] In some embodiments of any of the LNP compositions disclosed herein, the LNP composition is administered at a dose (e.g., total dose) of about 0.1-10 mg / kg, about 0.1-9.5 mg / kg, about 0.1-9 mg / kg, about 0.1-8.5 mg / kg, about 0.1-8 mg / kg, about 0.1-7.5 mg / kg, about 0.1-7 mg / kg, about 0.1-6.5 mg / kg, about 0.1-6 mg / kg, about 0.1-5.5 mg / kg, about 0. 1-5mg / kg, about 0.1-4.5mg / kg, about 0.1-4mg / kg, about 0.1-3.5mg / kg, about 0.1-3mg / kg, about 0.1-2.5mg / kg, about 0.1-2mg / kg, about 0.1-1.5mg / kg, about 0.1-1mg / kg, about 0.1-0.9mg / kg, about 0.1-0.8mg / kg, about 0.1-0.7mg / kg, about 0.1-0.6mg / kg or about 0.1-0.5mg / kg.
[0819] In some embodiments of any of the LNP compositions disclosed herein, the LNP composition is administered at a dose (e.g., total dose) of about 0.2-10 mg / kg, about 0.3-10 mg / kg, about 0.4-10 mg / kg, about 0.5-10 mg / kg, about 0.6-10 mg / kg, about 0.7-10 mg / kg, about 0.8-10 mg / kg, about 0.9-10 mg / kg, about 1-10 mg / kg, about 1.5-10 mg / kg, about 2-10 mg / kg. kg, about 2.5-10 mg / kg, about 3-10 mg / kg, about 3.5-10 mg / kg, about 4-10 mg / kg, about 4.5-10 mg / kg, about 5-10 mg / kg, about 5.5-10 mg / kg, about 6-10 mg / kg, about 6.5-10 mg / kg, about 7-10 mg / kg, about 7.5-10 mg / kg, about 8-10 mg / kg, about 8.5-10 mg / kg, about 9-10 mg / kg or about 9.5-10 mg / kg.
[0820] In some embodiments, any of the LNPs disclosed herein are administered intramuscularly (IM).
[0821] Diseases and conditions
[0822] In one embodiment of any of the methods of treatment or compositions disclosed herein for use, the subject suffers from or is identified as suffering from cancer. In one embodiment, the LNP disclosed herein is administered to the subject to treat or ameliorate the symptoms of cancer. In one embodiment, the LNP disclosed herein is administered to the subject to stimulate an immune response in the subject.
[0823] In one embodiment, the cancer is a solid tumor, such as a locally advanced or metastatic solid tumor. In one embodiment, the cancer is melanoma. In some embodiments, the melanoma is a skin melanoma. In some embodiments, the skin melanoma is 1L skin melanoma IIIB+ stage. In one embodiment, the cancer is non-small cell lung cancer (NSCLC). In some embodiments, the NSCLC is 1L NSCLC. In one embodiment, the cancer is bladder cancer. In some embodiments, the bladder cancer is non-muscle invasive bladder cancer. In one embodiment, the cancer is head and neck cancer. In some embodiments, the head and neck cancer is head and neck squamous cell carcinoma. In one embodiment, the cancer is colorectal cancer. In some embodiments, the colorectal cancer is microsatellite stable colorectal cancer. In one embodiment, the cancer is basal cell carcinoma. In one embodiment, the cancer is breast cancer. In some embodiments, the breast cancer is triple-negative breast cancer.
[0824] In one embodiment, the subject is a mammal, such as a human.
[0825] Other combination therapies
[0826] In some embodiments, the methods of treatment or compositions disclosed herein for use include administering a combination of LNP disclosed herein and another agent. In one embodiment, the other agent is a standard of care for a disease or disorder (e.g., an autoimmune disease). In one embodiment, the other agent is mRNA.
[0827] In some aspects, the subject to which the methods or compositions of the present invention are directed has been treated with one or more standard of care therapies. In other aspects, the subject to which the methods or compositions of the present invention are directed is unresponsive to one or more standard of care therapies.
[0828] For example, a checkpoint inhibitor, such as an anti-PD1 antibody or an anti-CTLA4 antibody, is additionally administered to the subject. In some embodiments, the anti-PD-1 antibody is pembrolizumab.
[0829] The dosing of the combination therapy can be determined by a person skilled in the art. In some embodiments, an anti-PD-1 antibody (e.g., pembrolizumab) is administered to a subject (e.g., intravenously) at a dose of 200 mg once every three weeks or 400 mg once every six weeks, for example, for a total of twenty-four weeks. In some embodiments, an anti-PD-1 antibody (e.g., pembrolizumab) is administered to a subject (e.g., intravenously) at a dose of 400 mg once every 6 weeks (e.g., on the first day of every 3-week cycle, e.g., on the first day of cycle 1, cycle 3, cycle 5, cycle 7, and cycle 9).
[0830] In some embodiments, the additional therapy is administered to the patient simultaneously with the LNP composition (e.g., on the same day). In some embodiments, the additional therapy is administered separately from the LNP composition (e.g., on a separate day).
[0831] Sequence optimization and its methods
[0832] In some embodiments, the polynucleotides of the present disclosure comprise a sequence-optimized nucleotide sequence encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides. In some embodiments, the polynucleotides of the present disclosure comprise an open reading frame (ORF) encoding one or more IDO antigen peptides and one or more PD-L1 antigen peptides, wherein the ORF has been sequence optimized.
[0833] The sequence-optimized nucleotide sequences disclosed herein differ from corresponding wild-type nucleotide sequences and other known sequence-optimized nucleotide sequences, for example, in that these sequence-optimized nucleic acids have unique combinatorial properties.
[0834] In some embodiments, the percentage of uracil or thymine nucleobases in a sequence-optimized nucleotide sequence (e.g., encoding a checkpoint cancer vaccine) changes (e.g., decreases) relative to the percentage of uracil or thymine nucleobases in a reference wild-type nucleotide sequence. Such sequences are referred to as uracil-modified or thymine-modified sequences. The percentage of uracil or thymine content in a nucleotide sequence can be determined by dividing the number of uracil or thymine in the sequence by the total number of nucleotides and multiplying by 100. In some embodiments, the uracil or thymine content of a sequence-optimized nucleotide sequence is lower than the uracil or thymine content in a reference wild-type sequence. In some embodiments, the uracil or thymine content in a sequence-optimized nucleotide sequence of the present disclosure is greater than the uracil or thymine content in a reference wild-type sequence and still maintains a beneficial effect, such as an increase in expression and / or signal transduction response compared to a reference wild-type sequence.
[0835] In some embodiments, the optimized sequences of the present disclosure contain a unique range of uracil or thymine (if DNA) in the sequence. The uracil or thymine content of the optimized sequence can be expressed in various ways, such as relative to the theoretical minimum (UTM% or TTM%), relative to the wild type (UWT% or TWT%), and relative to the total nucleotide content (UTL% or TTL%) of the optimized sequence. For DNA, it is recognized that thymine is present instead of uracil, and T will be substituted where U appears. Therefore, all disclosures about RNA related to, for example, UTM%, UWT% or UTL% are equally applicable to TTM%, TWT% or TTL% about DNA.
[0836] The uracil content or thymine content relative to the theoretical minimum of uracil or thymine refers to a parameter determined by dividing the number of uracil or thymine in the sequence-optimized nucleotide sequence by the total number of uracil or thymine in a hypothetical nucleotide sequence (wherein all codons in the hypothetical sequence are replaced by synonymous codons with the lowest possible uracil or thymine content) and multiplying by 100. This parameter is abbreviated herein as UTM% or TTM%.
[0837] In some embodiments, the uracil modified sequence encoding the checkpoint cancer vaccine of the present disclosure has a reduced number of consecutive uracils relative to the corresponding wild-type nucleic acid sequence. For example, two consecutive leucines can be encoded by the sequence CUUUUG, which includes a four-uracil cluster. This subsequence can be replaced, for example, by CUGCUC, which removes the uracil cluster. Phenylalanine can be encoded by UUC or UUU. Therefore, even if the phenylalanine encoded by UUU is replaced by UUC, the synonymous codon still contains a uracil pair (UU). Therefore, the number of phenylalanine in the sequence establishes the minimum number of uracil pairs (UU), and the uracil pairs cannot be eliminated without changing the number of phenylalanine in the encoded polypeptide.
[0838] In some embodiments, the uracil modified sequence encoding the checkpoint cancer vaccine of the present disclosure has a reduced number of uracil triplets (UUU) relative to the wild-type nucleic acid sequence. In some embodiments, the uracil modified sequence encoding the checkpoint cancer vaccine has a reduced number of uracil pairs (UU) relative to the number of uracil pairs (UU) in the wild-type nucleic acid sequence. In some embodiments, the uracil modified sequence encoding the checkpoint cancer vaccine of the present disclosure has a number of uracil pairs (UU) corresponding to the minimum possible number of uracil pairs (UU) in the wild-type nucleic acid sequence.
[0839] The phrase "uracil pairs (UU) relative to uracil pairs (UU) in a wild-type nucleic acid sequence" refers to a parameter determined by dividing the number of uracil pairs (UU) in a sequence-optimized nucleotide sequence by the total number of uracil pairs (UU) in the corresponding wild-type nucleotide sequence and multiplying by 100. This parameter is abbreviated herein as UUwt%. In some embodiments, the uracil modified sequence encoding a checkpoint cancer vaccine has a UUwt% of less than 100%.
[0840] In some embodiments, the polynucleotides of the present disclosure include uracil modification sequences encoding the checkpoint cancer vaccines disclosed herein. In some embodiments, the uracil modification sequences encoding the checkpoint cancer vaccines include at least one chemically modified nucleobase, such as 5-methoxyuracil. In some embodiments, at least 95% of the nucleobases (e.g., uracil) in the uracil modification sequences encoding the checkpoint cancer vaccines disclosed herein are modified nucleobases. In some embodiments, at least 95% of the uracils in the uracil modification sequences encoding the checkpoint cancer vaccines are 5-methoxyuracil. In some embodiments, the polynucleotides comprising the uracil modification sequences also include miRNA binding sites, such as miRNA binding sites that bind to miR-122. In some embodiments, the polynucleotides comprising the uracil modification sequences are formulated with a delivery agent, such as a compound having formula (I), such as any one of compounds No. 18, No. 25, No. 301, or No. 357.
[0841] In some embodiments, a polynucleotide of the present disclosure (eg, a polynucleotide comprising a nucleotide sequence encoding a checkpoint cancer vaccine (eg, a wild-type sequence, a functional fragment or variant thereof)) is sequence optimized.
[0842] The sequence-optimized nucleotide sequence (nucleotide sequence is also referred to herein as a "nucleic acid") comprises at least one codon modification relative to a reference sequence (e.g., a wild-type sequence encoding a checkpoint cancer vaccine). Thus, in the sequence-optimized nucleic acid, at least one codon is different from the corresponding codon in the reference sequence (e.g., a wild-type sequence).
[0843] In general, sequence-optimized nucleic acids are produced by at least one step comprising replacing codons in a reference sequence with synonymous codons (i.e., codons encoding the same amino acid). Such substitutions can be achieved, for example, by applying a codon substitution map (i.e., providing a table of codons that will encode each amino acid in a codon-optimized sequence), or by applying a set of rules (e.g., if glycine is adjacent to a neutral amino acid, then glycine will be encoded by a certain codon, but if it is adjacent to a polar amino acid, then it will be encoded by another codon). In addition to codon substitution (i.e., "codon optimization"), the sequence optimization methods disclosed herein also include additional optimization steps that are not strictly for codon optimization, such as removing harmful motifs (making motif substitutions unstable).
[0844] Additional and exemplary methods of sequence optimization are disclosed in International PCT Application WO2017 / 201325 filed on May 18, 2017, the entire contents of which are hereby incorporated by reference.
[0845] MicroRNA (miRNA) binding sites
[0846] The polynucleotides of the present invention may include regulatory elements, such as microRNA (miRNA) binding sites, transcription factor binding sites, structured mRNA sequences and / or motifs, artificial binding sites engineered to act as pseudo-receptors for endogenous nucleic acid binding molecules, and combinations thereof. In some embodiments, polynucleotides including such regulatory elements are referred to as including "sensor sequences".
[0847] In some embodiments, the polynucleotides of the invention (e.g., ribonucleic acids (RNA), e.g., messenger RNA (mRNA)) comprise an open reading frame (ORF) encoding a polypeptide of interest and further comprise one or more miRNA binding sites. Based on the tissue-specific and / or cell-type-specific expression of naturally occurring miRNAs, inclusion or incorporation of miRNA binding sites provides regulation of the polynucleotides of the invention, and thereby the polypeptides encoded therein.
[0848] The present invention also provides pharmaceutical compositions and formulations comprising any of the polynucleotides described above. In some embodiments, the composition or formulation further comprises a delivery agent.
[0849] In some embodiments, the composition or formulation may contain a polynucleotide comprising a sequence-optimized nucleic acid sequence encoding a polypeptide disclosed herein. In some embodiments, the composition or formulation may contain a polynucleotide (e.g., RNA, e.g., mRNA) comprising a polynucleotide (e.g., ORF) having significant sequence identity to a sequence-optimized nucleic acid sequence encoding a polypeptide disclosed herein. In some embodiments, the polynucleotide further comprises a miRNA binding site, e.g., a miRNA binding site that binds
[0850] MiRNA (e.g., naturally occurring miRNA) is a non-coding RNA of 19-25 nucleotides in length that binds to a polynucleotide and downregulates gene expression by reducing the stability of the polynucleotide or by inhibiting its translation. The miRNA sequence comprises a "seed" region, i.e., a sequence in the 2-8 region of a mature miRNA. The miRNA seed may comprise positions 2-8 or 2-7 of a mature miRNA.
[0851] MicroRNA is enzymatically derived from a region of an RNA transcript, which itself forms a short hairpin structure commonly referred to as pre-miRNA (precursor miRNA). Pre-miRNA generally has a dinucleotide overhang at its 3' end, and has a 3' hydroxyl and a 5' phosphate group. This precursor mRNA is processed in the nucleus and subsequently transported to the cytoplasm, where it is further processed by DICER (RNase III) to form a mature microRNA of about 22 nucleotides. The mature microRNA is then incorporated into ribonucleic acid particles to form an RNA-induced silencing complex RISC, which mediates gene silencing. The naming of mature miRNAs recognized in the art generally specifies the arm of the pre-miRNA from which the mature miRNA is derived; "5p" means that the microRNA is from the 5' arm of the pre-miRNA hairpin, and "3p" means that the microRNA is from the 3' end of the pre-miRNA hairpin. The miR mentioned herein by numbers may refer to either of the two mature microRNAs (e.g., 3p or 5p microRNAs) derived from the opposite arms of the same pre-miRNA. Unless the 3p or 5p nomenclature is specifically specified, all miRs referred to herein are intended to include both the 3p and 5p arms / sequences.
[0852] As used herein, the term "microRNA (miRNA or miR) binding site" refers to a sequence within a polynucleotide, such as a sequence within a DNA or within an RNA transcript, including a sequence in a 5'UTR and / or a 3'UTR, which is sufficiently complementary to the entirety of a miRNA or a region of a miRNA to interact, associate or bind to the miRNA. In some embodiments, the polynucleotides of the present invention comprise an ORF encoding a polypeptide of interest and further comprise one or more miRNA binding sites. In an exemplary embodiment, the 5'UTR and / or 3'UTR of a polynucleotide (e.g., ribonucleic acid (RNA), such as a messenger RNA (mRNA)) comprises one or more miRNA binding sites.
[0853] The miRNA binding site has sufficient complementarity with the miRNA, which refers to a degree of complementarity sufficient to promote miRNA-mediated polynucleotide regulation, such as miRNA-mediated translational inhibition or degradation of polynucleotides. In exemplary aspects of the present invention, the miRNA binding site with sufficient complementarity to the miRNA refers to a degree of complementarity sufficient to promote miRNA-mediated polynucleotide degradation, such as miRNA-guided RNA-induced silencing complex (RISC)-mediated mRNA cleavage. The miRNA binding site may have complementarity with, for example, a miRNA sequence of 19-25 nucleotides in length, a miRNA sequence of 19-23 nucleotides in length, or a miRNA sequence of 22 nucleotides in length. The miRNA binding site may be complementary to only a portion of the miRNA, such as a portion of less than 1, 2, 3 or 4 nucleotides of a full-length naturally occurring miRNA sequence, or a portion of less than 1, 2, 3 or 4 nucleotides of a miRNA sequence shorter than a naturally occurring miRNA sequence. When the desired regulation is mRNA degradation, full complementarity or complete complementarity (e.g., full complementarity or complete complementarity over the entire naturally occurring miRNA length or a significant portion thereof) is preferred.
[0854] In some embodiments, the miRNA binding site includes a sequence that has complementarity (e.g., partial or complete complementarity) with a miRNA seed sequence. In some embodiments, the miRNA binding site includes a sequence that has complete complementarity with a miRNA seed sequence. In some embodiments, the miRNA binding site includes a sequence that has complementarity (e.g., partial or complete complementarity) with a miRNA sequence. In some embodiments, the miRNA binding site includes a sequence that has complete complementarity with a miRNA sequence. In some embodiments, the miRNA binding site has complete complementarity with the miRNA sequence, but has 1, 2, or 3 nucleotide substitutions, terminal additions, and / or truncations.
[0855] In some embodiments, the miRNA binding site is the same length as the corresponding miRNA. In other embodiments, the miRNA binding site is one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve nucleotides shorter than the corresponding miRNA at 5' end, 3' end or both. In other embodiments, the microRNA binding site is two nucleotides shorter than the corresponding microRNA at 5' end, 3' end or both. The miRNA binding site shorter than the corresponding miRNA can still degrade the mRNA incorporated into one or more miRNA binding sites or prevent the mRNA from translating.
[0856] In some embodiments, the miRNA binding site binds to the corresponding mature miRNA as a part of the active RISC containing Dicer. In another embodiment, the binding of the miRNA binding site to the corresponding miRNA in RISC degrades the mRNA containing the miRNA binding site or prevents the mRNA from being translated. In some embodiments, the miRNA binding site has enough complementarity with the miRNA so that the RISC complex containing the miRNA cleaves the polynucleotide containing the miRNA binding site. In other embodiments, the miRNA binding site has incomplete complementarity so that the RISC complex containing the miRNA induces the instability of the polynucleotide containing the miRNA binding site. In another embodiment, the miRNA binding site has incomplete complementarity so that the RISC complex containing the miRNA inhibits the transcription of the polynucleotide containing the miRNA binding site.
[0857] In some embodiments, the miRNA binding site has one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve mismatches with the corresponding miRNA.
[0858] In some embodiments, a miRNA binding site has at least about ten, at least about eleven, at least about twelve, at least about thirteen, at least about fourteen, at least about fifteen, at least about sixteen, at least about seventeen, at least about eighteen, at least about nineteen, at least about twenty, or at least about twenty-one contiguous nucleotides complementary to at least about ten, at least about eleven, at least about twelve, at least about thirteen, at least about fourteen, at least about fifteen, at least about sixteen, at least about seventeen, at least about eighteen, at least about nineteen, at least about twenty, or at least about twenty-one contiguous nucleotides of a corresponding miRNA, respectively.
[0859] By engineering one or more miRNA binding sites into the polynucleotides of the present invention, the polynucleotides can be targeted for degradation or reduced translation, provided that the miRNA in question is available. This can reduce the off-target effect during polynucleotide delivery. For example, if the polynucleotides of the present invention are not intended to be delivered to tissues or cells, but eventually reach the tissues or cells, if one or more binding sites of miRNA are engineered into the 5'UTR and / or 3'UTR of the polynucleotides, the miRNA enriched in the tissues or cells can inhibit the expression of the gene of interest. Therefore, in some embodiments, incorporating one or more miRNA binding sites into the mRNA of the present invention can reduce the off-target effect hazards during nucleic acid molecule delivery and / or enable tissue-specific regulation of the expression of the polypeptide encoded by the mRNA. In other embodiments, incorporating one or more miRNA binding sites into the mRNA of the present invention can regulate the immune response during nucleic acid delivery in vivo. In other embodiments, incorporating one or more miRNA binding sites into the mRNA of the present invention can regulate the accelerated blood clearance (ABC) of the compounds and compositions comprising lipids described herein.
[0860] Conversely, miRNA binding sites can be removed from the polynucleotide sequence in which they naturally occur to increase protein expression in a specific tissue. For example, a binding site for a specific miRNA can be removed from a polynucleotide to improve protein expression in a tissue or cell containing the miRNA.
[0861] Regulation of expression in multiple tissues can be achieved by introducing or removing one or more miRNA binding sites (e.g., one or more different miRNA binding sites). Whether to remove or insert a miRNA binding site can be determined based on the miRNA expression pattern and / or analysis of the expression pattern in tissues and / or cells in development and / or disease. The identification of miRNAs, miRNA binding sites, and their expression patterns, as well as their biological roles have been reported (e.g., Bonauer et al., Curr Drug Targets 2010 11:943-949; Anand and Cheresh, Curr Opin Hematol 2011 18:171-176; Contreras and Rao, Leukemia 2012 26:404-413 (Dec. 20, 2011. doi:10.1038 / leu.2011.356); Bartel Cell 2009 136:215-233; Landgraf et al., Cell, 2007 129:1401-1414; Gentner and Naldini, Tissue Antigens. 2012 80:393-403 and all references therein; each of which is incorporated herein by reference in its entirety).
[0862] Examples of tissues in which miRNAs are known to regulate mRNA, and thereby protein expression, include, but are not limited to, liver (miR-122), muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), myeloid cells (miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart (miR-1d, miR-149), kidney (miR-192, miR-194, miR-204), and lung epithelial cells (let-7, miR-133, miR-126).
[0863] Specifically, it is known that miRNAs are differentially expressed in immune cells (also called hematopoietic cells), such as antigen presenting cells (APCs) (e.g., dendritic cells and macrophages), macrophages, monocytes, B lymphocytes, T lymphocytes, granulocytes, natural killer cells, etc. Immune cell-specific miRNAs are involved in immunogenicity, autoimmunity, immune responses to infection, inflammation, and undesirable immune responses after gene therapy and tissue / organ transplantation. Immune cell-specific miRNAs also regulate many aspects of the development, proliferation, differentiation, and apoptosis of hematopoietic cells (immune cells). For example, miR-142 and miR-146 are only expressed in immune cells, and are particularly abundant in myeloid dendritic cells. It has been shown that the immune response to polynucleotides can be turned off by adding miR-142 binding sites to the 3'-UTR of polynucleotides, thereby making gene transfer in tissues and cells more stable. miR-142 effectively degrades exogenous polynucleotides in antigen-presenting cells and suppresses cytotoxic elimination of transduced cells (e.g., Annoni A et al., blood, 2009, 114, 5152-5161; Brown BD et al., Nat med. 2006, 12(5), 585-591; Brown BD et al., blood, 2007, 110(13):4144-4152, each of which is incorporated herein by reference in its entirety).
[0864] In some embodiments, the polynucleotides of the invention comprise a miRNA binding site, wherein the miRNA binding site comprises one or more nucleotide sequences selected from Table 3C or Table 4A, including one or more copies of any one or more miRNA binding site sequences. In some embodiments, the polynucleotides of the invention further comprise at least one, two, three, four, five, six, seven, eight, nine, ten or more identical or different miRNA binding sites selected from Table 3C or Table 4A, including any combination thereof.
[0865] In some embodiments, the miRNA binding site binds to miR-142 or is complementary to miR-142. In some embodiments, miR-142 comprises SEQ ID NO: 200. In some embodiments, the miRNA binding site binds to miR-142-3p or miR-142-5p. In some embodiments, the miR-142-3p binding site comprises SEQ ID NO: 202. In some embodiments, the miR-142-5p binding site comprises SEQ ID NO: 204. In some embodiments, the miRNA binding site comprises a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 202 or SEQ ID NO: 204.
[0866] In some embodiments, the miRNA binding site binds to miR-126 or is complementary to miR-126. In some embodiments, miR-126 comprises SEQ ID NO: 205. In some embodiments, the miRNA binding site binds to miR-126-3p or miR-126-5p. In some embodiments, the miR-126-3p binding site comprises SEQ ID NO: 207. In some embodiments, the miR-126-5p binding site comprises SEQ ID NO: 710. In some embodiments, the miRNA binding site comprises a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 121 or SEQ ID NO: 123.
[0867] In one embodiment, the 3'UTR comprises two miRNA binding sites, wherein the first miRNA binding site binds to miR-142 and the second miRNA binding site binds to miR- 126. In a specific embodiment, the 3'UTR that binds to miR-142 and miR-126 comprises, consists of, or consists essentially of the sequence of SEQ ID NO: 249.
[0868] Table 3C. miR-142, miR-126 and miR-142 and miR-126 binding sites
[0869]
[0870] In some embodiments, the miRNA binding site is inserted into any position of the polynucleotide in the polynucleotide of the present invention (e.g., 5'UTR and / or 3'UTR). In some embodiments, the 5'UTR comprises a miRNA binding site. In some embodiments, the 3'UTR comprises a miRNA binding site. In some embodiments, the 5'UTR and the 3'UTR comprise miRNA binding sites. The insertion site in the polynucleotide may be located anywhere in the polynucleotide, as long as the insertion of the miRNA binding site in the polynucleotide does not interfere with the translation of the functional polypeptide in the absence of the corresponding miRNA; and in the presence of the miRNA, the insertion of the miRNA binding site in the polynucleotide and the binding of the miRNA binding site to the corresponding miRNA can degrade the polynucleotide or prevent the translation of the polynucleotide.
[0871] In some embodiments, the miRNA binding site is inserted at least about 30 nucleotides downstream of the stop codon of the ORF in the polynucleotide of the present invention comprising the ORF. In some embodiments, the miRNA binding site is inserted at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides, or at least about 100 nucleotides downstream of the stop codon of the ORF in the polynucleotide of the present invention. In some embodiments, the miRNA binding site is inserted about 10 nucleotides to about 100 nucleotides, about 20 nucleotides to about 90 nucleotides, about 30 nucleotides to about 80 nucleotides, about 40 nucleotides to about 70 nucleotides, about 50 nucleotides to about 60 nucleotides, about 45 nucleotides to about 65 nucleotides downstream of the stop codon of the ORF in the polynucleotide of the present invention.
[0872] In some embodiments, the miRNA binding site is inserted in the 3'UTR immediately after the terminator codon of the coding region in the polynucleotide (e.g., mRNA) of the present invention. In some embodiments, if there are multiple copies of terminator codons in the construct, the miRNA binding site is inserted immediately after the last terminator codon. In some embodiments, the miRNA binding site is inserted in the further downstream of the terminator codon, in which case there is a 3'UTR base between the terminator codon and the miR binding site. In some embodiments, three non-limiting examples of possible insertion sites of miR in 3'UTR are shown in SEQ ID NO:248, 249, and 250, which show that the miR-142-3p site is inserted into the 3'UTR sequence in one of the three different possible insertion sites in 3'UTR, respectively.
[0873] In some embodiments, one or more miRNA binding sites may be located at one or more possible insertion sites within the 5'UTR. For example, three non-limiting examples of possible insertion sites of miR in the 5'UTR are shown in SEQ ID NO: 251, 252 or 253, which show that the miR-142-3p site is inserted into the 5'UTR sequence in one of the three different possible insertion sites within the 5'UTR.
[0874] In one embodiment, the codon-optimized open reading frame encoding the polypeptide of interest comprises a stop codon, and at least one microRNA binding site is located within the 3'UTR of 1-100 nucleotides after the stop codon. In one embodiment, the codon-optimized open reading frame encoding the polypeptide of interest comprises a stop codon, and at least one microRNA binding site for the miR expressed in the immune cell is located within the 3'UTR of 30-50 nucleotides after the stop codon. In another embodiment, the codon-optimized open reading frame encoding the polypeptide of interest comprises a stop codon, and at least one microRNA binding site for the miR expressed in the immune cell is located within the 3'UTR of at least 50 nucleotides after the stop codon. In other embodiments, the codon-optimized open reading frame encoding the polypeptide of interest comprises a stop codon, and at least one microRNA binding site for the miR expressed in the immune cell is located within the 3'UTR immediately after the stop codon, or within the 3'UTR of 15-20 nucleotides after the stop codon, or within the 3'UTR of 70-80 nucleotides after the stop codon. In other embodiments, the 3'UTR comprises more than one miRNA binding site (e.g., 2-4 miRNA binding sites), wherein a spacer (e.g., 10-100, 20-70, or 30-50 nucleotides in length) may be present between each miRNA binding site. In another embodiment, the 3'UTR comprises a spacer between the end of the miRNA binding site and the poly A tail nucleotides. For example, a spacer of 10-100, 20-70, or 30-50 nucleotides in length may be located between the end of the miRNA binding site and the start of the poly A tail.
[0875] In one embodiment, the codon optimized open reading frame encoding the polypeptide of interest comprises a start codon, and at least one microRNA binding site is located within the 5'UTR of 1-100 nucleotides before (upstream) the start codon. In one embodiment, the codon optimized open reading frame encoding the polypeptide of interest comprises a start codon, and at least one microRNA binding site of the miR expressed in the immune cell is located within the 5'UTR of 10-50 nucleotides before (upstream) the start codon. In another embodiment, the codon optimized open reading frame encoding the polypeptide of interest comprises a start codon, and at least one microRNA binding site of the miR expressed in the immune cell is located within the 5'UTR of at least 25 nucleotides before (upstream) the start codon. In other embodiments, the codon optimized open reading frame encoding the polypeptide of interest comprises a start codon, and at least one microRNA binding site of the miR expressed in the immune cell is located within the 5'UTR immediately before the start codon, or within the 5'UTR of 15-20 nucleotides before the start codon, or within the 5'UTR of 70-80 nucleotides before the start codon. In other embodiments, the 5'UTR comprises more than one miRNA binding site (eg, 2-4 miRNA binding sites), wherein there may be a spacer region (eg, 10-100, 20-70, or 30-50 nucleotides in length) between each miRNA binding site.
[0876] In one embodiment, 3'UTR comprises more than one stop codon, wherein at least one miRNA binding site is positioned downstream of the stop codon. For example, 3'UTR may comprise 1, 2 or 3 stop codons. Non-limiting examples of usable triple stop codons include: UGAUAAUAG, UGAUAGUAA, UAAUGAUAG, UGAUAAUAA, UGAUAGUAG, UAAUGAUGA, UAAUAGUAG, UGAUGAUGA, UAAAUAAUAA and UAGUAGUAG. For example, in 3'UTR, 1, 2, 3 or 4 miRNA binding sites (such as miR-142-3p binding sites) may be positioned next to the stop codon or at any number of nucleotides downstream of the last stop codon. When 3'UTR comprises multiple miRNA binding sites, these binding sites may be positioned directly adjacent to each other in the construct (i.e., one by one), or alternatively, spacer nucleotides may be positioned between each binding site.
[0877] In one embodiment, the 3'UTR comprises three stop codons and a single miR-142-3p binding site located downstream of the 3rd stop codon. Non-limiting examples of 3'UTR sequences having three stop codons and a single miR-142-3p binding site located at different positions downstream of the last stop codon are shown in SEQ ID NOs: 237, 248, 249 and 250.
[0878] Table 4A. 5'UTR, 3'UTR, miR sequences and miR binding sites
[0879]
[0880]
[0881]
[0882]
[0883]
[0884]
[0885]
[0886]
[0887]
[0888]
[0889] Stop codon = bold
[0890] miR 142-3p binding site = underline
[0891] miR 126-3p binding sites = bold underlined
[0892] miR 155-5p binding site = italics
[0893] miR 142-5p binding sites = italics and bold underline
[0894] In one embodiment, the polynucleotide of the present invention comprises a 5'UTR, a codon-optimized open reading frame encoding a polypeptide of interest, a 3'UTR comprising at least one miRNA binding site for a miR expressed in an immune cell, and a 3' tailing region of linked nucleosides. In various embodiments, the 3'UTR comprises 1-4, at least two, one, two, three or four miRNA binding sites for a miR expressed in an immune cell (preferably expressed in large amounts or preferentially in an immune cell).
[0895] In one embodiment, the at least one miRNA expressed in the immune cell is a miR-142-3p microRNA binding site. In one embodiment, the miR-142-3p microRNA binding site comprises the sequence shown in SEQ ID NO:202. In one embodiment, the 3'UTR of the mRNA comprising the miR-142-3p microRNA binding site comprises the sequence shown in SEQ ID NO:220.
[0896] In one embodiment, the at least one miRNA expressed in the immune cell is a miR-126 microRNA binding site. In one embodiment, the miR-126 binding site is a miR-126-3p binding site. In one embodiment, the miR-126-3p microRNA binding site comprises the sequence shown in SEQ ID NO:207. In one embodiment, the 3'UTR of the mRNA of the present invention comprising the miR-126-3p microRNA binding site comprises the sequence shown in SEQ ID NO:235.
[0897] Non-limiting exemplary sequences of miRs to which the microRNA binding sites of the present disclosure can bind include the following: miR-142-3p (SEQ ID NO: 201), miR-142-5p (SEQ ID NO: 203), miR-146-3p (SEQ ID NO: 221), miR-146-5p (SEQ ID NO: 222), miR-155-3p (SEQ ID NO: 223), miR-155-5p (SEQ ID NO: 224), miR-126-3p (SEQ ID NO: 206), miR-126-5p (SEQ ID NO: 208), miR-16-3p (SEQ ID NO: 225), miR-16-5p (SEQ ID NO: 226), miR-21-3p (SEQ ID NO: 227), miR-21-5p (SEQ ID NO: 228), miR-223-3p (SEQ ID NO: 229), miR-224-5p (SEQ ID NO: 230), miR-225-5p (SEQ ID NO: 231), miR-226-3p (SEQ ID NO: 232), miR-226-5p (SEQ ID NO: 233), miR-227-5p (SEQ ID NO: 234), miR-228-3p (SEQ ID NO: 235), miR-228-5p (SEQ ID NO: 236), miR-229-3p (SEQ ID NO: 237), miR-229-5p (SEQ ID NO: 238), miR-229-3p (SEQ ID NO: 239), miR-229-5p (SEQ ID NO: 240), miR-229-3p (SEQ ID NO: NO: 143), miR-223-5p (SEQ ID NO: 230), miR-24-3p (SEQ ID NO: 231), miR-24-5p (SEQ ID NO: 232), miR-27-3p (SEQ ID NO: 233) and miR-27-5p (SEQ ID NO: 234). Other suitable miR sequences expressed in immune cells (e.g., expressed in large amounts or preferentially in immune cells) are known in the art and available, for example, in the microRNA database miRBase of the University of Manchester. Sites for binding to any of the above-mentioned miRs can be designed based on Watson-Crick complementarity to the miR (usually 100% complementarity to the miR) and inserted into the mRNA constructs of the present disclosure as described herein.
[0898] In another embodiment, the polynucleotides of the invention (e.g., and mRNA, e.g., 3'UTR thereof) may comprise at least one miRNA binding site to reduce or inhibit accelerated blood clearance, e.g., by reducing or inhibiting IgM production by B cells (e.g., to PEG) and / or reducing or inhibiting proliferation and / or activation of pDCs, and may comprise at least one miRNA binding site for regulating tissue expression of the encoded protein of interest.
[0899] miRNA gene regulation can be affected by the sequences surrounding the miRNA, such as, but not limited to, the species of the surrounding sequences, the sequence type (e.g., heterologous, homologous, exogenous, endogenous, or artificial), regulatory elements in the surrounding sequences, and / or structural elements in the surrounding sequences. miRNAs can be affected by 5'UTR and / or 3'UTR. As a non-limiting example, a non-human 3'UTR can increase the regulatory effect of a miRNA sequence on the expression of a polypeptide of interest compared to a human 3'UTR of the same sequence type.
[0900] In one embodiment, other regulatory elements and / or structural elements of the 5'UTR may affect miRNA-mediated gene regulation. An example of a regulatory element and / or structural element is a structured IRES (internal ribosome entry site) in the 5'UTR, which is necessary for binding translation elongation factors to initiate protein translation. The binding of EIF4A2 to this secondary structural element in the 5'-UTR is necessary for miRNA-mediated gene expression (Meijer HA et al., Science, 2013, 340, 82-85, which is incorporated herein by reference in its entirety). The polynucleotides of the present invention may also include this structured 5'UTR to enhance microRNA-mediated gene regulation.
[0901] At least one miRNA binding site can be engineered into the 3'UTR of the polynucleotide of the present invention. In this case, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten or more miRNA binding sites can be engineered into the 3'UTR of the polynucleotide of the present invention. For example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 2 or 1 miRNA binding site can be engineered into the 3'UTR of the polynucleotide of the present invention. In one embodiment, the miRNA binding site incorporated into the polynucleotide of the present invention can be the same or can be different miRNA sites. The combination of different miRNA binding sites incorporated into the polynucleotide of the present invention can include a combination of more than one copy of any different miRNA sites incorporated into. In another embodiment, the miRNA binding site incorporated into the polynucleotide of the present invention can target the same or different tissues in vivo. As a non-limiting example, by introducing tissue-specific, cell type-specific or disease-specific miRNA binding sites in the 3'-UTR of the polynucleotides of the invention, the expression level in specific cell types (eg, myeloid cells, endothelial cells, etc.) can be reduced.
[0902] In one embodiment, in the polynucleotides of the present invention, the miRNA binding site can be engineered near the 5' end of the 3'UTR, about midway between the 5' end and the 3' end of the 3'UTR, and / or near the 3' end of the 3'UTR. As a non-limiting example, the miRNA binding site can be engineered near the 5' end of the 3'UTR and about midway between the 5' end and the 3' end of the 3'UTR. As another non-limiting example, the miRNA binding site can be engineered near the 3' end of the 3'UTR and about midway between the 5' end and the 3' end of the 3'UTR. In another non-limiting example, the miRNA binding site can be engineered near the 5' end of the 3'UTR and near the 3' end of the 3'UTR.
[0903] In another embodiment, the 3'UTR may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 miRNA binding sites. The miRNA binding sites may be complementary to the miRNA, the miRNA seed sequence and / or the miRNA sequences flanking the seed sequence.
[0904] In some embodiments, the expression of the polynucleotides of the invention can be controlled by incorporating at least one sensor sequence in the polynucleotide and formulating the polynucleotide for administration. As a non-limiting example, the polynucleotides of the invention can be targeted to tissues or cells by incorporating miRNA binding sites and formulating the polynucleotides of the invention in lipid nanoparticles comprising ionizable lipids, including any lipids described herein.
[0905] Based on the expression pattern of miRNA in different tissues, cell types or biological conditions, the polynucleotides of the present invention can be engineered to perform more targeted expression in specific tissues, cell types or biological conditions. By introducing tissue-specific miRNA binding sites, the polynucleotides of the present invention can be designed for optimal protein expression in tissues or cells or under biological conditions.
[0906] In some embodiments, the polynucleotides of the present invention can be designed to incorporate a miRNA binding site that has 100% identity to a known miRNA seed sequence or has less than 100% identity to a miRNA seed sequence. In some embodiments, the polynucleotides of the present invention can be designed to incorporate a miRNA binding site that has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to a known miRNA seed sequence. The miRNA seed sequence can be partially mutated to reduce miRNA binding affinity, and thus cause the reduction of polynucleotides. In essence, the match or mismatch between the miRNA binding site and the miRNA seed can be used as a modulator (rheostat) to more finely regulate the ability of miRNA to regulate protein expression. In addition, mutations in the non-seed region of the miRNA binding site can also affect the ability of miRNA to regulate protein expression.
[0907] In one embodiment, the miRNA sequence may be incorporated into the loop of the stem-loop.
[0908] In another embodiment, a miRNA seed sequence may be incorporated into the loop of the stem-loop, and a miRNA binding site may be incorporated into the 5' or 3' stem of the stem-loop.
[0909] In one embodiment, a miRNA sequence in the 5'UTR can be used to stabilize the polynucleotides of the invention described herein.
[0910] In another embodiment, the miRNA sequence in the 5'UTR of the polynucleotide of the present invention can be used to reduce the accessibility of the translation start site (such as but not limited to the start codon). See, for example, Matsuda et al., PLoS One. 2010 11 (5): e15057; incorporated herein by reference in its entirety, which uses antisense locked nucleic acid (LNA) oligonucleotides and exon junction complexes (EJC) around the start codon (-4 to +37, wherein the A of the AUG codon is +1) to reduce the accessibility to the first start codon (AUG). Matsuda showed that using LNA or EJC to change the sequence around the start codon affects the efficiency, length and structural stability of the polynucleotide. The polynucleotide of the present invention can include a miRNA sequence near the translation start site instead of the LNA or EJC sequence described by Matsuda et al. to reduce the accessibility of the translation start site. The translation start site can be before, after or within the miRNA sequence. As a non-limiting example, the translation start site can be located within the miRNA sequence, such as a seed sequence or a binding site.
[0911] In some embodiments, the polynucleotides of the present invention may include at least one miRNA to inhibit antigen presentation of antigen presenting cells. The miRNA may be a complete miRNA sequence, a miRNA seed sequence, a miRNA sequence without seeds, or a combination thereof. As a non-limiting example, the miRNA incorporated into the polynucleotides of the present invention may be specific to the hematopoietic system. As another non-limiting example, the miRNA incorporated into the polynucleotides of the present invention to inhibit antigen presentation is miR-142-3p.
[0912] In some embodiments, the polynucleotides of the present invention may include at least one miRNA to inhibit the expression of the encoded polypeptide in the tissue or cell of interest. As a non-limiting example, the polynucleotides of the present invention may include at least one miR-142-3p binding site, a miR-142-3p seed sequence, a miR-142-3p binding site without seeds, a miR-142-5p binding site, a miR-142-5p seed sequence, a miR-142-5p binding site without seeds, a miR-146 binding site, a miR-146 seed sequence, and / or a miR-146 binding site without a seed sequence.
[0913] In some embodiments, the polynucleotides of the present invention may include at least one miRNA binding site in the 3'UTR to selectively degrade mRNA therapeutics in immune cells, thereby inhibiting undesirable immunogenic responses caused by therapeutic delivery. As a non-limiting example, the miRNA binding site may render the polynucleotides of the present invention less stable in antigen presenting cells. Non-limiting examples of these miRNAs include miR-142-5p, miR-142-3p, miR-146a-5p, and miR-146-3p.
[0914] In one embodiment, the polynucleotide of the present invention comprises at least one miRNA sequence in a region of the polynucleotide that can interact with an RNA binding protein.
[0915] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) of the invention comprises (i) a sequence-optimized nucleotide sequence (e.g., ORF) encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides, and (ii) a miRNA binding site (e.g., a miRNA binding site that binds to miR-142) and / or a miRNA binding site that binds to miR-126.
[0916] IVT polynucleotide architecture
[0917] In some embodiments, the polynucleotides of the present disclosure comprising mRNA encoding a checkpoint cancer vaccine are IVT polynucleotides, wherein the checkpoint cancer vaccine comprises (i) one or more IDO antigen peptides and (ii) one or more PD-L1 antigen peptides. Traditionally, the basic components of an mRNA molecule include at least a coding region, a 5'UTR, a 3'UTR, a 5' cap, and a poly A tail. The IVT polynucleotides of the present disclosure can function as mRNA, but differ from wild-type mRNA in their functional and / or structural design features, which are used, for example, to overcome existing problems in effectively producing polypeptides using nucleic acid-based therapeutics.
[0918] The primary construct of the IVT polynucleotide comprises a first region of linked nucleotides, flanked by a first flanking region and a second flanking region. This first region may include, but is not limited to, the encoded checkpoint cancer vaccine. The first flanking region may include a sequence of linked nucleosides that functions as a 5' untranslated region (UTR), such as a 5'UTR of any nucleic acid encoding a natural 5'UTR or a non-natural 5'UTR (such as, but not limited to, a heterologous 5'UTR or a synthetic 5'UTR) of a polypeptide. The IVT encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides may include a signal sequence region encoding one or more signal sequences at its 5' end. The flanking region may include a linked nucleotide region containing one or more complete or incomplete 5'UTR sequences. The flanking region may also include a 5' terminal cap. The second flanking region may include a linked nucleotide region containing one or more complete or incomplete 3'UTRs, which may encode a natural 3'UTR or a non-natural 3'UTR (such as, but not limited to, a heterologous 3'UTR or a synthetic 3'UTR) of a checkpoint cancer vaccine. The flanking region may also include a 3' tailing sequence. The 3' tailing sequence may be (but is not limited to) a poly A tail, a poly AG quadruplex and / or a stem-loop sequence.
[0919] Additional and exemplary features of the IVT polynucleotide architecture are disclosed in International PCT Application WO 2017 / 201325 filed on May 18, 2017, the entire contents of which are incorporated herein by reference.
[0920] 5'UTR and 3'UTR
[0921] The UTR may be homologous or heterologous to the coding region in the polynucleotide. In some embodiments, the UTR is homologous to an ORF encoding a checkpoint cancer vaccine comprising (i) one or more IDO antigenic peptides and (ii) one or more PD-L1 antigenic peptides.
[0922] In some embodiments, the polynucleotide comprises two or more 5'UTRs or functional fragments thereof, each having the same or different nucleotide sequences. In some embodiments, the polynucleotide comprises two or more 3'UTRs or functional fragments thereof, each having the same or different nucleotide sequences.
[0923] In some embodiments, the 5'UTR or a functional fragment thereof, the 3'UTR or a functional fragment thereof, or any combination thereof is sequence optimized.
[0924] In some embodiments, the 5'UTR or a functional fragment thereof, the 3'UTR or a functional fragment thereof, or any combination thereof comprises at least one chemically modified nucleobase, such as N1-methylpseudouracil or 5-methoxyuracil.
[0925] The UTR may have features that provide regulatory effects, such as increasing or decreasing stability, localization, and / or translation efficiency. A polynucleotide comprising a UTR may be administered to a cell, tissue, or organism, and one or more regulatory features may be measured using conventional methods. In some embodiments, a functional fragment of a 5'UTR or 3'UTR comprises one or more regulatory features of a full-length 5' or 3'UTR, respectively.
[0926] Natural 5'UTRs carry features that play a role in translation initiation. They bear a signature like the Kozak sequence, which is well known to be involved in the process by which ribosomes initiate translation of many genes. Kozak sequences have in common CCR(A / G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), followed by another 'G'. 5'UTRs are also known to form secondary structures that are involved in the binding of elongation factors.
[0927] By engineering features that are typically found in abundantly expressed genes in a particular target organ, the stability and protein production of the polynucleotide can be enhanced. For example, introduction of a 5'UTR of a liver-expressed mRNA (e.g., albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha fetoprotein, erythropoietin, or factor VIII) can enhance the expression of the polynucleotide in a hepatic cell line or liver. Likewise, 5'UTRs from other tissue-specific mRNAs can be used to improve expression in the following tissues: muscle (e.g., MyoD, Myosin, Myoglobin, Myogenin, Herculin), endothelial cells (e.g., Tie-1, CD36), myeloid cells (e.g., C / EBP, AML1, G-CSF, GM-CSF, CD11b, MSR, Fr-1, i-NOS), leukocytes (e.g., CD45, CD18), adipose tissue (e.g., CD36, GLUT4, ACRP30, Adiponectin), and lung epithelial cells (e.g., SP-A / B / C / D).
[0928] In some embodiments, the UTR is selected from a family of transcripts that share a common function, structure, characteristic, or property of proteins. For example, the encoded polypeptide may belong to a family of proteins that are expressed in a particular cell, tissue, or at a certain time during development (i.e., share at least one function, structure, characteristic, location, origin, or expression pattern). The UTR from any gene or mRNA may be replaced with any other UTR of the same or different protein family to generate a new polynucleotide.
[0929] In some embodiments, the 5'UTR and 3'UTR may be heterologous. In some embodiments, the 5'UTR may be derived from a different species than the 3'UTR. In some embodiments, the 3'UTR may be derived from a different species than the 5'UTR.
[0930] Commonly owned International Patent Application No. PCT / US2014 / 021522 (Publication No. WO / 2014 / 164253, herein incorporated by reference in its entirety) provides a list of exemplary UTRs that can be used as flanking regions of ORFs in the polynucleotides of the present invention.
[0931] Other exemplary UTRs of the present application include, but are not limited to, 5'UTRs and / or 3'UTRs of one or more nucleic acid sequences derived from: globin, such as α-globin or β-globin (e.g., Xenopus, mouse, rabbit, or human globin); a strong Kozak translation initiation signal; a CYBA (e.g., human cytochrome b-245 alpha polypeptide); an albumin (e.g., human albumin 7); HSD17B4 (hydroxysteroid (17-β) dehydrogenase); a virus (e.g., tobacco etch virus (TEV), Venezuelan equine encephalitis virus (VEEV), Dengue virus, cytomegalovirus (CMV) (e.g., CMV immediate early 1 (IE1)), a hepatitis virus (e.g., hepatitis B virus), a sindbis virus (e.g., virus or PAV barley yellow dwarf virus); heat shock proteins (e.g. hsp70); translation initiation factors (e.g. eIF4G); glucose transporters (e.g. hGLUT1 (human glucose transporter 1)); actins (e.g. human α or β actin); GAPDH; tubulins; histones; citric acid cycle enzymes; topoisomerases (e.g. 5'UTR (oligopyrimidine tract) of TOP genes lacking the 5'TOP motif); ribosomal protein large 32 (L32); ribosomal proteins (e.g. human or mouse ribosomal proteins, such as rps9); ATP synthases (e.g. ATP5A1 or mitochondrial H +-ATP synthase beta subunit); growth hormone e (e.g., bovine (bGH) or human (hGH)); elongation factors (e.g., elongation factor 1 alpha 1 (EEF1A1)); manganese superoxide dismutase (MnSOD); myocyte enhancer factor 2A (MEF2A); beta-F1-ATPase, creatine kinase, myoglobin, granulocyte colony stimulating factor (G-CSF); collagens (e.g., collagen type I alpha 2 (Col1A2), collagen type I alpha 1 (Col 1A1), collagen type VI alpha 2 (Col6A2), collagen type VI alpha 1 (Col6A1); ribosome binding proteins (e.g., ribosome binding protein I (RPNI)); low-density lipoprotein receptor-related protein (e.g., LRP1); cardiotrophin-like cytokine factors (e.g., Nnt1); calreticulin (Calr); procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (Plod1); and nuclear ligins (e.g., Nucb1).
[0932] In some embodiments, the 5'UTR is selected from the group consisting of: β-globin 5'UTR; a 5'UTR containing a strong Kozak translation initiation signal; cytochrome b-245 alpha polypeptide (CYBA) 5'UTR; hydroxysteroid (17-β) dehydrogenase (HSD17B4) 5'UTR; tobacco etch virus (TEV) 5'UTR; Venezuelan equine encephalitis virus (TEEV) 5'UTR; the 5' proximal open reading frame of German measles virus (RV) RNA encoding a non-structural protein; dengue virus (DEN) 5'UTR; heat shock protein 70 (Hsp70) 5'UTR; eIF4G 5'UTR; GLUT1 5'UTR; functional fragments thereof and any combination thereof.
[0933] In some embodiments, the 3'UTR is selected from the group consisting of: β-globin 3'UTR; CYBA 3'UTR; albumin 3'UTR; growth hormone (GH) 3'UTR; VEEV 3'UTR; hepatitis B virus (HBV) 3'UTR; α-globin 3'UTR; DEN 3'UTR; PAV barley yellow dwarf virus (BYDV-PAV) 3'UTR; elongation factor 1 alpha 1 (EEF1A1) 3'UTR; manganese superoxide dismutase (MnSOD) 3'UTR; β subunit of mitochondrial H(+)-ATP synthase (β-mRNA) 3'UTR; GLUT1 3'UTR; MEF2A 3'UTR; β-F1-ATPase 3'UTR; functional fragments thereof and combinations thereof.
[0934] A wild-type UTR derived from any gene or mRNA may be incorporated into the polynucleotides of the present invention. In some embodiments, the UTR may be altered relative to the wild-type or native UTR to produce a variant UTR, such as by changing the orientation or position of the UTR relative to the ORF; or by incorporating additional nucleotides, deleting nucleotides, exchanging nucleotides or transposing nucleotides. In some embodiments, a variant of a 5' or 3' UTR may be used, such as a mutant of a wild-type UTR, or a variant in which one or more nucleotides are added to or removed from the end of the UTR.
[0935] Additionally, one or more synthetic UTRs may be used in combination with one or more non-synthetic UTRs. See, e.g., Mandal and Rossi, Nat. Protoc. 2013 8(3):568-82, the contents of which are incorporated herein by reference in their entirety.
[0936] The UTR or portion thereof may be placed in the same orientation as the transcript from which it was selected, or its orientation or position may be altered. Thus, the 5' and / or 3' UTR may be inverted, shortened, extended, or combined with one or more other 5' UTRs or 3' UTRs.
[0937] In some embodiments, the polynucleotide comprises multiple UTRs, such as a doublet, triplet, or quadruple 5'UTR or 3'UTR. For example, a doublet UTR comprises two copies of the same UTR in tandem or substantially in tandem. For example, a doublet β-globin 3'UTR can be used (see US2010 / 0129877, the contents of which are incorporated herein by reference in their entirety).
[0938] In certain embodiments, the 5'UTR and / or 3'UTR sequences of the invention comprise a nucleotide sequence that is ...
Claims
1. A lipid nanoparticle (LNP) composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
2. A lipid nanoparticle (LNP) composition for immunomodulation, e.g., for inducing an immune response and / or breaking immune tolerance (e.g., stimulating T effector cells), the composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides.
3. A lipid nanoparticle composition for stimulating T effector cells, the composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4 or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4 or more) PD-L1 antigen peptides.
4. An mRNA construct comprising a polynucleotide encoding a checkpoint cancer vaccine, wherein the checkpoint cancer vaccine comprises (i) one or more (e.g., 1, 2, 3, 4, or more) IDO antigen peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) PD-L1 antigen peptides.
5. The LNP composition or mRNA construct of any of the preceding claims, wherein the IDO antigenic peptide comprises a fragment of a naturally occurring IDO molecule or a variant thereof.
6. The LNP composition or mRNA construct of any one of the preceding claims, wherein the IDO antigenic peptide is derived from IDO1 or IDO2.
7. The LNP composition or mRNA construct of claim 6, wherein the IDO antigenic peptide is derived from IDO1.
8. The LNP composition or mRNA construct of any of the preceding claims, wherein the IDO antigenic peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:
1.
9. The LNP composition or mRNA construct of any of the preceding claims, wherein the polynucleotide encoding the IDO antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 2 or an antigenic fragment thereof.
10. The LNP composition or mRNA construct of any one of the preceding claims, wherein the PD-L1 antigenic peptide comprises a fragment of a naturally occurring PD-L1 molecule or a variant thereof.
11. The LNP composition or mRNA construct of any of the preceding claims, wherein the PD-L1 antigen peptide comprises an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:
3.
12. The LNP composition or mRNA construct of any of the preceding claims, wherein the polynucleotide encoding the PD-L1 antigen fragment comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 4 or an antigenic fragment thereof.
13. The LNP composition or mRNA construct of any of the preceding claims, wherein the checkpoint cancer vaccine comprises two IDO antigenic peptides and two PD-L1 antigenic peptides.
14. The LNP composition or mRNA construct of any one of claims 1-12, wherein the checkpoint cancer vaccine comprises three IDO antigen peptides and three PD-L1 antigen peptides.
15. The LNP composition or mRNA construct of any one of claims 1-12, wherein the checkpoint cancer vaccine comprises four IDO antigen peptides and four PD-L1 antigen peptides.
16. The LNP composition or mRNA construct of any of the preceding claims, wherein the checkpoint cancer vaccine comprises alternating IDO and PD-L1 antigenic peptides.
17. The LNP composition or mRNA construct of claim 15 or 16, wherein the checkpoint cancer vaccine comprises (i) an IDO antigen peptide, (ii) a PD-L1 antigen peptide, (iii) an IDO antigen peptide, (iv) a PD-L1 antigen peptide, (v) an IDO antigen peptide, (vi) a PD-L1 antigen peptide, (vii) an IDO antigen peptide, and (viii) a PD-L1 antigen peptide.
18. The LNP composition or mRNA construct of any one of claims 15-17, wherein the alternating IDO and PD-L1 antigenic peptides comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the IDO amino acid sequence provided in Table 1A, e.g., SEQ ID NO: 5, or an antigenic fragment thereof.
19. The LNP composition or mRNA construct of any one of claims 16-18, wherein the polynucleotide encoding the alternating IDO and PD-L1 antigenic peptides comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 6, 300, 301 or 302, or an antigenic fragment thereof.
20. The LNP composition or mRNA construct of any of the preceding claims, which results in: (i) Stimulation of T effector cells; (ii) cytotoxic T cell-mediated killing of suppressive immune cells and tumor cells that overexpress PD-L1 or IDO; and / or (iii) Inducing anti-tumor immune responses.
21. The LNP composition or mRNA construct of any of the preceding claims, which improves or delays cancer progression in a subject, e.g., as described herein.
22. The LNP composition or mRNA construct of any of the preceding claims, wherein the polynucleotide comprising mRNA comprises at least one chemical modification, the mRNA encoding the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
23. The LNP composition or mRNA construct of claim 22, wherein the chemical modification is N1-methyl pseudouridine.
24. The LNP composition of any of the preceding claims, wherein the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structured lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
25. The LNP composition of claim 24, wherein the ionizable lipid comprises Compound 25.
26. The LNP composition of claim 24, wherein the PEG lipid is PEG DMG.
27. The LNP composition of claim 24, wherein the LNP composition comprises (i) Compound 25, (ii) cholesterol, (iii) DSPC, and (iv) PEG DMG.
28. A pharmaceutical composition comprising the LNP composition or mRNA construct of any one of claims 1-27.
29. A method of modulating, e.g., stimulating an immune response in a subject, the method comprising administering to the subject in need thereof an effective amount of an LNP composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
30. A method of stimulating T effector cells in a subject, the method comprising administering to the subject an effective amount of an LNP composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine, the checkpoint cancer vaccine comprising one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
31. A method for treating or preventing cancer or a symptom thereof, the method comprising administering to a subject in need thereof an effective amount of an LNP composition comprising a polynucleotide comprising an mRNA encoding a checkpoint cancer vaccine comprising (i) one or more (e.g., 1, 2, 3, 4, or more) indoleamine-pyrrole 2,3-dioxygenase (IDO) antigenic peptides and (ii) one or more (e.g., 1, 2, 3, 4, or more) programmed death-ligand 1 (PD-L1) antigenic peptides.
32. The method of claim 31 , wherein the cancer is a locally advanced or metastatic solid tumor.
33. The method of claim 31, wherein the cancer is melanoma.
34. The method of claim 33, wherein the melanoma is cutaneous melanoma.
35. The method of claim 34, wherein the cutaneous melanoma is IL cutaneous melanoma stage IIIB+.
36. The method of claim 31, wherein the cancer is NSCLC.
37. The method of claim 36, wherein the NSCLC is 1L NSCLC.
38. The method of claim 31, wherein the cancer is bladder cancer.
39. The method of claim 38, wherein the bladder cancer is non-muscle invasive bladder cancer.
40. The method of claim 31, wherein the cancer is head and neck cancer.
41. The method of claim 40, wherein the head and neck cancer is head and neck squamous cell carcinoma.
42. The method of claim 31, wherein the cancer is colorectal cancer.
43. The method of claim 42, wherein the colorectal cancer is microsatellite stable colorectal cancer.
44. The method of claim 31, wherein the cancer is basal cell carcinoma.
45. The method of claim 31, wherein the cancer is breast cancer.
46. The method of claim 45, wherein the breast cancer is triple negative breast cancer.
47. The method of any one of claims 29-46, wherein the mRNA encoding the checkpoint cancer vaccine comprises a nucleic acid sequence of SEQ ID NO: 300, 301 or 302.
48. The method of any one of claims 29-47, wherein the LNP composition comprises: (i) an ionizable lipid, such as an amino lipid; (ii) a sterol or other structural lipid; (iii) a non-cationic helper lipid or phospholipid; and (iv) a PEG-lipid.
49. The method of claim 48, wherein the ionizable lipid comprises Compound 25.
50. The method of claim 48, wherein the LNP composition comprises (i) Compound 25, (ii) cholesterol, (iii) DSPC, and (iv) PEG DMG.
51. The method of claim 48, wherein the method further comprises administering to the subject a checkpoint inhibitor selected from the group consisting of anti-PD-1 and anti-CTLA4.
52. The method of claim 51, wherein the checkpoint inhibitor comprises pembrolizumab.
53. The method of any one of claims 29-52, wherein the LNP composition is administered at a dose of 100 μg to about 1 mg.
54. The method of claim 53, wherein the LNP composition is administered at a dose of 50 μg to 150 μg, 150 μg to 250 μg, 250 μg to 350 μg, 350 μg to 450 μg, 450 μg to 550 μg, 550 μg to 650 μg, 650 μg to 750 μg, 750 μg to 850 μg, 850 μg to 950 μg, or 950 μg to 1 mg.
55. The method of claim 54, wherein the LNP composition is administered at a dose of 50 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg, or 1 mg.
56. The method of any one of claims 29-55, wherein the LNP composition is administered intramuscularly.
57. The method of any one of claims 29-56, wherein the LNP composition is administered once every three weeks.
Citation Information
Cited By
Spleen targeting lipid nanoparticle and application thereof
CN120305220A
Spleen-targeting lipid nanoparticles and uses thereof
CN120305220B
